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ABSTRACT
Large efforts have been made to target integrin αVβ3 of endothelial cells. We have successfully
developed a new class of protein (Ref to as ProAgio) by rational protein design using a stable
host protein, domain 1 of cell adhesion protein CD2. ProAgio is designed to target integrin αVβ3
at a novel site and induces angiogenic endothelial cell apoptosis by recruiting and activating
caspase 8 to the cytoplasmic domain of the targeted integrins. Tests with tumor xenograft models
show that ProAgio strongly inhibits tumor growth. Histology analyses indicate that tumor vessels
are reduced, while the established vasculatures are not affected. Toxicity analyses demonstrate
that ProAgio is not toxic to mouse. Our study develops an effective anti-angiogenesis agent and
provides a new platform for development of therapeutics by targeting integrins. We have
i

successfully developed an anti-angiogenesis protein targeting integrin αVβ3at a novel site by
rational protein design. The developed agent is not toxic to non-cancerous blood vessels and
other tissue/organs, providing an excellent candidate for future potential clinical development.
Our developed protein is one of the very few examples that do not act through targeting
VEGF/VEGFR or any other RTK pathways. The βA groove is present in almost all other β
integrins. This approach may be applicable to develop agents targeting the similar βA groove of
other integrin pairs, which can address wide array of pathological conditions such as AMD,
Rheumatoid Arthritis, Osteoporosis etc.

INDEX WORDS: Integrin αVβ3, Angiogenesis, Hepatic stellate cells, Liver fibrosis, Apoptosis,
Sinusoidal remodeling, Cirrhosis.

ii

PROAGIO
(A PROTEIN DESIGNED TO TARGET INTEGRIN αVβ3)

by

RAVI CHAKRA TURAGA

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2017
iii

Copyright by
Ravi Chakra Turaga
2017

iv

PROAGIO
(A PROTEIN DESIGNED TO TARGET INTEGRIN αVβ3)

by

RAVI CHAKRA TURAGA

Committee Chair:

Committee:

Zhi-Ren Liu

Jenny. J. Yang
Ritu Aneja

Hans. E. Grossniklaus

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
June 2017
v

ACKNOWLEDGEMENTS
I may be the forefront of this thesis getting a degree but many people have put their efforts and
their valuable time to generate this master piece “ProAgio”.
I offer my gratitude to many people who have supported me throughout the duration of my
doctoral studies. Primarily my advisor Zhi-Ren Liu, thank you for the opportunity and
experiences you have provided me within this lab, along with your support, patience, expert
advice and trust has always been available to provide me with stanch guidance and encouraging
me to think and work independently and voice my opinions. The other members of my
dissertation committee, Ritu Aneja, Jenny Yang and Hans E. Grossniklaus have always
positively reinforced me, and offered stimulating discussions and guidance. I also would like to
Chun Jiang who was a great mentor for beginning my research career.
This dissertation would not be possible without the support of several present and past members
and my fellow-graduate students from various laboratories who enhanced my graduate
experience would have been incomplete, who have helped me throughout these years, including
Liangwei Li, Yinwei Zhang, Chen Zhang, Gary, Lucy, Heena dey, Sushma Gundala, Vaishali
Pannu, Falguni Mishra, Ganesh Satyanarayana, Neha Panchbai, Hongwei Han and Guangda
Peng. My acknowledgments extend to Malvika Sharma for majority of corrections in thesis and
continuing ProAgio’s journey.
Most of the research we perform has been translated in to preclinical setup and this would not
have been possible with the training and hourly assistance provided by Department of Animal
Resources at GSU, a fantastic facility with always expanding abilities and skills. The following
staff and veterinarian were integral part of this project Dean A. Blake, Courtnye D. Billingsley,
Joi Darcel Scott, Michael Lawton Morrison, Evan Micheal Hutto, Matthew Robert Davis, Dr.
Michael W. Hart.
The following staff and research personnel at GSU were integral to the successful completion of
my dissertation: LaTesha Warren, Tameka Hudson, Siming Wang, Cheng Ma, Sonja Young,
Debbie Walthall, Mary Karom, Tamara Gross, Barry Grant, Karon Mackey, Lifang Wang.
Molecular basis of Disease (MBD) program has been instrumental for enhancing my experience
at GSU through technical presentations and enhanced learning and collaborative skills. A special
thanks to a lot of people who denied help because we did it ourselves.
I will also have to extend my thanks to Rajesh Venkatesh, Raghavendar Ravi Kumar, and
Lakshmi Kollepara for supporting me in different ways to keep my research going unhindered.
Thank you, Shreya Thacker, for being supportive all along and keeping confidence up when it
really mattered. Above all, I want to thank my family, Turaga Venkata Rama Mohana Sarma,
Turaga Koti Naga Sai and Turaga Maruti Krishna Prasad and the rest of my family for always
ignoring my mistakes and standing with me through their words of confidence and inspiration
despite the long distance.
There might have been many people who might have missed in this list but you will be always
remembered for your help.
vi

vii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ........................................................................................................... vi
LIST OF TABLES ....................................................................................................................... xiv
LIST OF FIGURES ...................................................................................................................... xv
LIST OF ABBREVIATIONS ..................................................................................................... xvii
1.

INTRODUCTION ................................................................................................................... 1
1.1. Integrin in physiology .......................................................................................................... 1
1.1.1. The integrin family ....................................................................................................... 1
1.1.2. Integrin αVβ3 regulation of integrin function: Activation and Inactivation ................. 2
1.1.3. Ligand binding to αVβ3 ................................................................................................ 3
1.1.4. Mechanism of βA activation ......................................................................................... 4
1.2. Integrin αVβ3 in cell development or cell death.................................................................. 4
1.3. Angiogenesis in physiology and pathology ......................................................................... 5
1.3.1. Early evidence of tumor angiogenesis by Judah Folkman............................................ 6
1.3.2. Tumor angiogenesis as a therapeutic target .................................................................. 8
1.4. Endogenous inhibitors targeting angiogenesis..................................................................... 9
1.4.1. Endostatin ..................................................................................................................... 9
1.4.2. Tumstatin .................................................................................................................... 10
1.4.3. Thrombospondin-1 ...................................................................................................... 10
1.5. Non-matrix-derived endogenous angiogenesis inhibitors ................................................. 11
1.5.1. Angiostatin .................................................................................................................. 11
1.5.2. Pigment epithelium-derived factor ............................................................................. 11
1.5.3. Anginex ....................................................................................................................... 11
1.6. Endogenous anti-angiogenic peptides, why did they fail?................................................. 12
viii

1.7. Fibrosis in physiology and pathology ................................................................................ 12
1.7.1. Fibrosis ........................................................................................................................ 12
1.7.2. Properties of the fibrotic ECM .................................................................................... 14
1.7.3. Epithelial injury and dysfunction ................................................................................ 15
1.7.4. Sources of fibrogenic cells .......................................................................................... 17
1.8. Liver Fibrosis ..................................................................................................................... 20
1.9. Liver Sinusoidal Endothelial cells (LSEC) Sinusoidal Endothelial Fenestrae .................. 22
1.10. HSCs and Sinusoidal Remodeling in Portal Hypertension and Cirrhosis ....................... 23
1.11. Myofibroblast apoptosis................................................................................................... 25
1.12. Integrin TGF-β crosstalk .................................................................................................. 26
1.13. Therapies for Fibrosis ...................................................................................................... 28
1.13.1. TGF-β pathway ......................................................................................................... 28
1.13.2. αVβ6 integrin ............................................................................................................ 29
1.13.3. LPA1 (LPA receptor) ................................................................................................ 29
1.13.4. IL-4 and IL-13 inhibitors .......................................................................................... 29
1.13.5. Lysyl oxidase like protein 2 inhibition ..................................................................... 30
1.13.6. Pentraxin-2 ................................................................................................................ 30
1.13.7. Pirfenidone ................................................................................................................ 31
1.14. Therapeutic targeting of integrin αVβ3 ........................................................................... 31
1.14.1. Sequences binding to Integrin: Cilengitide ............................................................... 31
1.14.2. Disintegrins ............................................................................................................... 32
2. MATERIALS AND METHODS ............................................................................................. 33
2.1. Mammalian cell techniques ............................................................................................... 33
2.1.1. Mammalian cell culture and storage ........................................................................... 33
ix

2.1.2. Transient transfection method..................................................................................... 34
2.1.3. RNA Interference ........................................................................................................ 34
2.1.4. Growth factor treatment of cells ................................................................................. 35
2.1.5. Whole cell lysate preparation...................................................................................... 35
2.1.6. Nuclear extract and cytoplasmic extract preparation .................................................. 35
2.2. Site-directed mutagenesis to produce anti-angiogenic protein cDNA ............................... 36
2.2.1. Site-directed mutagenesis ........................................................................................... 36
2.2.2. Multi site-directed mutagenesis .................................................................................. 36
2.2.3. Transformation Escherichia coli (E. coli) strains ....................................................... 37
2.2.4. Cloning of the CD2 variants into pGEX-2T expression vector .................................. 37
2.2.5. DNA concentration and quality measurement ............................................................ 39
2.2.6. Agarose gel electrophoresis ........................................................................................ 39
2.2.7. Agarose gel extraction of DNA .................................................................................. 40
2.2.8. Restriction enzyme digestion ...................................................................................... 40
2.2.9. Ligation of CD2 variants and pGEX-2T expression vector........................................ 41
2.3. Expression of the Glutathione (GST)-tagged proteins....................................................... 41
2.3.1. Optimization of expression for the GST-tagged proteins ........................................... 41
2.3.2. Expression of CD2 variants in Luria Bertani (LB) medium ....................................... 42
2.3.3. Purification of CD2D1 and ProAgio........................................................................... 42
2.3.4. Purification of ProAgio-PEG ...................................................................................... 43
2.3.5. Purification of ProAgio-PEG using ion exchange chromatography ........................... 43
2.4. Protein stability test............................................................................................................ 44
2.4.1. Determination of protein concentration ...................................................................... 44
2.5. Conformational analyses by 1D 1H NMR ......................................................................... 45
x

2.6. Assays to determine the in vitro effects of ProAgio .......................................................... 45
2.6.1. Determination of cell growth ...................................................................................... 45
2.6.2. Cell proliferation assay (BrdU) ................................................................................... 45
2.6.3. Tube formation assay .................................................................................................. 46
2.7. GST Pull-down assay ......................................................................................................... 47
2.8. Western blot ....................................................................................................................... 47
2.9. In vivo effects of ProAgio and ProAgio-PEG using xenograft nude mice model ............. 48
2.9.1. Animal care ................................................................................................................. 48
2.9.2. In vivo xenograft model .............................................................................................. 49
2.9.3. Determination of tumor size and tumor weight measurement at the end point .......... 49
2.10. Statistics analysis ............................................................................................................. 50
3. RATIONAL DESIGN OF A PROTEIN INTEGRIN V3 .................................................... 51
3.1. Abstract .............................................................................................................................. 51
3.2. Introduction ........................................................................................................................ 51
3.3. Results ................................................................................................................................ 52
3.3.1. Designing a protein agent binds to a novel site of integrin αVβ3 .............................. 52
3.3.2. ProAgio induces apoptosis by recruiting caspase 8 to integrin 3 tails ..................... 68
3.3.3. ProAgio effectively inhibits tumor growth and reduces tumor blood vessels ............ 72
3.3.4. ProAgio is not toxic to normal tissue and organs ....................................................... 79
3.4. Discussion .......................................................................................................................... 81
3.5. Materials and Methods ....................................................................................................... 85
3.5.1. Reagents, antibodies, cell lines, and protein expression/purifications........................ 85
3.5.2. Computation modeling/docking.................................................................................. 85
3.5.3. ELISA binding ............................................................................................................ 86
xi

3.5.4. SPR ............................................................................................................................. 86
3.5.5. Nude mice xenograft treatments and toxicity ............................................................. 87
3.5.6. Determination of the integrin binding site by chemical crosslinking followed by MS
analyses ................................................................................................................................. 87
3.5.7. Endothelial tube formation assays .............................................................................. 89
3.5.8. Cell attachment assays ................................................................................................ 89
3.5.9. Apoptosis assays ......................................................................................................... 89
3.5.10. Immunofluorescence staining ................................................................................... 89
3.5.11. Vessel quantitation .................................................................................................... 90
3.6. Statistical calculations ........................................................................................................ 90
4. INDUCTION OF INTEGRIN V3 MEDIATED APOPTOSIS BY A RATIONALLY
DESIGNED PROTEIN IS AN EFFECTIVE TREATMENT FOR CHRONIC LIVER
DISEASES .................................................................................................................................... 91
4.1. Abstract .............................................................................................................................. 91
4.2. Introduction ........................................................................................................................ 91
4.3. ProAgio induces cell death in activated HSCs .................................................................. 92
4.4. ProAgio effectively reduces portal hypertension ............................................................... 94
4.5. ProAgio decreases liver fibrosis in TAA induced fibrosis model ..................................... 94
4.6. ProAgio is non-toxic to liver............................................................................................ 103
4.7. Materials and methods ..................................................................................................... 106
4.7.1. Cell culture ................................................................................................................ 106
4.7.2. Kupffer cells.............................................................................................................. 106
4.7.3. Immunoblotting......................................................................................................... 107
4.7.4. Immunostaining of tissue sections ............................................................................ 107
4.7.5. Enzyme-linked immunosorbent assay ...................................................................... 108
xii

4.7.6. Collagenase assay ..................................................................................................... 108
4.7.7. Statistical calculations ................................................................................................... 108
5. TARGETING INTEGRIN V3 FOR OCULAR ANGIOGENESIS ................................... 109
5.1. Introduction ...................................................................................................................... 109
5.2. ProAgio decreases retinal angiogenesis. .......................................................................... 111
5.3. Discussion ........................................................................................................................ 112
6. CONCLUSIONS AND DISCUSSION .................................................................................. 114
6.1. ProAgio – engineered protein with a novel mechanism and enhanced pharmacological
features .................................................................................................................................... 114
6.1.1. ProAgio binds to integrin αVβ3 and induces apoptosis ............................................ 114
6.1.2. ProAgio has enhanced pharmacological properties .................................................. 115
6.1.3. ProAgio has fewer side effects ................................................................................. 115
6.1.4. Why ProAgio can be a better anti-angiogenic agent? ............................................... 116
6.1.5. ProAgio induces cell death in endothelial cells ........................................................ 117
6.1.6. ProAgio inhibits angiogenesis in in vivo xenograft tumors...................................... 118
6.2. Fibrosis conclusion .......................................................................................................... 121
6.3. Why integrin αVβ3?......................................................................................................... 123
6.4. Integrin αVβ3 direct access to the apoptotic machinery .................................................. 123
6.5. Conclusions and Future directions ................................................................................... 125
REFERENCES ........................................................................................................................... 130

xiii

LIST OF TABLES
Table 3.1. Mass of the crosslinked peptides identified using pLink and corresponding regions in
integrin αVβ3.……………………………………………………………………………………64
Table 3.2. CD31 Quantification of PC3 xenograft tumors treated with Buffer (PBS), Endostar, Avastin
and ProAgio (n = 6)……………………………………………………………………………………….78

xiv

LIST OF FIGURES
Figure 1. The integrin receptor family. ........................................................................................... 2
Figure 2. Schematic representation of angiogenesis inhibitor as a therapeutic target. ................... 8
Figure 3. Events in fibrosis progression and regression. .............................................................. 13
Figure 4. Figure depicts fibrosis development in response to injured epithelium. ....................... 15
Figure 5. Docking of a physiological ligand of integrin αVβ3. .................................................... 55
Figure 6. Design of protein agent, ProAgio that binds to integrin v3 at a novel site. ............... 57
Figure 7. ProAgio binds to integrin v3 at the designed site. ..................................................... 61
Figure 8. ProAgio binds to integrin αVβ3 at βA domain. ............................................................ 62
Figure 9. ProAgio induces apoptosis in HUVEC and downregulates integrin αVβ3 signaling. .. 65
Figure 10. ProAgio is highly specific for integrin αVβ3, but not for other αV integrin pairs. ..... 67
Figure 11. ProAgio recruits and activates caspase 8 at cytoplasmic domain of integrin 3. ........ 69
Figure 12. ProAgio induces apoptosis via targeting integrin v3. .............................................. 71
Figure 13. PEGylated ProAgio effectively decreases angiogenesis in iv vivo matrigel plug assay.
....................................................................................................................................................... 73
Figure 14. ProAgio effectively inhibits tumor growth and disrupts tumor vessels. ..................... 75
Figure 15. ProAgio decreases angiogenesis in xenograft and orthotopic tumors. ........................ 78
Figure 16. ProAgio is non-toxic to normal tissues. ...................................................................... 80
Figure 17. ProAgio and integrin v3 interaction is independent of RGD binding. ..................... 82
Figure 18. Figure depicting the folding of integrin β3 with αV and αIIb. .................................... 84
Figure 19. ProAgio effectively induces HSC and LX-2 apoptosis. .............................................. 93
Figure 21: ProAgio induces HSC apoptosis and decreases collagen deposition in liver fibrosis. 95
Figure 22: (A) Raw images of normal, buffer and ProAgio liver. (B-H) Quantitative analysis of
liver function tests. ........................................................................................................................ 96
Figure 23. ProAgio reduces collagen crosslinking in fibrotic liver. ............................................. 99
Figure 24. ProAgio reduces sinusoidal remodeling effectively. ................................................. 102
Figure 25. CD31 expression of liver tissue. ................................................................................ 103
Figure 26. Hif1α expression of liver tissue. ................................................................................ 104
Figure 27. ProAgio does not induce cell death in hepatocytes and kupffer cells. ...................... 104
xv

Figure 28. Cartoon depicting ProAgio acting on HSC, LSEC in pathological fibrosis.............. 105
Figure 30. Integrin αVβ3 is upregulated in retinal angiogenesis. ............................................... 110
Figure 31. ProAgio decreases retinal angiogenesis. ................................................................... 111
Figure 32. Representative H&E stained cross-sections of subretinal choroidal neovascularization
lesions. ........................................................................................................................................ 112
Figure 33. Schematic representation of integrin targeting drugs inducing cell death through
different mechanisms. ................................................................................................................. 124

xvi

LIST OF ABBREVIATIONS

Abbreviations: Biochemistry and Chemistry
BrdU

5-bromo-2-deoxyuridine

BSA

Bovine serum albumin

CD

Circular Dichroism

cDNA

complementary DNA

DNA

Deoxyribonucleic acid

DTT

Dithiothreitol

ED50

Half maximal effective concentration

EDTA

Ethylenediaminetetraacetic acid

FPLC

Fast performance liquid chromatography

GAG

Glycosaminoglycan

GS4B

Glutathione sepharose 4B

GST

Glutathione-S-transferase

HBSS
H&E
HEPES

Hank's Buffered Salt Solution
Hematoxylin and Eosin
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HRP

Horse radish Peroxidase

IPTG

Isopropyl β-D-thiogalactoside

Kd

Dissociation constant

kDa

Kilodalton

Kon

Association rate constant

Koff

Dissociation rate constant

LB medium

Luria-Bertani medium

MES

2-morpholin-4-ylethanesulfonate

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

mg

Milligram
xvii

µg

Microgram

ml

Milliliter

mM

10−3 mol/dm3

µM

10−6 mol/dm3

MW

Molecular weight

ng

Nanogram

nm

nanometer

nM

10−9 mol/dm3

NMR
NO
O. D.

Nuclear magnetic resonance
Nitric oxide
Optical Density (Absorbance)

PBS

Phosphate buffer saline

PCR

Polymerase chain reactions

PDB

Protein databank

PEG

Polyethylene glycol

pM
SDS-PAGE

10−12 mol/dm3
Sodium dodecyl sulfate polyarcylamide gel electrophoresis

Tris

2-Amino-2-(hydroxymethyl)-1,3-propanediol

UV

Ultraviolet
Abbreviations - Biology

APC

Antigen presenting cell

Ang

Angiopoietin

CD2

Cluster of differentiation 2

CD31

Cluster of differentiation 31

CD48

Cluster of differentiation 48

CD58

Cluster of differentiation 58

CHO

Chinese hamster ovary

CRD

Carbohydrate recognition domain

CTLs

Cytotoxic T lymphocytes
xviii

EC

Endothelial cell

E. coli.

Escherichia coli

ECM

Extracellular matrix

EGF

Epidermal growth factor

FBS

Fetal bovine serum

FGF

Fibroblast growth factor

FGFR

Fibroblast growth factor receptor

EPC

Endothelial progenitor cell

FIGF

Fos-induced growth factor

FLK

Fms-like tyrosine kinase

FN

Fibronectin

FU

Fluorouracil

Gal-1

Galectin-1

GFR

Growth factor reduced

GIST

Gastrointestinal stromal tumor

HCC

Hepatocellular carcinoma

HIF

Hypoxia-inducible factor

HUVEC
IF
IgSF
INF
IL

Human umbilical cord vein endothelial cell
Immunofluorescence
Immunoglobulin superfamily
Interferon
Interleukin

i.p.

Intraperitoneal

LV

leucovorin

mAb
MAPK

Monoclonal antibody
Mitogen-activated protein kinase

MHC

Major Histocompatibility complex

MMP

Matrix Metalloproteinase

mTOR

Mammalian target of rapamycin
xix

MVD
NC domain

Mean vascular density
Non-collagenous domain

NK cell

Natural killer cell

NSCLC

Non-small-cell lung cancer

PCR
PDGF
PDGFR
PEDF

Polymerase chain reaction
Platelet-derived growth factor
Platelet-derived growth factor receptor
Pigment epithelium-derived factor

PF-4

Platelet factor-4

PIGF

Placental-induced growth factor

PK/PD
PKC
PLC-γ
Raf-1
Rb

Pharmacokinetic/Pharmacodynamic
Protein kinase c
Phospholipase C-γ
V-raf-1 murine leukemia viral oncogene homolog
Retinoblastoma

RCC

Renal cell carcinoma

RET

Rearranged during transfection

RGD

Arginine-glycine-aspartic acid

RTK

Receptor tyrosine kinase

TcR

T cell receptor

TGF

Transforming growth factor

TIMP
TKI
TSP-1
TSR
VEGF
VEGFR

Tissue inhibitors of matrix metalloproteinases
Tyrosine kinase inhibitor
Thrombospondin-1
Thrombospondin-1 type 1 repeat
Vascular endothelial growth factor
Vascular endothelial growth factor receptor

xx

Miscellaneous
ATCC

American type Culture Collection

DAR

Department of Animal Research

FDA

Food and Drug Administration

GSU

Georgia State University

IACUC

Institutional Animal Care and Use Committee

1D

1 dimensional

2D

2-dimensional

3D

3-dimensional

rpm

Revolutions per minute

xxi

1. INTRODUCTION
1.1. Integrin in physiology
1.1.1. The integrin family
Integrins are transmembrane cell surface adhesion receptors confined to the metazoan
species. They are present in the entire animal kingdom ranging from the simplest animals such as
sponges to humans. In lower metazoans, cnidarians and drosophila, pairs of integrins are present
whereas in mammals, a set of 18 α and 8 β subunits are known to form 24 distinct pairs of αβ
integrin. Similarly, RGD and laminin binding integrins are present in smaller species, whereas
integrins binding to collagen and other receptors such as VCAM-1 are present in mammals in
addition to RGD and laminin binding integrins. Each heterodimer formed is very specific and
functionally non-redundant. The phenotypes range from a complete block in pre-implantation
development (β1) to perinatal lethality (α3, α6, α8, αv, β4, β8), major developmental defects (α4,
α5, αV, β8), defects in leukocyte function (αL, αM, αE, β2, β7), inflammation (β6), hemostasis
(αIIb, β3, α2), bone remodeling (β3), and angiogenesis (α1, β3) as well as others (Figure 1.1)
(Hynes 1987, De Arcangelis and Georges-Labouesse 2000, Bouvard, Brakebusch et al. 2001,
Hynes 2002).
Integrins are the cell surface receptors necessary for attachment of the cell to the
surrounding tissues. These are well studied since decades and play a key role in development.
The integrin receptors’ signals cross in both the directions. So far, 18 α and 8 β subunits of
integrins have been identified, and their heterodimeric combinations have generated 24 different
pairs of integrins, which have no redundancy in their functional role. Knocking out these
integrins has shown developmental defects or perinatal lethality.
Each heterodimer has 3 subunits, a large extracellular domain, which interacts with
extracellular environment, a single transmembrane domain and a short cytoplasmic tail, which is
linked to cytoskeletal fibers through cytoskeletal adaptor proteins. Integrins have a wide range of
ligands, extracellular matrix glycoproteins such as collagen, fibronectin, laminin and vitronectin
etc.
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Figure 1.1. The integrin receptor family.
The figure illustrates the mammalian subunits and their αβ combinations; 18 α subunits can associate
with 8 β subunits to form 24 distinct integrins.

Integrins control several key cellular functions including cell proliferation, migration,
adhesion and apoptosis. These are non-covalent heterodimers and this unique structure enables
them to signal bi directionally.
1.1.2. Integrin αVβ3 regulation of integrin function: Activation and Inactivation
Integrins are present on the cell membrane in an inactive form and therefore cannot signal
downstream. Constitutively active integrins can lead to several pathological conditions. For
example, thrombosis is due to αIIbβ3 integrin activation. αVβ3 integrin are mostly present on
activated endothelial cells, which are associated with proliferation and migration. Nascent resting
endothelial cells express very little or no αVβ3 integrin. Activation of integrins can be in two
independent ways i.e. Inside-out signaling or Outside-In signaling. Both these ways involve
transmembrane signaling, and hence are hard to decipher from each other. Recent structural
evidences have given major insights into the mechanism of integrins. In outside-in signaling,
2

integrins get activated when they are bound to their extracellular ligands, which is vitronectin in
case of αVβ3 and fibronectin in case of α5β1. These ligands once bound to their respective
integrins, lead to clustering and activation of downstream signaling. During the process of
activation of integrins in either inside-out or outside-in signaling, conformational changes occur
in integrin structure, which are discussed in the next section.
However, it is believed that integrins mainly function in a localized fashion in an absolute
way, as integrins function mainly during cell migration, neurite outgrowth, cell adhesion
regulation in a spatiotemporal fashion, which requires high mechanical energy (Lauffenburger
and Horwitz, 1996) (Ginsberg, Du et al. 1992, Hynes 1992). We will discuss the nature of
integrin activation in detail later.
1.1.3. Ligand binding to αVβ3
The following integrin description is mainly focused on integrin αVβ3. Integrins are
known to be heterodimers; their existence of monomer is not yet proven. The most inter subunit
surface contact between αV and β3 is at βA and β propeller interface. Arg 621 forms the
interface core; it protrudes from a 310 helix of βA domain into the center of the propeller
channel, and is confined into position by two rings of predominantly aromatic amino acids. This
interface resembles structure of the G proteins, Gα (an αA-like fold) and Gβ (a seven-bladed βpropeller) suggesting that integrin αV and β3 interface is also dynamic (Xiong et al. 2001). A
similar core arrangement is also seen in αIIbβ3 in which the binding interface is formed from the
βA domain and propeller from integrin αIIb (Xiao et al. 2004). Additional contacts bury a
surface area of about 1500 A˚ 2 in each integrin. Eight residues from βA [L258, D259, R261,
L262 (from the 310 helix), S291 and Y321, D217, and T254] contact (≤3.5A) αV propeller. The
SDL segment is also known to contribute to other integrins’ heterodimer interface that includes
α6β1, αVβ1, and αLβ2 but not α5β1, α4β1, or α6β4 (Takagi et al. 2002a). Even though SDL
fragment contributes to the interface inclusion of β3, SDL region in the interface with αIIb is
from longer B2-C2 (of blade 2) and D2-A3 loops (between blades 2 and 3) of the αIIb propeller
when compared to αV integrin. These structural changes define and alter the ligands specificity
to their respective integrins, αIIbβ3 and αVβ3.
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1.1.4. Mechanism of βA activation
βA activation has been the center of integrin αVβ3 structural changes leading to its
function in inside-out and in outside-in signaling events. To understand this domain regulation,
three distinct models have been in contention: (i) In the crystal structures of αVβ3 in which no
movement of α7 helix is observed, when the MIDAS site is unoccupied in the absence of ligand,
it was suggested that βA may be regulated by exposing the MIDAS site. It could also be due to
the method used to generate crystal structure, which was generated in presence of Ca2+ buffer.
(ii) Based on comparative studies by electron microscopy, inactive (Ca2+-occupied) and active
(Mn2+-occupied) head region of αVβ3 are predicted to be coupled to downward shift of the α7
helix equivalent to that in αA domains. (iii) This activation mechanism is slightly different as it
was suggested that the outward swing of the hybrid domain regulates activation of αIIbβ3
integrin. It was also hypothesized that the activation of βA domain involves rotating away its
contact from the β-propeller, as the quaternary structure of βA domain is highly similar to
heterotrimeric G-proteins. In this scenario, the position of α7 helix remains fixed but the rotation
of βA results in same net movement of α7, as seen in αA domains. The detailed mechanism of
movement of α7 helix during βA activation is yet to be elucidated.
1.2. Integrin αVβ3 in cell development or cell death
The role of integrins as angiogenesis promoting receptors came into question when
Reynolds et al., demonstrated that integrin β3-null or β3/β5-null mice showed enhanced tumor
angiogenesis and growth when compared to normal mice. It made us reconsider the role of
integrin αVβ3 in angiogenesis. Upregulation of integrin expression is seen in vascular sprouts in
developmental angiogenesis (even in pathological conditions when stimulated by growth
factors). Targeting integrins have exhibited decreased EC proliferation, migration and even
apoptosis in certain cases. Considering many vital roles of integrins in angiogenesis, it has
become a potential target for developing anti-angiogenic therapies. Neither developmental nor
pathological angiogenesis was affected in absence of β3 or β5 integrin demonstrating the
unsubstantial role of these integrins in angiogenesis. Absence of these integrins has increased the
angiogenic response and tumor progression significantly. In vitro and in vivo findings from
Reynolds et al. have shown that αVβ3 ligand based antagonists (targeting RGD binding site on
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integrin) enhance pathological angiogenesis when their serum levels fall below IC50
concentration (Reynolds, Wyder et al. 2002). These data collectively suggest that integrin αVβ3
can affect angiogenesis but are not mandatory for either developmental or pathological
angiogenesis. Enhanced angiogenesis in β3 and β5 null mice suggests that it has more prominent
role in inhibition than in promoting angiogenesis.
1.3. Angiogenesis in physiology and pathology
In the development of any physiological system beyond a certain limit, there is always a
necessity for the development of vasculature around it for the supply of growth factors, nutrients,
gases, and for the removal of metabolic wastes. Heart and the vascular system are one of the first
organs formed during the embryonic development. Each stage of vascular development is a
coordination of both genetic and epigenetic mechanisms, and the growth regulation also depends
on the stimulus from molecules and the cellular responses regulated spatiotemporally (Jain 2003,
Adams and Alitalo 2007). Endothelial cells line the blood vessels in arteries and veins. During
the formation of new blood vessels, endothelial cells get activated and undergo a series of events
resulting in four main physiological events such as proliferation, migration, branching and
anastomosis. Tumors, wet macular degeneration, rheumatoid arthritis and many other diseases
associated with growth and development have pathological angiogenesis. In both developmental
and pathological angiogenesis, new vessels form as per the requirement in response to increase
in demand for the oxygen and nutrients, and in case of tumor growth, this forms a major
oncogenic transformation since the pathological condition keeps the angiogenesis persistent
(Mazure, Chen et al. 1996, Shchors, Shchors et al. 2006). Tumor growth beyond 3-4 mm
typically results in a hypoxic environment as the requirement of nutrients; oxygen and growth
factors surpass the supply. This hypoxic condition transcriptionally activates HIFs, which are
heterodimers comprising of α and β subunits. The HIF-1α is regulated through the oxygen levels,
and is elevated in hypoxic conditions but maintained at very low levels during normoxia and also
it is regulated through ubiquitin-mediated proteasome degradation through von Hippel-Lindau
(VHL)(Pugh and Ratcliffe 2003). These HIFs can induce the expression of proangiogenic stimuli
such as VEGF-A to stimulate growth. Hypoxia facilitates sprouting angiogenesis, upregulating
the number of genes that are necessary for vessel formation and maturation such as NOS, which
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secrete NO. Secreted NO dilates the existing vessels, making the vessels leaky and angiopoietin2 facilitates the sprout formation in response to VEGF through Tie-1 and 2 receptors (Carmeliet
2000, Carmeliet and Jain 2000, Yancopoulos, Davis et al. 2000, Jain and Carmeliet 2001).
VASCULAR MATURATION: the endothelial cells lined up are nascent, and are stabilized by
pericytes recruitment, basement membrane formation in capillaries and elastic lamina formation
along with vascular smooth muscle cells (mural cells) in higher vessels such as arteries or veins.
Several different growth factor families program this maturation processes, few of them are
listed as follows. PDGFR-β, expressed in cells of different origin, has a prominent role in
vascular smooth muscle cells proliferation, migration eventually leading to vascular maturation
(Hellstrom, Gerhardt et al. 2001). Ang1, 2 and Tie receptors are also critical for vessel formation
and stabilization. Mural cells secreting angiopoietin stabilize the existing nascent vessels. The
role of Ang-1 is well known for vessel stabilization when used in absence of mural cells. In
presence of VEGF, Ang-2 is congruous with Ang-1, whereas in absence of VEGF, it is known
for its antagonistic behavior in destabilizing vessels (Carmeliet 2000, Yancopoulos, Davis et al.
2000, Jain and Carmeliet 2001, Uemura, Ogawa et al. 2002). The physiological angiogenesis
involves the development of structurally normal vessels, whereas the pathological angiogenesis
involves the formation of immature vasculature. VEGF stimulates the formation of nascent
vascular networks in vasculogenesis as well as angiogenesis. VEGF not only stimulates
endothelial cells but also initiates the final step in developmental vasculature such as branching,
remodeling and pruning. Other than ephrins and neurolipins that define the vessels as arteries or
veins, various basement membrane and ECM components provide the stimulus to regulate the
endothelial cell proliferation and migration. The basement membrane and ECM are dissolved in
response to MMP-2, 3, and 9. The sprouts formed anastomose complete the vascular network.
1.3.1. Early evidence of tumor angiogenesis by Judah Folkman
In 1971, Folkman proposed the hypothesis that tumor growth is angiogenesis-dependent
(Folkman 1971). It is the first report to demonstrate that tumors need to recruit new capillary
vessels (microvessels) and without it, they cannot grow beyond few millimeters. He
hypothesized that tumors secrete diffusible substance, which can stimulate endothelial cell
proliferation in the host capillary blood vessels. This 1971 report also introduced the concept of a
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novel form of tumor dormancy, which is caused by blockage of angiogenesis. In that paper,
Folkman for the first time introduced the concept of “anti-angiogenesis” as a potential novel
anticancer therapy. Folkman's 1971 supposition initiated a field of angiogenesis research that has
produced more than 89,000 reports on angiogenesis in peer-reviewed journals, and around 1800
monographs and books. The hypothesis proposed by Judah Folkman has been remarkably
prolific. During the subsequent 37 years, it led to an almost uninterrupted series of new findings
and discoveries, not only in his laboratory but also in hundreds of laboratories worldwide. Their
studies involved clinical testing of molecules targeting circulating VEGF and they eventually got
U.S. Food and Drug Administrative (FDA) approval of Avastin®, ranibizumub (Lucentis®),
which are anti-VEGF antibodies and Pegaptanib (Macugen®), which is an aptamer of VEGF.
VEGF inhibitors are approved in many countries including European Union, India, and
Switzerland. After a few months of local therapy with Lucentis, about 40% of blind patients
(visual acuity of 20/300) regained their eyesight (Rosenfeld, Brown et al. 2006). Folkman wrote
in 1971, “If a tumor could be held indefinitely in the non-vascularized dormant state, it is
possible that metastases will not arise.” He also speculated that a supposed tumor-derived
angiogenic factor could be therapeutically targeted. “It has not been appreciated that the
population of tumor cells and the population of capillary endothelial cells within a neoplasm
may constitute a highly integrated ecosystem. In this ecosystem, the mitotic index of the two cell
populations may depend on each other”. It is Folkman’s hypothesis that not only tumors but also
other non-neoplastic diseases such as rheumatoid arthritis, ocular neovascularization and
psoriasis may be angiogenesis-dependent and therefore he suggested that angiogenesis inhibitors
that are being developed for cancer therapy can be used to treat angiogenesis-dependent diseases
which are non-neoplastic. During the mid-1990s, Folkman and colleagues published a series of
papers demonstrating that vascular endothelial growth factor (VEGF) is a critical mediator of
retinal neovascularization, which can be targeted for AMD. Folkman and colleagues also
reported that macromolecules and proteins could be released from polymers implanted in the
cornea, a methodology that was critical for proof of angiogenic bioactivity of a given molecule in
vivo. His research also identified the existence of a family of angiogenic peptides, and he showed
that removing an angiogenic stimulus leads to regression of neovascularization.
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1.3.2. Tumor angiogenesis as a therapeutic target
Angiogenesis involvement in tumor progression has been around for 8 decades. It was in
1939, Ide et al. suggested that specific factors released by tumors could stimulate blood vessel
growth. Later in 1945, Algire and Chalkley showed that tumor induces high vasoproliferative
response and that tumor development is connected with vascular network. In 1956, Melwin and
Algire demonstrated that vasoproliferation of normal tissues and neoplastic tissues are very
similar, but stronger when implantation was performed in resection area. Tumor tissues also had
a long range in induction of neovascularization even when implanted 50 µM away, and this
could be attributed to the dynamics of growth factors in current date. Dr. Judah Folkman started
the extensive study on angiogenesis and established angiogenesis as a therapeutic target.

Figure 1.2. Schematic representation of angiogenesis inhibitor as a therapeutic target. "From [L. B. Rivera
G. Bergers, Tumor angiogenesis, from foe to friend. Science 349 (6249), 694-695 (2015)]. Reprinted with
permission from AAAS."
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1.4. Endogenous inhibitors targeting angiogenesis
1.4.1. Endostatin
Endogenous angiogenic inhibitors were well studied and documented. Endostatin is one
of the earliest documented and well-studied endogenous inhibitors among all the endogenous
inhibitors. Endostatin mechanistically differs with drugs targeting growth factors or their
receptors. But it has been observed by Abdollahi et al., that endostatin has an effect on over 10%
of genome in microarray. Endostatin has been approved in China as Endostar® but has not been
approved in the US or elsewhere as it failed in three independent clinical trials. Endostatin is a 20
KDa fragment cleaved from C-terminal of NC1 domain in collagen XVIII by elastase or
cathepsin L. Even though endostatin was one of the first endogenous inhibitors to be discovered
and studied, yet its mechanism has not been elucidated completely. Various proposed
mechanisms include binding to integrin αvβ3, αvβ5 and α5β1 in RGD sequence dependent
manner and causing cell cycle arrest in G1 phase. It also inhibits endothelial cell migration,
which could be due to interaction with α5β1 integrin, cell surface glypicans and the acting
binding protein, tropomyosin. It could also be due to G1 arrest in ECs, blocking activities of
MMP-2, 9 and 13, preventing VEGF isoforms binding to VEGFR, and stabilizing adhesion
junctions (Dhanabal, Ramchandran et al. 1999, Dixelius, Cross et al. 2002, Hanai, Dhanabal et
al. 2002, Kim, Hwang et al. 2002, Nyberg, Heikkila et al. 2003). The mechanisms of how
endostatin inhibits tumor angiogenesis remain elusive. Endostatin contains RGD motifs and is
known to associate with integrin αVβ3, αVβ5 and α5β1 (Wickstrom, Alitalo et al. 2002,
Sudhakar, Sugimoto et al. 2003). Cell surface glypicans and the actin-binding protein,
tropomyosin, are also possible receptors for endostatin (Sasaki, Larsson et al. 1999). Although
endostatin affects about 10% of genes in EC genome and induces EC apoptosis, endostatin does
not interfere with wound healing (Abdollahi, Hahnfeldt et al. 2004, Folkman 2006). Toxicities
have not been observed in animal models or in clinical settings. Four cancer patients with
continuous self-administration of a daily dose of endostatin for more than 3.5 years did not report
any side effects (Reviewed in (Folkman 2006)).

9

1.4.2. Tumstatin
Tumstatin is a 28 KDa cleaved fragment formed when MMP-9 cleaves NC1 domain of
the α3 chain of human type IV collagen. Like endostatin, tumstatin also acts through integrin.
Tumstatin is known to bind to αVβ3 integrin on two sites in an RGD sequence-independent
manner, thereby inhibiting the endothelial cell proliferation and inducing apoptosis. Tumstatin
inhibits FAK-phosphorylation followed by inhibition of Akt activation and eventually decreasing
cell proliferation. Tumstatin does not affect the migration of endothelial cells unlike endostatin.
The active residues possessing anti-angiogenic effects in tumstatin have been identified. Cterminal half of the protein has tumor cell cytotoxicity whereas N-terminal half possesses antiangiogenic effect. Tumstatin has been further shortened to peptides, T3 (amino acids 69-88) and
T7 (amino acids 74-98) and is located between N-terminal amino acid residues 54 and 132
(known as Tum-5). T7 is known to possess similar efficacy as entire Tumstatin in in vitro and in
vivo studies.
1.4.3. Thrombospondin-1
TSP-1 was the first endogenous inhibitor of angiogenesis to be identified. Each TSP-1
monomer is formed by an N-terminal globular domain, followed by the coiled-coil
oligomerization domain, a von willebrand factor type C procollagen domain, three properdin-like
type I repeats, two epidermal growth factor like type II repeats and a signature domain
comprising a third type II repeat, the calcium-binding wire-type III repeats, and the lectin-like Cterminal globular domain. Thrombospondin-1 affects ECs directly by interacting with specific
receptors. Fatty Acid Translocase (CD36) is known to be a receptor for TSP-1 through CLESH-1
domain. CD36 constitutively associates with β1 integrin and VEGF receptor 2 (VEGFR-2) in
ECs, thereby effecting integrins as well as growth factor signaling. TSP-1 is also known to
decrease neovascularization by inhibiting NO-cGMP signaling by interacting with CD47
(Integrin Associated Protein [IAP]).
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1.5. Non-matrix-derived endogenous angiogenesis inhibitors
1.5.1. Angiostatin
Angiostatin is an internal fragment of plasminogen protein. Upon proteolytic degradation
of plasminogen, various sizes ranging from 38 to 45 KDa of angiostatin have been identified. It
may contain either the first three (K1–3) or four (K1–4) kringle domains of plasminogen.
1.5.2. Pigment epithelium-derived factor
Pigment epithelium-derived factor (PEDF)/Serpin F1, is a 50 KDa multifunctional
glycoprotein secreted from human retinal pigmented epithelial (RPE) cells. PEDF initially was
identified to have neurotrophic activity in retina and cerebellar granule cells and induce neuronal
differentiation in retinoblastoma (Rb) cells. Dawson et al. showed PEDF as a potent anti
angiogenic protein. PEDF is known to decrease migration of endothelial cells and induce
apoptosis. PEDF predominantly inhibits VEGF induced neovascularization. PEDF has been
investigated as a therapeutic candidate for treatment of choroidal neovascularization, heart
disease, and cancer.
1.5.3. Anginex
Due to increased focus on endogenous anti-angiogenic peptides, Griffioen et al., studied
the potential reasons for their failure and went on to develop a potential anti-angiogenic peptide
(Griffioen, van der Schaft et al. 2001). They have developed a series of 33 amino acid
polypeptides with parallel amphipathic β-sheets. Among the peptides designed, βpep 25 possess
the maximum efficacy in inhibiting angiogenesis in vitro and in vivo. These β sheet peptides are
inspired from PF4, IL8 and BPI (bactericidal permeability increasing protein) (Dings, Arroyo et
al. 2003, Dings, Chen et al. 2006, Dings, Kumar et al. 2013). Even though the mechanism of
anginex is not completely elucidated, based on the research performed by Dings, et al., it is
believed that it acts through Galectin-1. Anginex upon binding to galenctin-1 significantly
increases its affinity for certain ligands, including biologically relevant glycoproteins. Anginex
forms aggregates (dimers and larger aggregates), which could be due to galectin-1. Anginex
induces ECs apoptosis in vitro and inhibits tumor growth in xenograft mice models. From the
NMR studies, it is deduced that β-sheet structure is the bioactive form of anginex. A detailed
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study showed that the SVQMKL and IIVKLN of N and C- terminal are critical for the antiangiogenic activity (Griffioen, van der Schaft et al. 2001, van der Schaft, Dings et al. 2002,
Dings, Yokoyama et al. 2003, Mayo, Dings et al. 2003).
1.6. Endogenous anti-angiogenic peptides, why did they fail?
None of the endogenous angiogenesis inhibitors have made their way to the clinic and the
drugs approved mostly target pro-angiogenic signaling pathways (growth factor receptors
[VEGF, FGF or EGF]). Endogenous peptides are the cleaved fragments of ECM derived proteins
due to their composition and the solubility and shelf life of these proteins is very low. To
summarize, even though there are several endogenous proteins or peptide based drugs, they
could not transition from laboratory to clinic due to their lack of efficacy and weak
pharmacological properties, such as solubility, shelf-life etc. A few managed to enter clinical
trials but failed in efficacy studies in phase II and phase III.
1.7. Fibrosis in physiology and pathology
1.7.1. Fibrosis
Excessive tissue scarring, also known as fibrosis, is one of the most common features in
most of the chronic diseases associated with epithelial organs, especially lung, liver, skin, and
kidney. Each organ is unique in its function and so is the cell type that forms the organ, which
maintains the entire normal physiology of animal. The normal functional tissue is replaced with
collagen-rich scar tissue and the deposition of this collagen leads to the architectural distortion.
Retraction of the collagen fibers is a major factor associated with progressive loss of organ
function and eventual failure. There are however, certain core features shared by pathological
fibrosis in all these organs. Diseases associated with fibrosis have been overlooked largely;
instead they constitute about 45% of industrialized deaths. Understanding the pathological
fibrosis so far was based on a narrow purview of how tissues accumulate collagen and other
ECM components in response to tissue injury. Therefore, a deeper understanding of the
molecular pathways resulting in fibrosis progression will subsequently lead to better therapeutic
interventions.
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Figure 1.3. Events in fibrosis progression and regression.
Representation of the common events in progression and regression of fibrosis across various
tissues such as lung, kidney and liver. "From [S. L. Friedman, D. Sheppard, J. S. Duffield, S.
Violette, Therapy for fibrotic diseases: Nearing the starting line. Sci. Transl. Med. 5, 167sr1
(2013)]. Reprinted with permission from AAAS."

13

1.7.2. Properties of the fibrotic ECM
In healthy organs, ECM proteins are concentrated in the basement membrane between
epithelial cells and endothelial cells that provide structural support. ECM in basement membrane
is mainly composed of type IV collagen, laminins, and a mixture of proteoglycans. However, in
pathological conditions, this composition and location of ECM is distinctly altered. Type I and
III collagens are most abundant matrix proteins in fibrotic tissues, but there is also a significant
increase in fibronectin, osteopontin, hyaluronan, and proteoglycans. The secreted collagen differs
from normal collagen as it is extremely crosslinked and forms physically integrated structures,
which displace and distort the architecture of normal tissue. In thin sections, it may seem like
collagen accumulation is discrete, 3D structures indicate that collagen networks extend through
entire fibrotic region (fibroblast foci). The abnormal fibrotic ECM alters behavior of both
resident cell and pathologic myofibroblasts along with tissue distortion. For instance, tissue
fibronectin signaling helps in transdifferentiation of HSCs into myofibroblasts (Jarnagin, Rockey
et al. 1994) and facilitates EMT of lung epithelial cells (Kim, Kugler et al. 2006).
Tissue resident fibroblasts are very responsive to tissue stiffness, which is affected in
both normal and pathologic cellular responses. They remain quiescent when plated on or within
matrices with stiffness resembling that of healthy organs, but undergo differentiation to form
myofibroblasts when plated on stiff matrices, mimicking conditions of fibrotic organs (Wells
2005, Huang, Yang et al. 2012). Increased tissue stiffness stimulates resident fibroblast
proliferation (Mih, Sharif et al. 2011) and facilitates TGF-β activation by integrin. The degree of
stiffness of substrate can activate TGF-β in fibroblasts or epithelial cells, as on a low stiffness
surface, these cells cannot generate sufficient force for TGFβ activation. A positive feedback
loop is generated through fibrosis-induced tissue stiffness, which further enhances ECM
accumulation; and targeted reduction of stiffness may break this cycle. Modifications in the actin
cytoskeleton due to increased tissue stiffness occurs in many cell types, which increases the size
and number of focal adhesion signaling complexes, which in turn enhances signaling through
integrin and receptors that concentrate in these structures (Levental, Yu et al. 2009). An
approach to reduce stiffness is allosteric antibody inhibitor of LoxL2, one of the enzymes
responsible for collagen crosslinking, could potentially inhibit pathologic fibrosis of lung and
liver in animal models and it is therefore being tested for pulmonary fibrosis in clinic (Barry14

Hamilton, Spangler et al. 2010). The mechanistic effect of this drug is yet to be evaluated since
LoxL2 also interacts with Snail1 to deaminate a specific lysine residue in histoneH3, by
facilitating Snail-mediated transcriptional regulation. Regardless of its mechanism, antagonism
of LoxL2 has emerged as an appealing antifibrotic strategy.

Figure 1.4. Figure depicts fibrosis development in response to injured epithelium. "From [S. L. Friedman,
D. Sheppard, J. S. Duffield, S. Violette, Therapy for fibrotic diseases: Nearing the starting line. Sci.
Transl. Med. 5, 167sr1 (2013)]. Reprinted with permission from AAAS."

1.7.3. Epithelial injury and dysfunction
Tissue injury initiates and endures progressive fibrosis. The responses to injury-induced
physical or functional damage of epithelial cells can provoke tissue fibrosis as mentioned below.
(a) Cell death (Necrosis or apoptosis), is a consequence of tissue injury (Fiers, Beyaert et al.
1999). It is not well understood how epithelial injury directly initiates fibrotic pathways in
fibroblasts and there is no specific marker indicating that injury has been enough to induce tissue
fibrosis, (b) Dysregulation of cellular metabolic pathways results in cell stress and activation.
Cellular and tissue injury alters the tissue microenvironment and effects microperfusion, oxygen,
nutrient delivery, pH maintenance, and toxin clearance. Cells while responding to hostile
environment and intracellular stress responses have enhanced cell survival. In a normal healthy
state, this insult to the tissue results in cell death, whereas in case of chronic diseases, stress
responses are continuously activated due to cell survival adaptation responses that secrete
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various pro-inflammatory cytokines, chemokines, and other factors that stimulate myofibroblasts
and their precursors promoting cell survival (Lawson, Cheng et al. 2011). Endoplasmic reticulum
(ER) stress or the unfolded protein response is a defensive mechanism that can reduce the
consequences of accumulated poorly folded or unfolded proteins (Hetz 2012). Certain secretory
cells, such as pancreatic β cells, type 2 alveolar epithelial cells, and hepatocytes, may be
susceptible to ER stress because of the protein transiting the ER in these cells in large amount.
For instance, mutations in two main secretory products of alveolar epithelial cells, such as
surfactant proteins A (Maitra, Wang et al. 2010) and C (Thomas, Lane et al. 2002, Mulugeta,
Nguyen et al. 2005), cause disease in families with dominantly inherited pulmonary fibrosis as
these mutations impair protein folding and provoke ER stress (Whitsett 2002, Mulugeta, Nguyen
et al. 2005). Likewise, alteration of cells triggered by injury such as epithelial-to-mesenchymal
transition (EMT) and secretion of growth factors or cytokines, generates a discrete pattern of
gene expression changes that parallels a similar process, which occurs during normal
development (Zeisberg, Yang et al. 2007, Kalluri 2009). During EMT, genes are upregulated by
transcription of Twist and Snail and there is downregulation of epithelial surface markers such as
E-cadherin. Twist- and Snail-driven cellular reprogramming is known to contribute to tissue
fibrosis, although it is not yet completely understood. Loss of Snail in hepatocytes protects mice
from CCl4 induced liver fibrosis (Rowe, Lin et al. 2011). Transforming growth factor-β (TGF-β),
a major inducer of fibrosis, induces EMT markers partially through induction of Twist and Snail
expression. Loss of TGF-βR II protects mice from bleomycin-induced lung fibrosis, although the
EMT alone is not considered as an important source of fibrogenic cells. The last and most
common epithelial response to injury involves the interactions between TGF-β and integrin.
TGF-β is the most profibrogenic growth factor secreted by nearly all cells and organs in
mammals and excessively stored in ECM in a chemically crosslinked form. TGF-β is secreted as
a homodimer in association with N-terminal cleavage fragment that forms a disulfide bridge.
This cleavage fragment is called the latency-associated peptide (LAP), and a shorter C-terminal
fragment is an active cytokine. LAP is also linked to members of another protein family (the
latent TGF-β binding proteins) through disulfide bridges, which are cross-linked to ECM
proteins through an extracellular enzyme, tissue transglutaminase (Munger, Harpel et al. 1997).
Upon tissue injury, epithelial cells in the lung, kidney, biliary tract express high levels of the
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integrin αVβ6 and liver, pancreas express high levels of αVβ3 which bind to LAP fragment of
latent TGF-β1 and TGF-β3 (Breuss, Gillett et al. 1993, Munger, Huang et al. 1999, Annes,
Rifkin et al. 2002, Giacomini, Travis et al. 2012).
1.7.4. Sources of fibrogenic cells
Resident mesenchymal cells are the major source of myofibroblasts. Stromal cells are
prominent during organogenesis as they are in a loose matrix (stroma). Stromal cells are
mesenchymal cells that perform critical functions during organ formation, patterning and
maturation. Development of microvasculature requires stromal cells to stabilize vessels
(pericytes). Stromal cells use Wnt, PDGF, FGF, EGF, VEGF, TGF-β superfamily members,
hedgehog, notch, ephrins, and angiopoietins during development to regulate critical functions
(Yu, Carroll et al. 2009, Yin, Wang et al. 2011). The knowledge about stromal or mesenchymal
cells is very less, even though these cells represent around 5-6% of the entire cell population in
adult organs and are known to play a critical role in organ development, homeostasis,
physiology, and repair. Depending on the context, mesenchymal cells are commonly known as
fibroblasts if embedded in stroma between organ units, or mural cells, Rouget cells, perivascular
cells, pericytes, or pericytes-like cells when attached to the microvasculature (Armulik,
Abramsson et al. 2005, Schrimpf and Duffield 2011). Fibrosis origin has been in question for
decades but most of the data now points towards the myofibroblast or fibroblasts activated by
physiological or pathological stimuli. Fibroblasts were originally discovered in wounded skin
and contractures commonly known as “wound fibroblasts” and are known to express contractile
proteins which are commonly seen in smooth muscle cells and in virtual spaces between the
organ structures (Gabbiani and Majno 1972). These fibroblasts have dense rough ER, lack
lysosomal vacuoles, and have intermediate filaments (desmin, vimentin, and αSMA).
Myofibroblasts express high αSMA in all diseased organs and generate interstitial or fibrillar
matrix composed of type I and III collagen (Skalli, Schurch et al. 1989, Lin, Kisseleva et al.
2008, Taura, Miura et al. 2010). Many organs have related but distinct resident cell types that
form myofibroblasts. In normal liver, resident HSCs have long perisinuoidal processes and
contain lipid droplets to store vitamin A. HSCs are located in the space of Disse between hepatic
sinusoids and the brush border hepatocytes. Many laboratories have demonstrated in various
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models of liver diseases that HSCs are the primary source of myofibroblasts in vivo in a number
of liver diseases, although a rarer population of portal fibroblasts also contributes to the
myofibroblast population in models of biliary disease (Chu, Diaz et al. 2011, Kisseleva and
Brenner 2012). Pancreatic stellate cells and intestinal fibroblasts are similar to those in liver,
which get activated upon tissue injury.
Cellular activation refers to activation of resident mesenchymal cells, such as stellate
cells into myofibroblasts in response to tissue injury and the pathways underlying the
pathological activation are similar to that of their embryonic development. At times, tissue
recapitulates their developmental processes in order to regenerate the damaged tissue (Boulter,
Govaere et al. 2012). These uncontrolled developmental pathways during chronic injury often
promote fibrosis rather than restoring the normal structure due to dysregulated signaling (Hecker,
Vittal et al. 2009). The proclivity of fibrosis can be both genetically and epigenetically regulated.
Zeybel et al. showed that myofibroblasts in liver were able to induce heritable epigenetic
changes (through a secreted factor that affects sperm) that attenuate fibrogenesis in the offspring,
suggesting that transmission of fibrosis propensity can be both epigenetic and genetic (Zeybel,
Hardy et al. 2012). Myofibroblasts activation is a true cellular transdifferentiation event as
transcriptomic analyses from HSCs activation and other recent functional studies suggest that
myofibroblasts have lost the homeostatic properties of pericytes or resident fibroblasts from
which they were differentiated through epigenetic regulations such as DNA methylation. It is
also possible to believe that fibrosis can also be a state of pericyte deficiency as they are
differentiated to myofibroblasts, undermining the cellular homeostasis beyond matrix deposition
(Schrimpf and Duffield 2011). Even so, phenotype plasticity is preserved at least in HSCs as
some evidences show that HSCs can be reverted back to normal stellate cells (Kisseleva, Cong et
al. 2012, Troeger, Mederacke et al. 2012).
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Figure 1.5. Mechanisms by which injury to the epithelial tissue can lead to fibrosis. "From [S. L. Friedman,
D. Sheppard, J. S. Duffield, S. Violette, Therapy for fibrotic diseases: Nearing the starting line. Sci. Transl.
Med. 5, 167sr1 (2013)]. Reprinted with permission from AAAS."
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1.8. Liver Fibrosis
Fibrosis is often associated with aberrant wound healing. It is a response in the damaged
tissue, which is characterized by the accumulation of extracellular matrix (ECM). In case of
acute hepatic injury, hepatic fibrosis generates a temporary scar at the site of injury to protect the
liver from further damage, followed by restoration of the tissue. However, in chronic liver injury,
accumulation of ECM persists, eventually substituting liver parenchyma with mesenchyme and
leading to the formation of a thick scar. Fibrosis of liver gradually leads to liver cirrhosis, which
has high mortality, as the fibrotic liver cannot be reversed. Unchecked wound healing is a
complication leading to the buildup of excessive connective tissue in an organ. Accumulation of
ECM can either be due to excess synthesis of matrix proteins (collagens, proteoglycans, and noncollagenous glycoproteins) or inefficient degradation or both.
Hepatic fibrosis itself causes no potential symptoms but it often leads to portal
hypertension (the scarring distorts blood flow through the liver) or cirrhosis (the scarring results
in disruption of normal hepatic architecture and liver dysfunction). Diagnosis is based on the
liver biopsy. Hepatic fibrosis can be due to autoimmune hepatitis, genetic errors in metabolism
(α1-Antitrypsin deficiency, copper storage diseases (e.g., Wilson disease), fructosemia,
galactosemia, glycogen storage diseases (especially types III, IV, VI, IX, and X), iron-overload
syndromes (hemochromatosis), lipid abnormalities (e.g. Gaucher disease), peroxisomal disorders
(e.g. Zellweger syndrome), Tyrosinemia), congenital hepatic fibrosis, infections [bacterial (e.g.
brucellosis), parasitic (e.g. echinococcosis), viral (e.g. chronic hepatitis B or C)], nonalcoholic
steatohepatitis (NASH), primary biliary cirrhosis, primary sclerosing cholangitis. Treatment
involves correcting the underlying condition when possible. Simultaneous use of anti-fibrotic
drugs may prove to be more beneficial rather than just targeting the condition. Current treatments
include corticosteroids, penicillamine, which are being used to reverse fibrosis, are usually too
toxic for long-term use and also have no proven efficacy. Other anti-fibrotic treatments are under
study. Silymarin, present in milk thistle, is a popular alternative medicine used to treat hepatic
fibrosis, as it appears to be safe but lacks efficacy.
Liver fibrosis is one of the complications of chronic liver diseases, characterized by an
excessive synthesis and persistent deposition of ECM, which mainly consists of collagens,
proteoglycans, and non-collagenous glycoproteins. Chronic damage induced by viruses,
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autoimmunity or toxins such as alcohol, initiates a wound healing response that results in hepatic
fibrosis and cirrhosis. HSCs and myofibroblasts are the fibrogenic effector cells, which
proliferate and produce excessive amounts of ECM on activation. This process is unbalanced by
fibrolysis, which ultimately leads to the formation of a thick scar. Alteration of balance between
liver fibrogenesis and fibrolysis, tipping in favour of fibrolysis, and developing safe and
efficacious antifibrotic treatment for patients with chronic liver diseases still remains a challenge.
Persistent ECM deposition in the space of Disse results in the loss of normal fenestrations of the
endothelial lining, which impairs the normal metabolic exchange between hepatocytes and portal
venous flow. ‘Capillarization of the sinusoids’ is the term given to this process. Different forms
of fibrosis progression have been defined on the basis of their etiology, major fibrogenic
mechanisms, fibrogenic cells source, and the region of injury (e.g. portal or central). Chronic
viral hepatitis B and C are the major causes of bridging fibrosis, which is characterized by
interface hepatitis and portal-central vein bridging necrosis, resulting in portal-central fibrotic
septa formation. Perisinusoidal or pericellular fibrosis is mainly found in alcohol-related and
nonalcoholic fatty liver disease. Alcohol-related fibrosis is characterized by deposition of ECM
in the space of Disse around hepatocytes or sinusoids. Biliary fibrosis incorporates the
proliferation of bile ductules and periductular myofibroblasts (MF), which leads to the formation
of portal-portal fibrotic septa surrounding liver nodules. Conditions that alter venous outflow are
the main cause of centrolobular fibrosis, which is characterized by central-central fibrotic septa.
Sustained fibrogenesis and progression of liver fibrosis leads to cirrhosis, which is
characterized by perturbation of the liver function and distortion of parenchyma and vascular
architecture. The major pathological feature of cirrhosis is the formation of nodules of
regenerative parenchyma surrounded by fibrotic septae, which may incorporate terminal hepatic
venules and portal tracts when the nodules are especially large (i.e. macronodular cirrhosis). It
often leads to porto-systemic shunts and venous occlusion, resulting in liver function impairment
and portal hypertension. The formation of vascularized fibrous septa that link portal tracts and
central veins is stimulated by angiogenesis and contributes to porto-systemic shunting that
bypasses the liver parenchyma. Progression to cirrhosis confers a risk of mortality and morbidity
owing to the asymptomatic feature of hepatic fibrosis. Cirrhosis is the most common
nonneoplastic cause of mortality in the US amongst the digestive diseases.
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1.9. Liver Sinusoidal Endothelial cells (LSEC) Sinusoidal Endothelial Fenestrae
Steffan et al. provided the first evidence of LSEC fenestrae as the inducible structures in
1986(Steffan, Gendrault et al. 1986). In situ and in vitro treatment of LSEC with cytochalasin B,
a microfilament-inhibiting drug, resulted in an increased number of fenestrae, which was
attributed to the alteration of cytoskeleton. This observation came into light when detergenttreated LSEC were observed under scanning electron microscope. Interestingly, this effect of
cytochalasin B on the cytoskeleton and increased number of fenestrae could be reversed on drug
removal. However, treatment of LSEC with a microtubule disrupting agent, colchicine, had no
effect on the number of fenestrae, which indicates that microtubules do not form endothelial
pores. These observations suggest the dynamic nature of fenestrae that may undergo changes in
response to the external stimuli, suggesting the major role of actin-cytoskeleton in this process.
Later, Bingen et al. observed in freeze-fracture replicas of LSEC treated by cytochalasin B that
areas which were devoid of intramembrane particles have size of the fenestrae. They proposed in
general, that opposite sheets of plasma membrane, which are depleted of intramembrane particles
fuse to form fenestrae. These authors proposed the process of fenestrae formation in the
following sequence: 1) it begins with the intramembrane particle depletion in small areas, 2)
followed by an encirclement of those zones by a microridge lacking intramembrane particles, 3)
later, membrane fusion occurs with simultaneous appearance of small pores inside the marked
zones, and 4) ultimately, there is an increase in the pore size leading to the formation of fenestra
and the microridge disappears gradually. Subsequently, Taira, who found some new evidence
about the formation of sieve plates, elaborated this hypothesis. Trabecular meshworks, which
appear as sieves on the cell membrane are attached to the P and E-faces of the cell body and
diminished cell processes were noticed while studying the luminal cell membrane of freezefractured LSEC (Taira 1994). Trabecular meshworks are basically a reticulum of anastomosing
trabeculae attached to the cell membrane and they are comprised of cytosol and cell membrane.
Taira hypothesized following events in the formation of sieve plates: 1) the process initiates with
invaginations in plasma lemma in response to external stimuli, 2) it further strengthens by rapid
clustering of the cell membrane invaginations leading to fusion and ballooning of these
invaginations by some mechanism, which still remains elusive, 3) consequently, the cytosol
found among the invaginations of plasmalemma turns thinner and remains as anastomosing
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trabeculae in these trabecular meshworks, 4) finally giving rise to the sieve plate formation by
flattening (Taira 1994).
Fenestrae also have a role in lipoprotein metabolism. Dietary fats when absorbed by
small intestine form chylomicrons upon their assembly with specific apolipoproteins and have a
size ranging from 100 to 1000 nm. After being synthesized by enterocytes, the chylomicrons rich
in triglycerides are secreted into the extracellular fluid and mesenteric lymph to ultimately enter
via thoracic duct to the systemic circulation. In circulation, hydrolysis of triglycerides into fatty
acids occurs in the adipose tissue capillaries and muscles by lipoprotein lipase present on
capillaries endothelium. The resulting particles of diameter 90-250 nm are chylomicronremnants, which are absorbed instantaneously by apo E receptors of liver parenchyma. Uptake of
chylomicron remnants requires them to pass through space of Disse through fenestrated
sinusoidal endothelium. It was earlier postulated by Wisse that fenestrae might play a vital role
in the lipid particle exchange between the parenchymal cells and sinusoidal blood. Fraser and coworkers further elaborated this hypothesis, demonstrating a filtration effect by comparing
chylomicrons in the space of Disse with those in the portal blood, indicating that such large
particles in the space of Disse were as large as fenestrae(Wisse, De Zanger et al. 1985, Fraser,
Day et al. 1986, Fraser, Dobbs et al. 1995).
1.10. HSCs and Sinusoidal Remodeling in Portal Hypertension and Cirrhosis
In cirrhosis, the syndrome of portal hypertension occurs in large part due to changes in
hepatic resistance. It has been elucidated by Ishak et al. that sinusoidal vasoconstriction
generates portal hypertension as activated HSCs operate as “contractile machinery” and
mechanics are regulated by nitric oxide. HSCs role as a regulator of vascular tone in normal liver
is yet to be established, but its vasoconstrictive function has a significant role in cirrhosis and
portal hypertension. Vasoactive agents such as carbon monoxide and endothelin result in the
change in sinusoidal diameter at places where HSCs reside. Other studies have also mentioned
that these vasoregulatory changes occur outside hepatic sinusoids (Ogawa 1982, Ito, Yamamoto
et al. 1983, Ogawa, Itoshima et al. 1984, Ishak, Zimmerman et al. 1991).
In cirrhosis, there is enhanced sinusoidal lumen coverage and HSCs density. The
increased coverage of sinusoidal vessels by HSCs and the contractile nature of HSCs will likely
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result in sinusoidal remodeling, that would eventually lead to a high resistance and constricted
sinusoidal vessel. The process at a cellular level involved in the active assembly of contractile
machinery around the sinusoidal channel in a fashion to generate vasoconstriction is still
unknown. However, enhanced motility and migration of HSCs play a very prominent role in
promoting enhanced coverage of HSCs around the sinusoids. Recent evidence at a cellular level
illustrates that changes in membrane structures of HSCs promote their migration and motility,
which are essential for sinusoidal remodeling. Although the role of TGF- in collagen deposition
by HSCs has been elucidated in various studies, a crosstalk between TGF- and PDGF is highly
significant in HSCs motility. In fact, these signals may converge at c-abl tyrosine kinase level.
Compound such as imatinib, which inhibits both of these pathways, has demonstrated limited
vascular remodeling in lungs, further suggesting that these pathways may be involved in hepatic
sinusoidal remodeling. Therefore, inducing HSCs apoptosis may prevent excessive sinusoidal
remodeling in portal hypertension.
Both advanced fibrosis and cirrhosis present models of HSCs behavior that show
similarities with the behavior of pericytes. In the first model, fibrosis development and its fast
resolution, HSCs get activated to become myofibroblasts. These cells are involved in the
remodeling of sinusoids and eventually secrete fibrillar collagen-rich matrix resulting in
perturbation of liver structure and function in advanced fibrosis. Various animal model studies
have demonstrated that spontaneous resolution of fibrosis is accompanied by matrix degradation
and HSC apoptosis. This process is therefore involved in the remodeling of the sinusoids,
returning them to the normal architecture, which may also require macrophages.
In more advanced cirrhosis, a further form of remodeling of sinusoids occur, wherein
dense fibrils linking vascular structures undergo remodeling and angiogenesis occurs. The scars
contain activated HSCs, also called the myofibroblasts. Interestingly, a comparison between a
less mature scar and a mature scar in cirrhotic liver elucidates that cells in the mature scar
express glial fibrillary acidic protein and desmin, which are the markers associated with HSCs.
They express these markers in the absence of smooth muscle actin, thereby illustrating their
association with HSCs than with myofibroblasts. Currently, the pathogenesis of remodeling
within fibrotic bands is not well defined, although their roles in hypoxia, as a potent stimulus for
VEGF secretion by HSCs, have been implicated in some models.
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In summary, HSCs share many phenotypic and anatomic similarities with pericytes in
other locations. This is paralleled by the vital role of HSCs in the fields of vascular remodeling
and angiogenesis, which are fundamental processes in cirrhosis/portal hypertension and liver
tumor angiogenesis.
1.11. Myofibroblast apoptosis
Myofibroblasts formed from HSCs are the source of ECM accumulation in liver.
Apoptosis of myofibroblasts is the final step of wound healing process. NF-κB signaling
regulates the balanced expression of survival and apoptosis genes. Studies from various reports
have concluded that the regulation of survival pathways is the key factor in inducing apoptosis.
Overall 2240 genes are differentially expressed upon HSC activation, which includes genes in
apoptotic pathways as well. These altered gene expression switching the cell from survival to
apoptotic mode remains a critical event in clearance of activated myofibroblasts upon wound
healing. Further studies have to be performed to elucidate the complete mechanism of regulation
of myofibroblasts during and after wound healing. The following survival pathways have been
extensively studied to induce apoptosis in myofibroblasts and hence their clearance during
fibrosis. Myriad studies have explored the underlying mechanisms that regulate switching of
myofibroblasts from survival to apoptotic mode, which is critical for the fibrosis resolution. For
instance, NF-κB prevents apoptosis by expressing anti-apoptotic Bcl-2 and suppressing
activation of p53 induced by JNK, thereby inhibiting PUMA and Bax expression. NF-κB
signaling regulates inflammation, wound-healing responses, innate and adaptive immunity and
cell survival. Five subunits of NF-κB, such as p50, p52, p65, ReIB, and cReI usually form
dimers that function as transcription factors. Hence, NF-κB plays a vital role in preventing
apoptosis of myofibroblasts, therefore detailed summary of its signaling is important. Canonical
and non-canonical pathways are the two signal transduction pathways that regulate the activation
of NF-κB. In the canonical pathway, NF-κB is the heterodimer p65:p50 that remains bound to its
inhibitory protein, IκBα in the cytoplasm. Several activators such as TNF-α, LPS can
phosphorylate IκBα, hence allowing its removal from the dimer, making NF-κB transcriptionally
active and permitting its translocation to the nucleus to initiate transcription. To prevent
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persistent NF-κB activation, NF-κB binds to its cognate promoters and as an auto regulatory
mechanism, it induces the expression of IκBα. NF-κB proteins are expressed in quiescent HSCs.
Activation of stellate cells to fibroblasts involves increase of transcriptionally active NFκB and this expression involves change in gene expression, which i) confers resistance to
apoptosis, ii) induces expression of pro-inflammatory genes IL-6, IL-8, MCP-1 and ICAM1, iii)
NF-κB increases the expression of pro-fibrotic genes (Rajendran, Li et al. 2012, Tergaonkar
2016).
During cellular activation, transcriptionally active NF-κB levels increase drastically,
which is important for two reasons: i) it induces the expression of pro-fibrotic genes and proinflammatory genes (MCP-1, IL-6, ICAM1 and IL-8), and ii) it confers apoptosis resistance.
Despite the auto regulatory ability of NF-κB to induce the expression of the IκBα gene, HSC
activation is associated with the suppression of IκBα that is mediated by CBF1 and MeCP2,
which are transcriptional repressors. There are other molecules that are implicated in
myofibroblast survival and apoptosis. For example, FXR stimulates apoptosis by inducing short
heterodimer partner, a nuclear receptor that interacts with JunD, and prevents FXR from binding
to the TIMP-1 promoter.
C/EBPβ is phosphorylated at threonine 127 by RSK, a regulatory molecule, which
activates caspase-8 and induces apoptosis. Endogenous cannabinoids can act on CB1 or CB2
receptor, and therefore stimulate or inhibit liver fibrosis. CB1−/− mice are resistant to fibrosis
induced by thioacetamide, CCl4, or bile duct ligation, and they exhibit high myofibroblast
apoptosis. Also, CB2 receptor stimulation results in myofibroblast apoptosis due to intracellular
oxidative stress.
Nerve growth factor, a neurotrophin, is also known to induce apoptosis in human
melanocytes by inhibiting NF-κB. NGF receptor belongs to TNF superfamily and can signal
downstream apoptosis. HGF suppresses PDGF-induced proliferation and promotes apoptosis of
human melanocyte in vitro and in vivo studies.
1.12. Integrin TGF-β crosstalk
Integrin-TGF-β crosstalk is found to be crucial for the development and pathogenesis of
fibrosis. The expressions of integrin α1β1 and α2β1 induced by TGF mediate myofibroblast
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contraction and collagen remodeling. Additionally, the integrin α3β1, αVβ5 and αVβ6 control
TGF-β signaling in fibrosis. The importance of integrin-TGF- interplay was highlighted by an
observation that the mice lacking β6-subunit were protected from bleomycin-induced pulmonary
fibrosis. The significance of αVβ6 for fibrogenesis has been elucidated thereafter in various
models. αVβ6 is not expressed normally in healthy epithelia; however, its expression is induced
in many human fibrotic disorders in the kidney, for example, diabetes mellitus, progressive
fibrosing glomerulonephritis and Alport syndrome, the liver (acute biliary fibrosis) and the lung
(sclerosis and idiopathic pulmonary fibrosis (IPF). In mice, αVβ6 constitutive expression in the
basal layer of the epidermis leads to increased activation of TGF-β1 and spontaneous chronic
ulcers development with severe fibrosis (Munger, Huang et al. 1999, Henderson and Sheppard
2013). On the contrary, β6 knockout mice are protected partially or completely from pulmonary
fibrosis induced by radiation, tubuleinterstitial fibrosis as a response to kidney obstruction, or
acute biliary fibrosis caused by bile duct ligation. In wild-type mice, treatment with TGF-
antagonists or αVβ6 antibody can inhibit fibrosis. However, inhibiting TGF- pathway has
serious adverse effects, such as autoimmunity development, therefore inhibition of αVβ6induced TGF-β activation at sites of injury could be a promising therapeutic target against TGFβ-mediated fibrosis. Additionally, it has been shown that low doses of antibodies against αVβ6
prevent radiation-induced or bleomycin-induced pulmonary fibrosis in mice, without causing
inflammation. Other integrins, which are not much focused, are αVβ3, αVβ5 and αVβ8 because
these integrins are thought to contribute to pathogenesis of scleroderma upon TGF-β activation.
Based on various observations, it is believed that integrins such as αVβ3, αVβ5 and αVβ8
provide additional therapeutic targets for this pathology. As already mentioned, αVβ3 and αVβ5
are thought to contribute to the pathogenesis of systemic sclerosis and scleroderma upon TGF-β
activation. In human fibrotic lungs, epithelial cells expressing αVβ5 co-localize with
myofibroblasts, and blocking αVβ5 reduces TGF-β-mediated pulmonary fibrosis in a mouse
model. Additionally, αVβ8 induced TGF-β activation can stimulate the differentiation of airway
fibroblasts into myofibroblasts, and the expression of αVβ8 is elevated in the airways of chronic
obstructive pulmonary disease patients. However, the importance of αVβ8 in this process has not
been supported by knockout or targeting studies. α3β1 also contributes to the development of
idiopathic pulmonary fibrosis (IPF) through a β-catenin–Smad2-dependent mechanism. In IPF,
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EMT derives a subset of differentiating fibroblasts initially from alveolar epithelial cells. The
deletion of lung-specific α3-subunit in a mouse model of IPF reduces accumulation of
myofibroblast, deposition of collagen, EMT-associated genes expression and progression to
fibrosis, further implicating that blocking α3β1 could also be an effective therapeutic target
against fibrosis(Sheppard 2001, Xu, Porte et al. 2009, Friedman, Sheppard et al. 2013,
Henderson, Arnold et al. 2013, Reed, Jo et al. 2015, Sheppard 2015).
1.13. Therapies for Fibrosis
In the last two decades, several clinical trials have been performed in the area of fibrosis
but none could reach primary endpoint (Cohen-Naftaly and Friedman 2011, Datta, Scotton et al.
2011). Although there is a limited success in treatment of fibrosis, more promising results are
expected in future clinical trials. Due to extensive studies performed in animal models, we have
considerably more insight into shared and unique molecular pathways that cause fibrosis in
various organs. Unraveling the mechanisms of fibrosis has augmented the development of
various therapies in clinic. More than 50 drugs are in development for targeting fibrosis (CohenNaftaly and Friedman 2011, Datta, Scotton et al. 2011, Kisseleva and Brenner 2011, Wynn and
Ramalingam 2012) and below are some of the examples of different pathways targeted, which
are being tested in clinical setup due to their unique advantages.
1.13.1. TGF-β pathway
TGF-β pathway and its role in initiation, maintenance of fibrosis in many fibrotic
diseases is known for more than 2 decades. Its role is well demonstrated in in vitro and preclinical setup that shows TGF-β to be a promising target in order to halt fibrosis. However, the
role of TGF-β in homeostatic activities such as immune regulation, tumor suppression, the
design of clinical study has been challenging, considering the adverse effects (Varga,
Rosenbloom et al. 1987, Roberts and Sporn 1989, Eickelberg, Kohler et al. 1999, Bierie and
Moses 2006, Li, Wan et al. 2006, Hawinkels and Ten Dijke 2011). GC1008® (Genzyme), a
humanized monoclonal antibody that blocks TGF-β1, TGF-β2, and TGF-β3 is being evaluated in
multiple clinical trials for fibrosis and cancer (attenuating signaling pathways between stroma
that enhance neoplastic growth). GC1008 was well tolerated in patients with advanced focal
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segmental glomerular sclerosis, scleroderma patients (ClinicalTrials.gov NCT01284322).
LY2382770® (Lilly), another humanized monoclonal antibody that selectively binds and inhibits
TGF-β1 cytokine, is currently undergoing phase 2 trial with multiple dosing in patients with
chronic kidney disease (ClinicalTrials.gov NCT0113801).
1.13.2. αVβ6 integrin
Another selective approach in blocking TGF-β pathway is to target αVβ6 integrin. αVβ6
integrin is expressed at very low levels in adult tissues, but is highly upregulated in epithelial
cells in response to tissue injury and fibrosis (26, 27). STX-100 (Biogen Idec), a humanized anti
αVβ6, prevents its binding from latent TGF-β, which locally inhibits TGF-β pathway, and is
currently being evaluated for phase 2 trial in IPF patients (ClinicalTrials.gov NCT01371305).
This trial also provides the potential biomarker strategy, as the efficacy of STX-100 can be
measured in the lungs by monitoring pSMAD2 levels and TGF-β regulated genes in
bronchoalveolar lavage (BAL) cells.
1.13.3. LPA1 (LPA receptor)
Due to its wide prognostic activities, LPA1 in fibrotic condition makes it a very attractive
and promising molecule to target. LPA1 is widely expressed in fibrosis and it is known to play a
pathogenic role in tissue injury and fibrosis in murine models(Tager, LaCamera et al. 2008,
Castelino, Seiders et al. 2011). LPA1 is known to promote fibroblast migration, resistance of
fibroblasts to apoptosis, vascular leak, and epithelial apoptosis, which are common prognostic
events in IPF. AM152 (Amira Pharmaceuticals), a small-molecule antagonist of the LPA1
receptor has protective effects in a mouse model of skin fibrosis. This drug is currently tested as
BMS-986202 (Bristol-Myers Squibb) and has completed phase I healthy volunteers trial
(Castelino, Seiders et al. 2011).
1.13.4. IL-4 and IL-13 inhibitors
IL-4 and IL-13 cytokines are important mediators of innate immune activation and Th2
cell responses (reviewed in detail). They play a significant role in regulation of fibrosis in several
preclinical animal models. The expression of these cytokines or their congnate receptors is
enhanced in fibrotic diseases, making them a suitable target for asthma and fibrotic disease
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treatment (Wynn 2007, Mitchell, Dimov et al. 2010). Lebrikizumab® (Genentech), an anti–IL13 antibody, has showed improvement in asthma patients with high serum periostin suggesting
that biomarkers can be used to identify patients who are sensitive to anti–IL-13 therapy in
fibrotic diseases. Several biotech and pharmaceutical companies are developing IL-4 and IL-13
antagonists for the treatment of asthma; those currently in clinical development for fibrotic
disease include QAX576 (Novartis), an anti–IL-13 antibody; tralokinumab (MedImmune), an
anti–IL-13 antibody. Along with individual cytokine or cytokine receptors targeting, antibodies
that bind to the shared IL-4Rα, and inhibit both IL-4 and IL-13 have also been considered. The
other approach is development of a bispecific-antibody SAR156597 (Sanofi), that targets both
IL-4 and IL-13 (ClinicalTrials.gov NCT01266135, NCT01629667, and NCT01529853).
1.13.5. Lysyl oxidase like protein 2 inhibition
It has been recognized by several groups individually that mechanical stress and tissue
stiffness promotes fibrosis. It has led to the development of several therapies targeting proteins
that crosslink and mechanically stabilize ECM as a means to attenuate fibrogenesis. LoxL2 is
commonly known to promote crosslinking but also has effects on gene expression. Decreased
LoxL2 activity in animal models leads to decrease in myofibroblasts, reduced TGF-β expression
and ECM production. This prompted the development of GS-6624 (Gilead), which is a
noncompetitive allosteric antibody inhibitor of LoxL2, and is in clinical development for fibrotic
disease and cancer (Barry-Hamilton, Spangler et al. 2010).
1.13.6. Pentraxin-2
Serum amyloid P regulates the innate immune response and inhibits the differentiation of
monocytes into fibrocytes or profibrotic, alternatively activates (M2a) macrophages by
functioning as a pattern recognition receptor. Pentraxin-2 localizes to sites of injury and shows a
dual therapeutic effect by inhibiting both fibrosis and promoting repair. PRM-151 (Promedior), a
human recombinant form of pentraxin-2 has exhibited protective effects in a variety of
preclinical models of fibrosis in multiple tissue types (Duffield and Lupher 2010). PRM-151 is
currently being tested in phase 2 trial in patients undergoing a trabeculectomy for glaucoma.
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1.13.7. Pirfenidone
The insight into pirfenidone’s role in fibrosis emerged from its trials by InterMune for
IPF. Pirfenidone is a small molecule known to possess anti-inflammatory activity that inhibits
TGF-β and p38 signaling.
1.14. Therapeutic targeting of integrin αVβ3
All the drugs targeting integrins were only targeted to ligand binding site (RGD binding
site). All the drugs such as cilengitide, LM609, which target RGD binding site inhibit
angiogenesis by competing with natural ligands from ECM and induce cell death by anoikis
(discussed in detail under cilengitide). The other targets of integrin αVβ3 include proteins
derived from cleavage of extracellular matrix such as endostatin, tumstatin etc., or non-matrix
derived integrin binding statins known as endogenous angiogenic inhibitors. The precise
mechanism of action for these endogenous inhibitors is not known, and the folding of these
inhibitors is very complex due to high charge and hydrophobicity, which led to their failure in
the clinic. Few examples are mentioned below.
1.14.1. Sequences binding to Integrin: Cilengitide
Integrin αVβ3 binds to its well-known ligand RGD with a pico-molar affinity. There are
in fact various proteins that bind to integrin αVβ3. One set of ligands includes a charge based
minor variation from RGD to KGD. Even though there are many ligands that lack RGD but still
bind to integrin αVβ3, it is unfortunate that they have not been paid much attention probably due
to simple rule pharmaceutical companies follow, i.e. lower the KD, better the drug. This idea has
probably sidelined many proteins, which may potentially be therapeutics in various fields. Even
RGD has been sidelined. Due to lack of studies about binding of various ligands to integrin, there
is not enough data to identify the important binding site. It is well obvious that RGD is
important, as recent light of evidence demonstrates the structural changes in βA domain of
integrin β3 upon ligand binding, highlighting the importance of integrin signaling through its
conformational changes. The other reason why we believe this is the most important and
interesting aspect of integrin signal is because folding of βA domain differs when β3 is partnered
with αV and αIIb. This shows the specificity of ligands for respective integrins (αVβ3 binds
31

strongly with vitronectin and αIIbβ3 binds strongly with fibrinogen even though the interacting
site is RGD in both the ligands). All the drugs targeting integrins were only targeted to ligand
binding site (RGD binding site) such as Cilengitide, LM609, which inhibits angiogenesis by
competing with natural ligands from ECM. This has been a serious concern for the RGD
targeting drugs as they bind to active ligand binding site and activate integrin, but when the drug
concentrations fall below the therapeutic levels, they still activate integrin without inducing cell
death by anoikis, as the concentration of RGD binding agent is not enough to completely remove
its adhesion from ECM Reynolds et.al, have demonstrated in xenograft model that RGD
mimetics used in concentrations below IC50 promote tumor growth.
1.14.2. Disintegrins
Several disintegrins from various different snake species have been very well
characterized and tested for their application in cancer treatment and other associated diseases.
Disintegrins are categorized into 5 classes: small (49-51 amino acids, 4 disulfide bonds), medium
(70 amino acids, 6 disulfide bonds), large (84 amino acids, 7 disulfide bonds), dimeric (67 amino
acids, 4 intra-chain disulfide bonds), and snake venom metalloproteinases (100 amino acids, 8
disulfide bond), based on the size of the protein and number of disulfide bonds. The following
are known disintegrins tested for their efficacy: albolabrin, applagin, barbourin, batroxostatin,
bitistatin, obtustatin, schistatin, echistatin, elegantin, eristicophin, flavoridin, halysin, kistrin,
mojastin (Crotalus scutulatus), rubistatin (Crotalus ruber), tergeminin, salmosin and triflavin.
The exact binding site and the mechanism are not yet well characterized; most of the disintegrins
were studied with respect to their activity against integrin αIIbβ3.
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2. MATERIALS AND METHODS
2.1. Mammalian cell techniques
2.1.1. Mammalian cell culture and storage
Human umbilical vein endothelium cells (HUVECs) were purchased from life
technologies, Grand Island, NY. M200 with 1xLSGS (low serum growth supplement) kit was
used to culture HUVECs. LSGS kit when added had final concentrations of following
components: 2% V/V of Fetal Bovine Serum (FBS), 1 µg⁄mL of Hydrocortisone, 10 ng⁄mL of
Human Epidermal Growth Factor (hEGF), 3 ng⁄mL of Basic Fibroblast Growth Factor (bFGF),
and 10 µg⁄mL of Heparin. The cryopreserved primary culture was recovered, frozen medium
containing 10% dimethyl sulfoxide (DMSO) was recovered into cell culture flasks at a density of
5×104 viable cells/mL using complete M200 medium. Cells were maintained at 37°C in
humidified 5% CO2 incubator.
Initial cultures were maintained for 2-3 days until they were 80% confluent with
medium-changing every other day. Confluent cultures were maintained by changing medium
every day. HUVECs were sub-cultured by digesting with 0.25% trypsin/EDTA (Mediatech,
Manassas, VA) for 10-12 sec and seeding cells into a new culture vessel at a cell density of
2.5x103 cells/cm2. Cryopreserved HUVECs (Invitrogen, Grand Island, NY) showed reduced
viability compared to the primary culture after 12-15 passages.
A human prostate cancer cell line, PC-3M-luc-C6 (PC3) (Caliper Life Sciences,
Hopkinton, MA) was a kind gift from The Aneja’s laboratory at Georgia State University (GSU).
PC-3M-luc-C6 is a cell line, which produces bioluminescent light, and is derived from PC3M
human adenocarcinoma cells by stable transfection of the North American Firefly Luciferase
gene, which was expressed from SV40 promoter. PC3 cells were maintained in MEM medium
(Mediatech, Manassas, VA) supplied with 10% FBS (HyClone, Waltham, MA), 1mM glutamine.
Cells were passed at 1:5 to 1:10 ratios every 2-3 days using 0.25% trypsin/EDTA.
Other human cell lines including HCT-116, SW480, SW620, WM115, WM266, T98G,
U87MG, H146 and H460 cell lines were purchased from ATCC and cultured by following the
manufacturer’s instructions. To freeze cells, cells were cultured to 60-70% confluence in a T75
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flask and trypsinized. Cell numbers were measured using a hemocytometer. Cell pellets were
harvested with centrifuged at 1,000 rpm for 10 min. Then, cells were resuspended in freezing
medium (10% v/v DMSO, 10% FBS, 80% culture medium) and aliquoted into freezing vials
(5x106 cells/vial). The vials were stored in a freezing container at -80°C overnight. The next day,
freezing vials were transferred to a liquid nitrogen reservoir for longer storage.
2.1.2. Transient transfection method
Mammalian cells applied in this project were transiently transfected with Fugene-HD
reagent (Roche) by following the manufacturer’s instructions. Mammalian cells were cultured in
a normal medium in 6-well plates. The next day, cells were 70-90% confluent depending on cell
types. The plasmids DNA-Fugene-HD mixture was prepared in polystyrene transfection tubes.
For each well, 2 g of plasmid DNA was added into 100 μl Opti-MEM medium and mixed
thoroughly. Then, 5 μl of Fugen-HD reagent was added into the tube and mixed with plasmid
DNA thoroughly. The transfection complex was formed in 20 min at room temperature. The
plates were washed with fresh normal medium twice and fed back with 1 ml normal medium.
Then, the transfection complex was added to each well dropwise. The transfected cells were
cultured in an incubator with/without 5% CO2 at 37°C for 48-72 hours before harvesting. For
immuno-stain experiments, cells were cultured in chambers 24 hours after transfection.
Fluorescent microscope was used to examine the fluorescent-tagged protein 48 hours after
transfection.
2.1.3. RNA Interference
RNA interference technique was applied to knock down endogenous protein expressions.
Cells were seeded to 30-50% confluence in a 6-well plate in normal medium one day before
performing knockdown experiment. The next day, 2 mL Opti-MEM medium was used to wash
each well to remove FBS. siRNA duplex for PKM2, p68, MEK5 or Stat3 was purchased from
Dharmacon RNA Technologies. RNA duplex was dissolved in DEPC-treated H2O to 40 pmol/μl.
200 pmol siRNA duplex was diluted in 250 μl Opti-MEM medium. 5 μl of transfection reagent,
lipofectamine RNAiMAX (invitrogen), was diluted into 250 μl Opti-MEM medium. The two
solutions were combined together and incubated for 30 min at room temperature. 0.75 ml of
Opti-MEM medium was added into each well. Then, the mixture was added into each well
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dropwise. Fresh medium was added into each well next day. For re-expressing wild type or
mutant proteins in knockdown cells, 24 hours later, knockdown cells were transfected using
FuGene HD by following the manufacturer’s instruction. 48 hours later, cells were lifted by cell
lifter and harvested by centrifuging at 1,000 rpm for 10 min at 4°C.
2.1.4. Growth factor treatment of cells
For growth factors stimulation, mammalian cells were starved for 6-12 hours with OptiMEM medium prior to treatment. Growth factors dissolved in either DMSO or ddH2O were
diluted in Opti-MEM medium. The starved cells were cultured in Opti-MEM medium containing
growth factor for a given amount of time. DMSO or ddH2O was used as a control. The cells were
harvested once the treatment was done and stored at -80°C immediately.
2.1.5. Whole cell lysate preparation
Cells were scraped after washing with 1X PBS and collected by centrifuging at 1,000
RPM for 10 min at 4°C. Mammalian cells were washed with cold 1X PBS twice and collected by
centrifuging at 1,000 rpm for 10 min at 4ºC. Whole cell lysate was prepared with cold 1X RIPA
buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25 % deoxycholic acid, and 1 mM
EDTA) supplemented with Protease Inhibitors Cocktail (PIC) (Sigma) and phosphatase
inhibitors cocktail (Pierce). In general, 1X106 cells were resuspended in 1 ml cold RIPA buffer
and incubated for 1 hour on a rotary plate at 4ºC. Then, cells were centrifuged at 13,200 rpm for
10 min at 4°C to get cell debris pellet. The supernatant was removed carefully and stored at 80ºC for later applications.
2.1.6. Nuclear extract and cytoplasmic extract preparation
Nuclear extract and cytosolic proteins were made with a nuclear extraction kit from
Active Motif. Mammalian cells were washed with cold 1X PBS twice supplemented with PIC to
completely remove culture medium. The attached cells were harvested gently with a cell lifter.
The suspension cells were harvested by centrifuging at 1,500 rpm for 10 min at 4ºC. In general,
1x106 cells were resuspended in 1 ml of 1X hydrophobic buffer supplemented with PIC and
incubated on ice for 15 min. Then, 50 μl of detergent was added into tube and the tube was
vortexed at a maximum speed for 30 seconds. The supernatant was collected and stored at -80ºC
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upto 2 months. The pellet, which was the nucleus, was washed with cold 1X PBS twice to avoid
cytoplasmic protein contamination. Then, the nuclear pellet was resuspended in AM1 lysis buffer
containing PIC and 1 mM DTT and incubated at 4ºC for 1 hour. Next, the tube was centrifuged
at 13,200 rpm for 10 min at 4ºC. The supernatant was collected and stored at -80ºC for further
applications.
2.2. Site-directed mutagenesis to produce anti-angiogenic protein cDNA
2.2.1. Site-directed mutagenesis
Desired mutations were introduced to plasmids of interest using QuikChange® II XL
Site-Directed Mutagenesis Kits (Stratagene, Santa Clara, CA). Complementary mutagenic
primers were designed either by placing desired point mutation, deletion or insertion in the
middle of the primer flanked with 10-15 unmodified base pairs (bps) on both sides or using the
online software, QuikChange primer design application (www.genomics.agilent.com). Sitedirected mutagenesis polymerase chain reactions (PCR) were carried out following the
manufacturer's exact instructions. After the reactions were complete, an amount of 10 units of
Dpn I was added to each reaction, which was incubated for 1 hour at 37°C to digest the parental
plasmid DNA. The mutated DNA plasmids were then transformed into XL-1-Blue competent
cells provided by the kit. Bacteria were applied to a LB agar plate containing 100 ng/mL
ampicillin and allowed to grow overnight. Usually 3-6 colonies were chosen to be mini-cultured
in 1-5 mL of ampicillin containing LB medium. Plasmids were purified and sent for sequencing
in a DNA sequencing core facility located at GSU.
2.2.2. Multi site-directed mutagenesis
QuikChange® Multi Sit-Directed Mutagenesis kits (Stratagene, Santa Clara, CA) were
used to generate multiple mutations that were located in the separate termini of the parental
cDNAs. Different from QuikChange® II XL Site-Directed Mutagenesis Kits, a single mutagenic
primer instead of a pair is required to mutagenize each site, using a double-stranded DNA
template. The kit contains a PCR enzyme blend featured with a unique Pfu fusion-based DNA
polymerase that provides a one-step mutation at multiple sites. Mutagenic primers were designed

36

using online software, QuikChange primer design application (www.genomics.agilent.com). The
manufacturer provided the protocols.
2.2.3. Transformation Escherichia coli (E. coli) strains
The DH5α (Promega, Madison, WI) competent cells were used for amplifying the desired
plasmid in large quantities. BL-21 (DE3), BL-21 (DE3) pLysS competent cell lines were gifted
from Dr. Jenny Yang from the Department of Chemistry at Georgia State University. A BL-21
CodonPlus® (DE3) competent cell line was purchased from (Stratagene, Santa Clara, CA). All
three BL-21 cell lines were used to express the proteins of interest in the current study. When
transformations were performed, suitable competent cells were thawed on ice in pre-chilled 1.5
ml polypropylene tubes (BD). BL-21 CodonPlus® (DE3) competent cells were incubated with βmercaptoethanol for 10 minutes prior to transformation as suggested by the manufacturer. Next,
10-100 ng of desired plasmids were added into 50-100 µl of competent cells followed by
incubation on ice for 30 min. Then the mixture was heat shocked for 20-90 seconds in water bath
at 42°C as recommended by manufacturers or established protocols. A volume of 500 µl of prewarmed S.O.C medium was added to each tube. After cooling for 2 minutes on ice, the tubes
were incubated at 225 rpm for 1 hour in a shaker set at 37°C. Each bacteria culture was then
spread onto individual LB agar plate containing a proper concentration of antibiotics for different
plasmids. LB plate was incubated overnight at 37°C.
2.2.4. Cloning of the CD2 variants into pGEX-2T expression vector
2.2.4.1. Mini prep
DNA purification from bacterial culture in small scales (0-20 µg) was performed using
Qiaprep® spin Mini Kit (Qiagen, Hamburg, Germany). A single colony from the freshly
transformed plate of bacteria was added to 1-5 mL of LB media containing proper concentrations
of antibiotics. The culture was incubated overnight in a shaker set at 37°C and 225 rpm. The
bacterial pellet was collected by centrifugation at 8,000 rpm for 5 minutes at room temperature
followed by removal of the LB media. Next, cells were re-suspended in 250 µL of buffer P1. An
equal volume of Buffer P2 (the cell lysis buffer) was then added to the solution. The tube was
gently inverted 4-6 times to mix followed by immediately adding 350 µL of Buffer N3 (the
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neutralization buffer). The solution was further mixed by gentle inversion for 4-6 times. The cell
debris was clarified from the mixture by centrifugation at 13,000 rpm for 10 minutes at room
temperature. Then the supernatant was transferred to a spin column and centrifuged at 13,000
rpm for 1 minute, which allowed the plasmid DNA bound to the column membrane. For endA+
bacteria strains, the column was washed once with 500 µL buffer PB by centrifugation at 13,000
rpm for 1 minute to remove trace nuclease activities. The column was then washed with buffer
PE and dried by centrifugation for additional 1-2 minutes after washing. The plasmids were
eluted with elution buffer (10Mm Tris-HCl, pH 8.5) or distilled water if further restriction
digestion or ligation was desired. The purified DNA usually was used for DNA sequencing to
verify the construction.
2.2.4.2. Midi prep
Moderate amounts (10µg - 200µg) of plasmids were purified using the Wizard® Plus
DNA Purification System (Promega, Madison, WI). The purification procedures were performed
according to the manufacturer’s instruction. An overnight plasmid-containing bacterial culture of
50-100 mL was collected by centrifugation at 8,000 rpm for 10 minutes at 4°C. The cell pellet
was completely re-suspended by pipetting in 3 mL of suspension buffer and transferred in an
autoclaved centrifuge tube (Nalgene, Rochester, NY). A volume of 3 mL of the lysis buffer was
added into the tube. Then the tube was gently inverted 4-6 times followed by immediately adding
3 mL of the neutralization buffer. The mixture was further gently inverted 4-6 times to mix. The
cell debris was clarified from the solution by centrifugation for 15 minutes at 14,000 rpm at 4˚C.
The resultant supernatant was transferred into a clean 50 mL conical tube and mixed with 10 mL
of DNA purification resins. The DNA/resin mixture was then loaded to a midi prep column
connected to a Vac-Man® Laboratory Vacuum (Promega, Madison, WI). The supernatant was
removed by vacuuming followed by washing twice with 15 mL of Column Wash Solution.
When the last run of wash was complete, the vacuum was allowed to run for additional 30
seconds to dry the resins. The column reservoir was then separated from the column, and excess
Column Wash Solution was removed by centrifugation at 13,000 rpm for 2 minutes. A volume
of 300 µL of pre-hearted (65°C) Elution buffer (Tris-HCl, pH 8.5) or distilled water was added
to each the column and incubated for 1 minute. Next, the eluate was collected by centrifugation
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at 13,000 rpm for 1 minute. The residual amount of ethanol that might interfere with following
enzymatic reactions was removed from the sample using an evaporation method by leaving the
cap open overnight at room temperature. The purified plasmids were then stored at -20°C or 80°C for longer time.
2.2.5. DNA concentration and quality measurement
The OD260 and OD280 of DNA solutions were measured using a spectrophotometer. DNA
concentrations were calculated based on the following formula using common extinction
coefficient of 50 (µg/mL)-1cm-1 for DNA as DNA concentration (µg/mL) = (OD260) × (dilution
factor) × (50 µg DNA/mL)/(1 OD260 unit). The ratio of OD260 and OD280 was calculated for each
sample to determine the purity. The accepted purity value is between 1.65 and 1.85. DNA
plasmids or fragments were further verified by agarose gel electrophoresis. Usually intact DNA
plasmids or fragments appear as sharp bands without smear.
2.2.6. Agarose gel electrophoresis
Separation of DNA molecules was performed by agarose gel electrophoresis and DNA
bands were visualized using double stranded DNA binding dye ethidium bromide (SigmaAldrich, St. Louis, MO). Low percent gels (0.8-1%) usually used for analyses of DNA plasmids
or DNA fragments of large MWs, while higher percent gels (~ 2%) were used for separation of
small molecular weight DNA fragments such as PCR products. An appropriate amount of
electrophoresis grade agarose (EMD Chemicals, Gibbstown, NJ) was weighed and mixed with
50-100 mL of 1X TAE (Tris-Base, Glacial Acetic Acid, EDTA, pH 8.0). Heating the mixture
using an electronic microwave melted the agarose. Then, the mixture was allowed to cool down
below 68°C before adding ethidium bromide at a final concentration of 0.5 µg/mL. Then the
liquid was poured into a casting apparatus with an appropriately sized and numbered comb. The
comb was removed after the agarose became firmly solidified at room temperature, and then the
gel was properly placed into an electrophoresis device filled with 1X TAE buffer. Each DNA
sample was mixed with an appropriate volume of 5X DNA loading dye (Fermentas, Glen Burnie,
Maryland) to make the final loading dye concentration to 1X. A volume of 5-20 µL of such
sample was loaded to each well. The gel was then subjected to electrophoresis for 45-90 minutes
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at 100-120 volts at room temperature. DNA fragments in the gel were visualized under the UV
light with a wavelength of 302 nm using a UV transilluminator equipped with a CCD camera.
2.2.7. Agarose gel extraction of DNA
Following gel electrophoresis, the DNA fragment of interest was extracted from the gel
for applications such as ligation, mutagenesis, and restriction enzyme digest. All gel extractions
were performed using the QIAquick Gel Extraction Kit (Qiagen, Hamburg, Germany) according
to the manufacturer’s instruction. The band of interest was excised from the agarose gel with UV
safety screens and protective eyewear during gel excision. The excised gel piece was weighed in
a pre-weighed microcentrifuge tube. Then buffer QG was added to the tube in a 3:1 ratio (for
example, 300 µL buffer QG to 100 mg gel). A 6:1 ratio of QG buffer was added to higher
percent gels (> 2%). Then, the mixture was incubated at 50°C for 10-15 minutes in order to
completely dissolve the gel. A pH indicator contained in buffer QG indicated the pH of the
resultant solution. The dissolved DNA only efficiently binds QIAquick membrane when the
color of the mixture shows yellow color, a color similar to buffer QG. Orange of purple color
after the gel was dissolved indicates a higher pH that has to be returned ≤ 7.5 by adding 10 µL of
3 M sodium acetate, pH 5.0 to the tube. After 1 gel volume of 100% isopropanol was added to
the sample and mixed, the solution was transferred to a QIAquick column and centrifuged at
13,000 rpm for 1 minute. In order to remove any residual agarose, 0.5 mL of Buffer QG was
added to the column and centrifuged again at 13,000 rpm for 1 minute. The column was then
washed with 0.75 mL of buffer PE to remove any excess salt by centrifugation at 13,000 rpm for
1 minute. The column was dried by centrifugation for an additional 1 minute, and then the DNA
was eluted with pre-warmed (65°C) Buffer EB (10 mM Tris-HCl, pH 8.5) or distilled water. The
eluate was stored at -20°C until use.
2.2.8. Restriction enzyme digestion
Restriction enzymes were purchased from Fermentas, (Glen Burnie, MD). Optimal
conditions and protocols followed manufacturer’s instructions. Typical reaction for restriction
digestion is usually composed of 3 µg of plasmid DNA, 1 µL of restriction enzyme, 2 µL of 10X
appropriate restriction digest buffer, and 16 µL of sterile distilled water. The reactions were
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scaled up accordingly and usually performed in 50 µL reactions with 5 – 10 µg of plasmid DNA
as substrate separately. The digestion of PCR products involved 0.2 µg of DNA, which was used
in a 20 µL reaction system. During the double digestion, Tango Buffer or proper buffer (Green
buffer/ Buffer R, Buffer O), suitable for both restriction enzymes was used. Sequential digestion
was also performed. A typical double digest with BamHI and EcoRI was composed of 3 µg of
plasmid DNA, 1 µL of BamHI, 1 µL of EcoRI, 2 µL of 10X Tango™ buffer (Fermentas, Glen
Burnie, MD), and 14 µL of distilled water. Reaction mixtures usually were incubated for 1-16
hours at 30°C and 5 minutes at 80°C to stop the reaction as per manufacturer’s
recommendations. The digested fragments were separated by 0.5% - 2.0% agarose gel
electrophoresis for extraction or analysis of plasmid constructions.
2.2.9. Ligation of CD2 variants and pGEX-2T expression vector
Desired CD2D1 cDNA or mutants purified from agarose gel were inserted into pGEX-2T
expression vector (GE Life sciences, Piscataway, NJ). A 3:1 to 5:1 cDNA to pGEX-2T was used
for the ligation reaction. To a 1.5 mL eppendorf tube, 50-100 ng of digested and purified pGEX2T vector, proper calculated amount of cDNA fragments, 1 to 2 µL of ligase buffer, 1 µL of T4
DNA ligase, and distilled water were mixed together to a total volume of 10 to 20 µL. The
reaction was placed at room temperature and then at 16°C overnight for maximum ligation. The
ligation mixture was then transformed to JM109 competent cells. Correct clones were confirmed
by DNA sequencing or restriction enzyme digestion after mini DNA purification.
2.3. Expression of the Glutathione (GST)-tagged proteins
2.3.1. Optimization of expression for the GST-tagged proteins
Each expression vector construction was tested in different cell lines for maxima
expression level. The BL-21 (DE3), BL-21 (DE3) pLysS and the BL-21 (DE3) CodonPlus®
competent cell lines were used in this project for protein expression. Usually 5-6 health colonies
were chosen from plates with transformed bacteria. Each colony was added to 2 mL LB medium
with 100 µg/mL and incubated 225 rpm for 2 to 3 hours in a shaker. Then isopropyl-β-D-thiogalactoside (IPTG) was added to a final concentration of 0.2 mM. The cultures were incubated
for another 3 to 4 hours. An aliquot of 1 mL of each culture was centrifuged in a 1.5 mL
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eppendorf tube and pellets were collected. Sample buffer (50 µL, 1X SDS buffer) were added to
each tube and boiled for 10 minutes. Samples were then analyzed by SDS gel electrophoresis.
The colony with highest expression level was chosen for further large scale protein expression. If
desired expression level was not achieved, the chosen colony was subjected to further
optimization on temperature (18°C to 37°C), induction time (2 to 16 hours), and IPTG
concentration (0.1 to 1mM).
2.3.2. Expression of CD2 variants in Luria Bertani (LB) medium
ProAgio cDNA bearing pGEX-2T expression plasmid was transformed into BL-21
(DE3) CodonPlus® competent cells. A healthy colony was inoculated into 3 mL LB medium
with 100 µg/mL of ampicillin, which was incubated at 37°C until the optical density (OD) 600
nm reaches 0.6 - 0.8. 50 µl of culture were transferred to 50 mL LB medium and incubated at
37°C overnight with agitations. 15 mL of such culture were added into 1L LB medium and
incubated at 250 rpm, 37°C. When the reading of OD 600 nm reached 0.8 - 1.0 (roughly 2 to 2.5
hours), a final concentration of 0.2 mM IPTG was added to the flask. Then temperature was
decreased to 30°C and protein expression was induced and incubated for 4 to 5 hours until the
OD reach 1.8 - 2.0. Bacteria were collected by centrifugation at 6,000 rpm for 15 min. Pellets
were transferred to a 50 mL centrifuge tube and temporarily stored at -20°C until usage.
2.3.3. Purification of CD2D1 and ProAgio
The cell pellet was defrosted and suspended in lysate buffer (30 mL of lysate buffer per
each liter growth). DTT was added to the pellet mixture to reach a final DTT concentration of 5
mM. EDTA was added to the pellet mixture to reach final concentration of 10 mM. The mixture
was blended for 30 seconds. The blended mixture was separated into multiple small plastic
beakers (< 25 mL per beaker) and each beaker was sonicated 6 times. The duration of each
sonication cycle is 10 seconds with a 10-minute interval between sonication cycles. For lysis of
ProAgio pellets, a light sonication was applied. Passing through a French press 40k cell further
disrupted lysates. Once the sonication cycles were complete, the content was centrifuged for 30
minutes at 17,000 rpm. The supernatant was filtered using 0.45 m syringe filter while the
remaining pellet was re-suspended in lysate buffer to repeat above purification steps. After cell
lysis, the fusion proteins in the supernatant were loaded onto a column of GS4B resin (GE
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lifesciences, Piscataway, NJ). After binding, each column was washed with 50 mL of 1X PBS
buffer. The fusion proteins were cleaved by thrombin (2.5 mL of 1X PBS buffer with 30 L of
thrombin (1 unit/L) on the beads following elution of waste materials. The column was first
kept at 4C with agitation for 14 hours, and then placed at room temperature for two hours before
elution. The proteins were eluted using 20 mL of 1X PBS buffer per column. The eluted proteins
were further purified using a superdex 75 column (GE lifesciences, Piscataway, NJ) in the FPLC
and 10 mM Tris elution buffer at pH 7.4. The size exclusion purification was used to further
purify ProAgio with 1X PBS buffer, while a SP Sepharose column (GE lifesciences, Piscataway,
NJ) was applied for the purification of CD2D1. The protein was bound to the cationic exchange
column using 20 mM acetate buffer at pH 3.5. The protein was eluted with an increasing pH
gradient from 3.5 to 8.0 (50 mM Tris buffer). The identities of CD2 variants were confirmed by
SDS-PAGE. The protein concentration was measured with ε280 = 11700 M−1 cm−1 for CD2D1
and ε280 = 8480 M−1 cm−1 for ProAgio. Concentrations were further confirmed by a Bradford
protein assay using bovine serum albumin (BSA) as a standard.
2.3.4. Purification of ProAgio-PEG
2.3.4.1. Site-specific PEGylation of ProAgio
After cleavage, Y-shaped maleimide PEG (Jenkem Technology, Allen, TX) powders
were directly added to column at molar ratio of 1:5 to 1:8 (protein to PEG). The molar
concentration of ProAgio protein was determined by Bradford protein assay using BSA as a
standard and calculated (as each fusion protein molecule only contains 1 molecule of ProAgio
recombinant protein). Typical binding for each column required an average of 100-250 mg of
PEG. Mixture was incubated at room temperature for 1 hour or at 4°C overnight. PEGylated
protein was eluted using 1X PBS.
2.3.5. Purification of ProAgio-PEG using ion exchange chromatography
ProAgio-PEG recombinant protein was dialyzed to 5 mM MES sodium salt pH 6.0 at
4°C. Further the protein was purified by an AKTA FPLC system (GE Life Sciences, Piscataway,
NJ) equipped with a SP high performance Sepharose TM Column (GE Life Sciences, Piscataway,
NJ). The purification program was performed with a flow rate at 5 mL/minute. All fractions were
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collected at 2 mL/tube. First, the instrument was equilibrated with 2 CV (column volume) of
Buffer A (5 mM MES sodium salt, pH 6.0). Samples were injected into a 10 or 50 mL sample
loop. Fractions were collected from this point onwards. Most free PEG and PEGylated GST did
not bind to column and formed major UV280 absorbance peaks, which were discarded. Nonspecific bound proteins were washed off with 5 CV of Buffer B gradients (5 mM MES sodium
salt, 1M NaCl, pH 6.0) from 0% to 10% to remove non-specific bound proteins. Elution of
ProAgio-PEG started around 50% Buffer B, fraction 35-40. The column was washed with 3 CV
of 100% of Buffer B and re-equilibrated with 5 CV of 100% of Buffer A.
A volume of 20 µL of fractions from each UV absorbance peak was loaded into a SDSPAGE gel analysis using coomassie blue staining. PEGylation was visualized by iodine staining.
The 20,000 Y-shape maleimide PEGylated ProAgio migrated between molecular weight (MW)
of 55-kDa to 70-KDa, which was much slower than the calculated MW of 31-kDa. Protein
fractions with ProAgio-PEG or CD2D1-PEG were pooled together (usually fractions were 36,
37, 38, and 39), concentrated, and further dialyzed to 1X PBS for further biology functional
assays and animal experiments.
2.4. Protein stability test
Purified ProAgio was mixed with FBS in a 1:1 ratio. The mixture was incubated at 37°C
for desired time. Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel electrophoresis was
performed to determine the degradation of ProAgio. The disappearance of ProAgio protein band
was attributed completely to degradation.
2.4.1. Determination of protein concentration
The concentration of ProAgio and ProAgio-PEG was determined using UV absorbance at
280 nm and calculated using an estimated extinction coefficient of 8480 M-1 cm-1. For example,
UV absorbance 280 nm of 0.848 was equal to 100 µM (11.28 mg/L) of ProAgio or (31.28 mg/L)
of ProAgio-PEG, because that the PEG chain increased the molecular weight of ProAgio but did
not affect the protein composition. Protein concentrations were further confirmed using Bradford
protein assay using bovine serum albumin as a standard.
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2.5. Conformational analyses by 1D 1H NMR
For 1D 1H NMR studies on ProAgio and CD2D1, NMR samples were prepared by
diluting proteins in 10 mM Tris-HCl with 10% D2O at pH 7.4. Protein concentrations were
varied from 150 to 300 M. For the NMR spectra, dioxane was used as an internal reference
(3.743 ppm). Recording of all NMR spectra was done using Varian Inova 500 MHz and 600
MHz NMR spectrometers. Spectra widths of 6600 Hz and 8000 Hz were used at 500 MHz and
600 MHz, respectively. A water suppression pulse sequence from Varian Biopack was used with
8 K complex data points at 25ºC. All the 1D NMR experiments were collected with 1024 scans.
The data were processed with the program FELIX98 (MSI). After Fourier transformation,
typically a squared sinebell window function shifted over 75º was used. Post-acquisition
suppression of the water signal was achieved by deconvolution of a Gaussian function with a
function width of 20.
2.6. Assays to determine the in vitro effects of ProAgio
2.6.1. Determination of cell growth
HUVECs were typsinized and seeded into a 96-well plate at 4x104 cells/mL. After 16-18
hours of attachment, cells were treated with 0-40 μM of ProAgio-6D31 or CD2D1 for 48 hours.
Cell proliferation rates were measured by Thiazolyl blue tetrazolium bromide (MTT) (SigmaAldrich, St. Louis, MO) assay. MTT power was diluted in Hank’s balanced salt solution at
5mg/mL. 1/10th of the total culture volume of MTT solution was added to each well and
incubated for additional 4 hours. Then the supernatant was carefully removed and DMSO was
added to dissolve the formed crystal. Photometry at 490 nm was performed using a PerkinElmer
Victor 3 microplate reader (PerkinElmer, Waltham, MA). The absorbance of cell control was
designated as 100%. The proliferation rates were calculated using the equation: proliferation rate
of treated cells = absorbance of treated cells/absorbance of cell control. The values were plotted
using Microsoft Excel.
2.6.2. Cell proliferation assay (BrdU)
Cell proliferation rates were determined using BrdU cell proliferation kit (Calbiochem,
La Jolla, CA). All procedures followed the manufacturer’s instruction. Briefly, HUVECs were
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trypsinized and seeded into 96 well plates at 4x104 cells/mL. Cells were allowed to attach for
overnight, and then treated with protein and peptide reagents at desired concentrations for 48
hours. Each concentration was tested in triplet wells. BrdU label was 1:2000 diluted into fresh
tissue culture media, and 20 µL of this working solution were added to each well to be labeled.
After incubation for an additional 12 hours, cells were fixed, and then incubated with 100 μL of
1:100 diluted anti-BrdU antibodies at room temperature for 1 hour. After washing 3 times with
wash buffer, a peroxidase goat anti-mouse IgG HRP conjugated antibody was added to each well
for 30 minutes followed by 3 times washes. Tetra-methylbenzidine substrate solution was
incubated with each well for 15 minutes and the reaction was stopped by 2.5N sulfuric acid. The
absorbance in each well was measured in PerkinElmer Victor 3 microplate reader (PerkinElmer,
Waltham, MA) at dual wavelengths of 450-540 nm. The proliferation rates of different
treatments were compared as folds change of control. Each treatment was repeated in triplicate,
and experiments were repeated 3 times.
2.6.3. Tube formation assay
The in vitro angiogenesis studies were performed using tube formation assay. HUVECs
were seeded into a 96 well plate coated with 50 µl of martigel (BD Biosciences, San Jose, CA)
for each well. Before usage, the coated plates were incubated for 30 minutes at 37°C and 5%
CO2 environment to allow matrix to polymerize. A volume of 50 µL of HUVEC suspension
(2x104 cells) was added to each well. For examine HUVECs and PC3 cells co-culture (1:1
mixture) formed tubules, a volume of 50 µL of HUVEC suspension containing 1x104 cells was
added to each well. Stimulators, such as 10% FBS or 1x104 cells PC3 cells were supplied with
the culture media to promote the formation of endothelial tubules. At the same time, protein and
peptide reagents were added at desired concentrations in duplicate wells for each concentration.
Then the angiogenesis assay plate was incubated for 6-8 hours at 37°C, 5% CO2 atmosphere.
Tube formations were observed under a light microscope at 50X magnification (10X Ocular lens
and 5X Obj. Lens). Three digital pictures were taken from each well. Experiments were repeated
three times. The total tubule length per 5X Obj. field for each picture was measured using the
ImageJ software (National Health Institution, Bethesda, Maryland). Branch points were counted
manually.
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2.7. GST Pull-down assay
GST pull-down assays were performed according to protocols described by Kaelin and
colleagues. GST fusion proteins (GST, GST-CD2D1, and GST-ProAgio) were expressed and
conjugated to GS4B. Freshly thawed and routinely maintained HUVECs at 80% confluence were
rinsed with 1X Hanks Balanced Salt Solution (HBSS), and incubated with 25 ng/mL human
recombinant VEGF (Invitrogen, Grand Island, NY) supplied in full-culture medium without
bFGF for additional 16 hours at 37°C, 5% CO2. Then cells were washed three times with cold
1X PBS, pH 7.4. All following procedures were performed on ice or under 4°C. Cell pellets were
collected by centrifugation at 8,000 rpm for 5 minutes after cells were physically detached from
culture flasks by scraping. Cell pellets were resuspended and incubated for 2 hours in NETN
lysis buffer supplied with 1X protease inhibitor cocktail (20 mM Tris, pH 8.0; 100 mM NaCl; 1
mM EDTA; 10 µg/nl phenylmethylsulfonyl fluoride; 0.1% Nonident P-40; 500 µM 4-(2Aminoethyl) benzenesulfonyl fluoride hydrochloride; 150 nM aprotinin; 1 µM E-64; and 1 µM
leupeptin hemisulfate). EDTA-free protease inhibitor cocktail set V was purchased from
Calbiochem, La Jolla, CA. Chemical reagents were purchased from Sigma-Aldrich, St. Louis,
MO. The lysates were centrifuged at maximum speed for 2 minutes in a microcentrifuge. Clear
supernatant was transferred to a clean microcentrifuge tube. Total proteins in supernatant were
diluted to 1 µg/µL, pre-cleared by GS4B beads for 2 hours, and then used for pull-down assay.
GS4B beads conjugated with 500 µg of GST, GST-CD2D1, or GST-ProAgio was
incubated with a total of 500 µg of above HUVEC lysate in a volume of 500 µL for overnight by
end-over-end mixing. Beads were washed three times in lysate buffer. Proteins were eluted by
boiling at 95°C for 8 minutes in 1X SDS sample buffer (50 mM Tris-HCl, pH 6.8; 12.5 mM
EDTA, 1% β-mercaptoethanol; 2% SDS; and 0.02% bromophenol blue; 10% glycerol). For each
sample, 20 µL of eluates were loaded to SDS-PAGE gel electrophoresis analysis.
2.8. Western blot
Proteins in SDS-PAGE gel were transferred to a nitrocellulose membrane by an
electronic transfer device (Bio-Rad, Hercules, CA) for 2 hours at 50 mA at room temperature in
transfer buffer. Protein bands in nitrocellulose membrane were visualized by staining with 2%
Ponceau Solution (Sigma-Aldrich, St. Louis, MO) for 1 minute, and then destaining completely
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by repeated washing in water and TBST. Membranes were incubated at room temperature for 2
hours in 1X TBST blocking buffer (150 mM NaCl; 50 mM Tris-HCl, pH 7.6; 0.1% Tween 20;
and 5% bovine serum albumin). A primary rabbit/mouse monoclonal antibody (Abcam,
Cambridge, MA) was incubated with the membrane at 1:1000 dilutions overnight at 4°C.
Membrane was washed 3 times for 5 minutes each in 1X TBST washing buffer (150 mM NaCl;
50 mM Tris-HCl, pH 7.6; and 0.1% Tween 20). A horse radish peroxidase (HRP)-conjugated
rabbit/goat anti-mouse/rabbit IgG secondary antibody (Thermo Fisher Scientific, Waltham, MA)
was incubated with the membrane at 1:2000 dilutions for 1-2 hours at room temperature.
Membranes were then washed again thrice in 1X TBST washing buffer and briefly dried on
light-duty tissue wipers. Luminata Western HRP substrates (Pierce, Thermo Fisher Scientific,
Waltham, MA) were added to each membrane and developed for 2 minutes. Membranes were
then exposed to X-ray film (Hy-Blot CL, Denville Scientific Inc. Metuchen, NJ) and examined
using an X-ray developer (KODAK).
2.9. In vivo effects of ProAgio and ProAgio-PEG using xenograft nude mice model
2.9.1. Animal care
Athymic Nude-Foxn1nu mice (Nude mice) at age of 3-4 weeks were purchased from
Harlan Laboratories, Indianapolis; IN. Animals were housed in animal facilities located at GSU
DAR (department of animal research). Experimental procedures for all animal studies were
reviewed and approved by Institutional Animal Care and Use Committee (IACUC) at GSU
according to the Public Health Service (PHS) guide for care and use of laboratory animals
(Protocol approval # 2007-0126). A standard operating procedure (SOP) for working with
laboratory animals as per GSU-DAR was followed for routine animal handling, intra-peritoneal
(i.p.) injection, tumor inoculation, tumor measurement, and endpoint euthanasia.
Animals were routinely monitored every day for any potential abnormality such as
movement, food intake, body weight, alertness, and skin color. For tumor-bearing mouse, all
tumors were measured at least twice a week. Mice with a tumor size exceeding 1.5 cm in any
direction were euthanized, as mentioned in the IACUC protocol. Pain levels were measured and
categorized according to the U.S. Department of Agriculture (USDA) classifications for pain as
follows: B represents that animal are breeding; C means that tests conducted involve no pain;
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and D indicates that procedures which involve pain or distress are relieved with anesthetics,
analgesics, or tranquilizing drugs. Pain levels from all procedures were accordingly recorded and
reported to staff members at the GSU-DAR.
2.9.2. In vivo xenograft model
PC-3M-luc-C6 cells were cultured in MEM (Minimum Essential Medium Eagle) medium
(Cellgro Inc,) with 10% FBS (Cellgro Inc,). Cells were trypsinized, washed at least 2 times in 1X
HBSS and suspended in 1X HBSS mixed with 50% volume of matrix gel. The mixture was kept
on ice until injection. Animals were placed in an anesthesia induction chamber in a bio-safety II
cabinet located in a standard operating room in DAR facilities. Animals were anesthetized using
isoflurane administrated by a vaporizer. Anesthetized animals were kept in a warm re-circulating
water heating pad during anesthesia. The injection area was sanitized with ethanol pads. A
volume of 100 µL suspension containing 5x106 cells was subcutaneously injected into one flank
of each nude mouse. Five to seven days after inoculation of tumor cells, treatments were initiated
after xenografts were established and tumor volume reached 50-100 mm3. All reagents were
administered by i.p. injection at desired doses (buffer: 1X PBS; ProAgio: 5 mg/kg/day; ProAgioPEG: 2.5-20 mg/kg/day; CD2D1-PEG: 20 mg.kg/day; Avastin: 20 mg/kg/twice weekly). Tumor
sizes and mice weights were measured and recorded every other day with a digital caliper and a
digital balance. Tumor volumes were measured using formula: Tumor volume (mm3) = π/6 x
(length x width x width).
2.9.3. Determination of tumor size and tumor weight measurement at the end point
At the end of treatment, animals were euthanized according to the established SOP
approved by DAR. Briefly, animals were placed in a plastic CO2 gas chamber in the DAR
facility procedure room. CO2 gas valve was slowly turned on, and gas flow was maintained for at
least a minute after apparent clinical death. Then, the gas valve was turned off. After animals
were removed from the gas chamber, unintended recoveries were voided by physical euthanasia.
Then, tumors were carefully dissected from the tumor-bearing mice without adjacent tissues or
skins. Tumors were weighed using a digital balance individually. The volume of the tumor was
measured and calculated after the nude mice were subcutaneously implanted with tumor cells for
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5 days. The width/ length/height of the tumor were measured every two days. The formula: 4p/3
× (width/2)2 × (length/2) was used to calculate the volume of the tumors. After around one
month later (4-5 weeks), the mice were euthanized. The tumors were isolated from the mice and
the weights of the tumor were measured.
2.10. Statistics analysis
Quantitative data from BrdU and MTT cell viability assays were described as mean ±
S.D. (standard deviation). In animal experiments, quantitative data were described as mean ±
S.E.M. (standard error of mean). Statistic evaluations of data from cell proliferation, tube
formation, and CD31 IF-staining were performed with unpaired student’s t tests (two-tailed). For
evaluation of in vivo data with normal distributions, ANOVA one-way tests were performed
using SPSS (IBM, Armonk, NY), a statistic software. Otherwise, Welch’s t tests were used in
order to compare the tumor growth curves of two different treatment groups. In any case, a
calculated possibility value less than 0.05 (P < 0.05) was considered statistically significant.
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3. RATIONAL DESIGN OF A PROTEIN INTEGRIN V3
OUTSIDE THE LIGAND-BINDING SITE
3.1. Abstract
Integrin αVβ3 expression is altered in various diseases and has been proposed as a drug
target. Here we use a rational design approach to develop a therapeutic protein, which we call
ProAgio that binds to integrin αVβ3 outside the classical ligand-binding site. We show ProAgio
induces apoptosis of integrin αVβ3 expressing cells by recruiting and activating caspase 8 to the
cytoplasmic domain integrin αVβ3. ProAgio also has anti-angiogenic activity and strongly
inhibits growth of tumor xenografts, but does not affect the established vasculature. Toxicity
analyses demonstrate that ProAgio is not toxic to mouse. Our study reports a new integrintargeting agent with a novel mechanism of action, and provides a template for the development
of integrin targeting therapeutics.
3.2. Introduction
Integrin are heterodimeric (combinations of different  and  subunits) cell surface
receptors. The molecules not only play critical role for the cell adhesion to extracellular matrix
(ECM) but also function as an inside-out and outside-in bidirectional signaling molecules to
allow cell response to many biological cues (Hynes 2002, Kim, Ye et al. 2011). Abnormal
expression of different pairs of integrin often associates with development and progression of
various pathological conditions (Wilder 2002, Cox, Brennan et al. 2010, Maile, Busby et al.
2010, Gerber, Gallo et al. 2013). Due to unique expression patterns and functionality of integrin
αVβ3 in angiogenic endothelial cells, activated macrophages, metastatic cancer cells, and
matured bone resorbing osteoclast cells (Clover, Dodds et al. 1992, Brooks, Clark et al. 1994,
Felding-Habermann, O'Toole et al. 2001, Antonov, Antonova et al. 2011). This pair of integrin
has been intensively studied as a potential target for development of drugs of anti-angiogenic and
anti-inflammatory (Guo and Giancotti 2004, Hodivala-Dilke 2008, Harburger and Calderwood
2009, Desgrosellier and Cheresh 2010). Studies yield a number of successful examples. Among
them are various antibodies against the integrin (Millard, Odde et al. 2011), and most recently,
Cilengitide, a RGD-based peptidomimetic (Mas-Moruno, Rechenmacher et al. 2010, Leblond,
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Meignan et al. 2011). Nevertheless, most of the current approaches in development of
therapeutics targeting integrin focus on ligand binding by using antibodies, cyclic peptides,
disintegrin, peptidomimetics, and small molecular antagonists (McLane, Sanchez et al. 2004,
Millard, Odde et al. 2011, Goodman and Picard 2012). A major draw-back of targeting ligandbinding of integrin is activation of integrin signaling by the developed agent, which largely limit
the clinical success of the integrin ligand based antagonist/agonist. There is an urgent need to
develop agents that target integrin at sites other than ligand-binding site. We report here the
development of a new class of therapeutic protein agent by rational protein design. The designed
protein targets integrin αVβ3 at a novel site, and triggers apoptosis of integrin αVβ3 expressing
cells via recruitment and activation of caspase 8 to the cytoplasmic domain of integrin 3. In
vitro and in vivo experiments demonstrate that the designed protein is very effective as an antiangiogenic agent, providing a confirmation for the specific targeting of integrin αVβ3 by the
designed protein agent.
3.3. Results
3.3.1. Designing a protein agent binds to a novel site of integrin αVβ3
We employed an approach of in silico and in situ analysis to search for proteins that
potentially bind to integrin αVβ3 at a site other than ligand binding site. We earlier observed a
very weak affinity of domain 1 of both human and rat CD2 (ref to as D1-CD2, the proteins that
were well studied in our laboratories (Yang, Wilkins et al. 2005, Yang, Yang et al. 2008), to the
integrin αVβ3. Thus, we particularly attempted to dock D1-CD2 to various sites of integrin
αVβ3. Because of the functional importance of A domain of 3 in ligand-binding and integrin
signaling (Arnaout, Mahalingam et al. 2005), we focused our attention on the A domain. To
validate our docking method, we first docked a physiologic ligand of integrin αVβ3, the tenth
type III RGD domain of wild-type fibronectin. The RGD domain docking completely matched
the crystal structure of the complex by Van Agthoven, J. F. and co-workers (Van Agthoven,
Xiong et al. 2014) (Figure 3.1A), indicating our docking method is appropriate. With validation
of our docking method, we carried out a randomized docking to the exposed surfaces of A
domain, D1-CD2 docked to a novel site, a groove in A domain of 3 formed by the “2 helix”,
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“B-C loop”, and “2–3 loop” (ref to as A-groove, with various different orientations (Figure
3.1A - Figure 3.1B). However, due to lack of strong contacts with residues of the A-groove, the
docking did not provide a favorable energy. To improve the docking, we made several mutations
on D1-CD2 residues that may form important interactions with A domain. Additional mutations
were also introduced to counter potential structure disturbance and to maintain stable -sheet
packing. As expected, the docking-energies of these D1-CD2 variants on the A-groove were
substantially decreased (Figure 3.1B). To verify the docking of D1-CD2 variant to integrin
V, we re-performed the docking of variant 3 with another crystal structure of integrin V
(4MMZ) (Van Agthoven, Xiong et al. 2014). The variant docked to the same site of A-groove.
Due to structure difference between 1L5G and 4MMZ, the variant twisted about 10-15 degree in
docking orientation (Figure 3.1C).
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Figure 3.1. Docking of a physiological ligand of integrin αVβ3.
(A), (B), and (C) Docking of a physiologic ligand of integrin αVβ3, the tenth type III RGD domain of
wild-type fibronectin (A), D1-CD2 (B), and the D1-CD2 variant 3 (C) to A-domain of integrin v 3
using software HADDOCK 1.2. In (A), the yellow colored RGD domain is the docking model, while the
purple colored RGD domain is crystal structure by Van Agthoven, J. F. and co-workers. In (B), different
models in various different orientations of D1-CD2 docking at A groove are shown. In (C), purple color
shows ProAgio docking to the crystal structure 1L5G, while yellow color shows D1-CD2 variant 3
docking to the crystal structure 4MMZ. Left and right images are same docking model with 90o twist to
show the difference in orientation of 1L5G and 4MMZ dockings (yellow and purple). (D) 1H-NMR
spectra of ProAgio and D1-CD2 were recorded using Varian Inova 600 MHz spectrometer. Protein
samples were prepared by dilution with 10 mM Tris and 10% D2O pH = 7.4 to final protein concentration
of 200 M. (E) The representative binding curves of binding of PEGylated ProAgio (Left) or D1-CD2
(Right, and smaller panel) to integrin Vwere monitored by SPR with integrin that were immobilized
on the Biacore chip. Thin black lines in left panel are the fitting curves based on one-to-one binding
mode.
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Figure 3.2. Design of protein agent, ProAgio that binds to integrin αVβ3 at a novel site.
(A) Docking of D1-CD2 to A-domain of integrin 3 using software Haddock 2.1. The regions from the
D1-CD2 docking site are highlighted. (B) Docking of D1-CD2 and three variants (mutations indicated) to
A-domain of integrin 3 as in (A). The (E) is the difference of docking energy between D1-CD2 and a
variant calculated by the docking program. (C) The representative scatchard plots of binding of ProAgio
to integrins v3 in presence of 3 mM poly Lysine (Left) and absence of poly Lysine (Right). The dots are
binding data. Solid line in left is fitting line. The fitting line clearly indicates n = 1 for one-to-one binding.
(D) The deduced disassociation (Kd) constants of ProAgio to integrins v 3, IIb 3, and 11 from the
ELISA and SPR binding analyses. The n.d means Kd could not be or were not determined. (E) and (F),
Attachment of indicated cells to culture plate on which ProAgio (filled bars) or D1-CD2 (open bars) was
coated was measured by counting the cells that attached to the plate after washing. (G) Attachment of
CHO (open bars) or COS-7 (filled bars) cells with/without (control) expression of v3 or IIb3 to culture
plate on which ProAgio was coated was measured by the same cell counting as in (E) and (F). The control
is CHO cells without integrin expression. The error bars in (E), (F), and (G) are standard deviations from
measurement of five independent experiments.
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To test the results of computation modeling/docking, the rationally designed D1-CD2
variants were expressed in bacterial E. coli and subsequently purified. Due to solubility, stability,
and other parameters, we chose one variant (Variant 3 in Figure 3.2B, which we call as
ProAgio), to carry out extensive characterizations. ProAgio exhibited structural properties very
similar to that of the parental protein as demonstrated by the 1H-NMR (Figure 3.1D), far UVCD, and fluorescent spectra - analyses, indicating that the engineered protein was well folded.
We carried out binding analyses to determine the binding affinity and stoichiometry of ProAgio
and integrin αVβ3 interaction. We first performed ELISA based binding assays. Scatchard plot
of the binding data indicated that ProAgio and integrin αVβ3 binding could not fit into a one-toone binding mode (Figure 3.2C). However, in the presence of 3 mM of poly Lysine, ProAgio and
integrin αVβ3 binding fitted well into a one-to-one binding mode with a deduced Kd of 4.3 nM
(Figure 3.2C & D). The results suggest that ProAgio may interact with integrin αVβ3 by both
specific and non-specific interactions, and the non-specific interaction is most likely due to
protein surface charges. To test whether ProAgio and integrin αVβ3 interaction is αVβ3 specific,
the ELISA based binding analyses were also performed with other two pairs of integrin. Clearly,
ProAgio interacted weakly with other two integrin pairs in the presence of poly Lysine (Figure
3.2D). To verify the ELISA based binding analyses, we also carried out SPR binding studies. To
avoid the problem of non-specific interactions, SPR binding experiments were carried out using
PEGylated ProAgio (30 kDa PEG-chain). PEGylated ProAgio bound to integrin αVβ3 via oneto-one binding mode with an affinity of deduced Kd 2 nM (Figure 3.2E and 3.2D), consistent
with the ELISA based binding analyses. The ProAgio and integrin interaction was metal ion
(Ca2+) dependent, as addition of EDTA abrogated the interaction, indicating that maintenance of
local structure of the A-domain is critical for the interaction.
To further verify ProAgio and integrin αVβ3 interaction, we carried out cell attachment
assays using culture plate coated with ProAgio. HUVECs have very high levels of αVβ3
expression (Figure 3.6A). The cells attached strongly to the ProAgio coated plates (Figure 3.2E).
CHO and COS-7 cells do not express αVβ3 (Stupack, Puente et al. 2001, Tani, Higashiyama et
al. 2003). The cells did not attach to the plates. We then exogenously expressed αVβ3 in CHO
and COS-7 cells (Figure 3.6B) and performed the same attachment analyses. Evidently, the
αVβ3 expressing CHO and COS-7 cells attached to the ProAgio coated plates (Figure 3.2F). As a
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control, CHO and COS-7 cells expressing integrin IIb3 did not attach to the plate (Figure
3.2G). Integrin V can authentically pair with 3, 5, and 6. To further test the specificity of
ProAgio-integrin interaction, we carried out attachment assays with COS-7 cells expressing
integrin αVβ3, V5, and V6 (Figure 3.6C). Clearly, only the cells expressing αVβ3 attached
strongly to the plate, while αVβ5 expressing cells exhibited a weak attachment (about three fold
less than that of αVβ3 expressing cells). The v6 expressing cells almost did not attached to the
plate (Figure 3.6D). The attachment assays suggested that ProAgio interacted with integrin αVβ3
on the cell surface. Interaction of ProAgio with the integrin was further verified by coimmunoprecipitation of ProAgio with integrin 3 in HUVEC extracts (Figure 3.6E).
We next analyzed whether ProAgio indeed bound to the A-groove. As predicted in our
docking, ProAgio-binding should not compete with RGD-binding (they bind to different sites).
We carried out an attachment assay. HUVECs were first incubated with Cilengitide, and
subsequently assayed for the attachment to ProAgio in the presence of Cilengitide. Clearly,
presence of RGD did not prevent HUVECs from attaching to ProAgio, (Figure 3.3A). Antibody
LM609, a monoclonal antibody target at the ligand-binding site of integrin αVβ3, is known to
recognize the ligand-binding site of integrin αVβ3. Thus, we tested whether the presence of
LM609 would block the ProAgio binding. Evidently, LM609 did not affect the interaction
between ProAgio and integrin αVβ3 (Figure 3.3B). To further test whether ProAgio indeed binds
to the A-groove, we carried out chemical crosslink of ProAgio with purified recombinant
integrin αVβ3 using Bis(Sulfosuccinimidyl)-glutarate (BS2G, Figure 3.4A) as a crosslinker.
Crosslinking followed by trypsin digestion and LC-MS-proteomic analyses indicated that
ProAgio WEKTSDKK (aa 35-43) crosslinked to integrin αV at the TEMKQER (aa 116-122)
(Figure 3.3C, 3.4B and 3.4E). We did not detect crosslinks of ProAgio with integrin 3 using
BS2G as a crosslinker.
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Figure 3.3. ProAgio binds to integrin V3 at the designed site.
(A) & (B) Attachment of HUVECs to ProAgio coated plates. The attachment assays were carried out in
the presence of 5 M of Cilengitide or BSA as control (A), or 40 g/ml antibody LM609 or IgG as
control (B). (C) The MS spectrum of peptide fragments resultant from trypsin digestion of crosslinks of
ProAgio with integrin v3 using BS2G as a crosslinker. The call-out is the enlarged region (indicated by
the arrow) containing ProAgio-integrin crosslinking peak and analyzed by ms/ms. The sequence on top is
derived crosslinking sequence from ms/ms using pLink. (D) The MS spectrum of peptide fragments
resultant from trypsin digestion of (Bottom) crosslinks of ProAgio with integrin v 3 using glutaraldhyde
as crosslinker and (Upper) ProAgio - integrin v3 mix without crosslinking. The deduced sequences of
the 2907.9 Da peaks from ms/ms analyses are indicated. (E) Docking model of ProAgio with integrin
v3 using Haddock 2.1 program by introducing the crosslinking restrains. The crosslinks are indicated by
dot lines. The mutation sites of the integrin 3 are indicated in red. (F) Attachment of CHO cells with
expression of integrin v 3 wild type or the mutant (3-KKQ) to ProAgio/Vitronectin coated plates. The
cell attachment to ProAgio is normalized to cell attachment to D1-CD2. (G) Co-immunoprecipitation of
3 or mutant (3-KKQ) with ProAgio (IP:integrin 3) from the HUVEC lysate was examined by
immunoblot (IB:ProAgio). The cells were treated with 5 M ProAgio for 6 hours prior to the extracts
preparation. IB:IgG indicates the amounts of antibody used in IP. Immunoblot of integrin 3 (IB:integrin
3) indicates amount of 3, which was precipitated down in the co-IPs. Error bars in (A), (B), and (F) are
standard deviations from measurement of five independent experiments.
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Figure 3.4. ProAgio binds to integrin αVβ3 at βA domain.
(A) Structure drawing of crosslinking agents BS2G and glutaraldhyde. (B) Crosslink of His-ProAgio with
recombinant integrin v 3 using BS2G were examined by immunoblots of integrin 3 (IB:3 Integrin)
(Left) and ProAgio (IB:ProAgio) (Right). The controls in both left and right panels are the ProAgiointegrin complex without crosslinking by BS2G. (C) Crosslinks of His-ProAgio with recombinant
integrin v3 using glutaraldhyde were examined by Gel-code staining (Right) and immunoblots of
integrin 3 (IB:3 Integrin) (Left). Control in right panel is the ProAgio-integrin complex without
crosslinking by glutaraldhyde. Crosslinking mixture was separated by denaturing and His-pull down (His
tag PD) or without pull-down (No HisTag PD) prior to electrophoresis and immunoblot. In (B) and (C),
arrows indicate the ProAgio-integrin crosslinks. The crosslinked bands were sliced out and subjected to
trypsin digestion and followed M/S analyses. (D) Expression of integrin v3wild type (COS7v3) and
3-KKN mutant (COS7v3KKN) in COS7 cells were examined by immunoblots of integrin
3(IB:Integrin 3). Immunoblot of GAPDH (IB: GAPDH) is a loading control. (E) Call-out regions
ms/ms (top, ProAgio-integrin crosslinking, middle and bottom, integrin-integrin crosslinking) of the MS
spectrum (MS2) of peptide fragments resultant from trypsin digestion of crosslinks of His-ProAgio with
integrin v 3 using BS2G. The sequence on top is derived sequences using pLink based on ms/ms of the
crosslinked peaks.
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Table 3.1. Mass of the crosslinked peptides identified using pLink and corresponding regions in integrin
αVβ3. Integrin αVβ3 and ProAgio were crosslinked at 1:0.7 ratio. δPPM is determined using the formula
above mentioned.
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It was possible that the bulky crosslinking reaction groups of BS2G prevented ProAgio
from crosslinking to integrin 3. To further unambiguously determine the ProAgio binding site,
we performed the crosslinking using another crosslinker glutaraldehyde (Figure 3.4A). Regions
of NLKVII (aa 99-105) of ProAgio crosslinked to FNEEVKKQ (aa 203-210) of 3 by
glutaraldehyde (Figure 3.3D and 3.4C). With the binding and crosslink results, we re-docked
ProAgio to integrin αVβ3 with application of the crosslinking restrains using Haddock 2.1
(Figure 3.3E). The modeling revealed several important contacts between ProAgio and the
integrin. Guided by the modeling, mutations were introduced into 3 (e.g. K233A, and K234A).
Computations showed that mutations weakened the ProAgio and integrins docking (the docking
energy increased by 107 kcal/mole in the same docking model as shown in Figure 3.3E). The
mutations indeed reduced the attachment of the mutant expressing CHO cells (Figure 3.4D) to
ProAgio (Figure 3.3F), and abolished ProAgio and integrin 3 co-immunoprecipitation (Figure
3.3G). Thus, we concluded from our binding, crosslinking, and mutational studies that ProAgio
interacted with integrin αVβ3 at the A-groove.
To test whether ProAgio treatment would have effects on the integrin activity, we
analyzed the formation of actin filament stress fibers and the focal adhesion complex in integrin
αVβ3 expressing HUVECs. Evidently, the actin filament stress fibers decreased and eventually
disappeared upon the ProAgio treatment. The accumulation of vinculin at the tips of stress fibers
was diminished upon treatment (Figure 3.7A), indicating disassociation of the focal adhesion
complex. Furthermore, ProAgio treatment led to a rapid inactivation of FAK that was activated
by attachment to ECM (Figure 3.5A). These results demonstrated that ProAgio abrogated the
integrin functions in endothelial cells.
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Figure 3.5. ProAgio induces apoptosis in HUVEC and downregulates integrin αVβ3 signaling.
(A) Cellular levels of phosphorylated FAK in HUVEC cells were examined by immunoblot (IB: pFAK).
The cells were treated by indicated agents. Immunoblot of FAK (IB: FAK) indicates the levels of total
cellular FAK. Immunoblot of GAPDH is a loading control. (B) Apoptosis of HUVEC cells was measured
by apoptosis kit 10 hours after treatment with different concentrations of ProAgio or D1-CD2. Cell
apoptosis is presented as Apoptosis (%) by defining the apoptosis of untreated cells as reference 0%
apoptosis. (C) Apoptosis of COS7 cells with exogenous expression of integrin v3, v5, and v6 in
the presence of 3 M ProAgio was measured by cell apoptosis kit. Cell apoptosis is presented as
Apoptosis (%) by defining the apoptosis of untreated cells as reference 0% apoptosis. Error bars in (B)
and (C) are standard deviations from measurement of five independent experiments.
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Figure 3.6. ProAgio is highly specific for integrin αVβ3, but not for other αV integrin pairs.
(A) & (B) The levels of endogenous and exogenous integrin V (IB: Integrin V), 3 (IB: Integrin 3),
and IIb (IB: Integrin IIb) of indicated cells were analyzed by immunoblot of cell lysates. CHOV3,
CHOIIb3, COS7V3, and COS7IIb3 are derived from CHO and COS7 cells with exogenous
expression of v3and IIb3respectively. (C) The levels of exogenous expressed integrin V(Integrin
V), 3 (Integrin 3), 3 (Integrin 5), and 6 (Integrin 6) in COS-7 cells were analyzed by immunoblot
of cell lysates from COS7V3, COS7V5, and COS7V6respectively. (D) Attachment of COS7
cells with exogenous expression of integrin v3, v5, and v6 to plate coated with ProAgio. The
attachment presented as number of cells attached per microscopic view field. Error bars are standard
deviations from measurement of five independent experiments. (E) Co-immunoprecipitation of integrin
3with ProAgio (IP: Integrin 3) from the HUVEC cell lysate was examined by immunoblot of ProAgio
(IB: ProAgio). The cells were treated with 5 M ProAgio for 6 hours prior to the extracts preparation.
IgG indicate the amounts antibody used in IP. Immunoblot of exogenous expressed integrin V(Integrin
V), 3 (Integrin 3), 3 (Integrin 5), and 6 (Integrin 6) in COS-7 cells were analyzed by immunoblot
of cell lysates from COS7V3, COS7V5, and COS7V6respectively. (D) Attachment of COS7
cells with exogenous expression of integrin v3, v5, and v6 to plate coated with ProAgio. The
attachment presented as number of cells attached per microscopic view field. Error bars are standard
deviations from measurement of five independent experiments. (E) Co-immunoprecipitation of integrin
3with ProAgio (IP: Integrin 3) from the HUVEC cell lysate was examined by immunoblot of ProAgio
(IB: ProAgio). The cells were treated with 5 M ProAgio for 6 hours prior to the extracts preparation.
IgG indicate the amounts antibody used in IP. Immunoblot of integrin 3(IB:Integrin 3) indicates
amount of 3was precipitated down in the co-IPs. Immunoblot of GAPDH in (A), (B), and (C) are
loading controls.
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3.3.2. ProAgio induces apoptosis by recruiting caspase 8 to integrin 3 tails
Preceding tests suggested that a rationally designed protein that targets a unique site of
integrin αVβ3 had been generated. We noted a strong effect of ProAgio in induction of apoptosis
of HUVECs while the cells were still attached in our previous assays.
To our knowledge, this effect is different from that of other integrin targeting agents.
Thus, we assessed the effectiveness of ProAgio in induction of cell apoptosis. ProAgio induced
HUVECs apoptosis with EC50 around 1.4 M (Figure 3.5B). We subsequently side-by-side
compared ProAgio with several other agents that are known to have effects on HUVECs, such as
Avastin, Endostar (an endostatin derivative approved for lung cancer treatment in China),
LM609, and Cilengitide, using HUVECs. ProAgio was much more effective in inducing
apoptosis than other agents (Figure 3.7B). We further tested whether the effects of apoptosis
induction were integrin αVβ3 dependent. To this end, cell apoptosis were analyzed with several
cell lines, HUVEC, PC-3, HEK, and COS-7 with/without exogenous expression of integrin
αVβ3, αVβ5 and αVβ6 HUVECs express high levels of αVβ3. PC-3 cells express marginal
levels of the integrin (Zhou, Kim et al. 2011). HEK cells express αV but not β3 (Taherian, Li et
al. 2011). COS-7 cells do not express αVβ3 (Stupack, Puente et al. 2001). ProAgio did not
induce apoptosis with COS-7 and HEK cells. The protein induced apoptosis of HUVEC and
COS-7 cells with exogenous expression of αVβ3 integrin, and ProAgio did not induce apoptosis
of αVβ5 and αVβ6COS-7 cells (Figure 3.7C, 3.7D and 3.5C). Moderate apoptosis was observed
when PC-3 cells were treated with high concentration of ProAgio (> 30 M). The observations
indicated that the effects of ProAgio in apoptosis induction were αVβ3 dependent.
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Figure 3.7. ProAgio recruits and activates caspase 8 at cytoplasmic domain of integrin 3.
(A) Representative phase contrast microscopic images of endothelial HUVECs that were treated by
indicated agents for 8 hours. (B) Levels of indicated cleaved caspases (C-caspases) in HUVEC lysates
were analyzed by immunoblot using antibodies against various cleaved caspases. The cells were treated
by 5 µM ProAgio for 10 hours. (C) Apoptosis of HUVECs that were treated by 5 µM ProAgio in the
presence of caspase 8/9 inhibitors was analyzed by apoptosis kit. Apoptosis was presented as %
Apoptosis by defining the cells that were untreated as 0%. Error bars are standard deviations from
measurement of five independent experiments. (D) Levels of cleaved casapases 8/9 (C-caspase 8/9) in
HUVEC lysates were analyzed by immunoblot using antibody against cleaved caspase 8/9. The cells
were treated with 5 µM ProAgio and caspase 8/9 inhibitors for 5 hours. (E) Co-immunoprecipitations of
caspase 8 (Upper) and caspase 9 (Bottom) with integrin β3 (IP:integrin β3) were analyzed by
immunoblots (IB:caspase 8/9). The cells were treated with the indicated agents 5 hours prior to the
preparation of extracts. Immunoblot of integrin β3 (IB:integrin β3) indicates amount of β3, which was
precipitated down in the co-IPs. Immunoblot of GAPDH (IB: GAPDH) in (B) and (D) are loading
controls.
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An intriguing question is how ProAgio induces endothelial cell apoptosis by binding to
the A-groove of the integrin 3. We noted in preceding apoptosis tests that, in contrast to the
effects of Cilengitide and other integrin targeting molecules, ProAgio treatment did not lead to
HUVEC floating/detaching (Figure 3.8A), indicating that ProAgio induced apoptosis by a
mechanism that is different from anoikis. To understand the molecular mechanism by which
ProAgio induces endothelial cell apoptosis, we analyzed the activation of various caspases in
HUVECs upon ProAgio treatment. Caspase 8, caspase 9, caspase 7, and caspase 3 were strongly
activated (Figure 3.8B). We then tested if the apoptosis induction by ProAgio was dependent on
activation of an initiation caspase, e.g. caspase 8 and/or caspase 9 using caspase 8 and caspase 9
inhibitors. Caspase 9 inhibitor did not abolish the effects of ProAgio in the apoptosis induction,
while caspase 8 inhibitor largely abolished the effects (Figure 3.8C).
On the other hand, caspase 9 inhibitor did not abrogate the activation of caspase 8, while
the activation of caspase 9 was largely inhibited by caspase 8 inhibitor (Figure 3.8D), suggesting
that the caspase 8 activation mediated the effects of ProAgio. It was observed by Stupack D. and
colleagues that unligated integrin 3 can trigger cell apoptosis by directly recruiting caspase 8 to
its cytoplasmic domain by a mechanism of so-called integrin mediated death (IMD) (Stupack,
Puente et al. 2001). Thus, we reasoned whether ProAgio-binding to the A-groove could
trigger/enhance a mechanism that is similar to that of IMD. We examined whether ProAgio
treatment led to direct recruitment and activation of caspase 8 to the cytoplasmic domain of
integrin 3 by co-immunoprecipitation. Clearly, caspase 8 was co-immunoprecipitated with
integrin 3 upon ProAgio treatment (Figure 3.8E). Caspase 9 did not co-immunoprecipitate with
integrin 3 upon the ProAgio treatment (Figure 3.8E). As a comparison, Cilengitide did not
result in strong recruitment of caspase 8 to 3 under the same conditions (Figure 3.8E). The
results suggest that ProAgio may induce endothelial cell apoptosis by mechanism that is similar
to that of IMD and is very different from that of other integrin antagonists.
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Figure 3.8. ProAgio induces apoptosis via targeting integrin V3.
(A) Representative confocal microscopic images of HUVECs stained by Rhodamine phalloidin (red),
antibody against vinculin (green), and DAPI (blue). The cells were treated by the indicated protein
agents for indicated times. (B), (C), and (D) Apoptosis of various different cells (B, HUVEC), (C,
indicated cells), and (D, COS-7 with (v3) or without (Control) integrin v3 expression) was measured
by cell counting 24 hours after treatment with indicated agents. Cell apoptosis is presented as %
apoptosis by defining the apoptosis of untreated cells as 0%. In all treatments, 5 M (final
concentration) of all agents were used except in one case in (B) wherein 50 M Cilengitide was used
(indicated). In (B), (C), and (D) the data represent the mean±s.d. and difference were tested by the
Student’s t-test; * means p < 0.05, ** means p < 0.01, and *** means p < 0.001. The data are
representative of five independent biological experiments.
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3.3.3. ProAgio effectively inhibits tumor growth and reduces tumor blood vessels
We next asked whether the integrin αVβ3 targeting ProAgio would be effective in the in
vivo experiments. We chose to test the effectiveness of ProAgio on inhibition of angiogenesis.
We first examined the anti-angiogenesis activity of ProAgio by the in vitro endothelial tube
formation assay using HUVECs. Evidently, ProAgio almost completely disrupted the endothelial
tube (Fig. 5A). To facilitate the in vivo test, ProAgio was site specifically PEGylated using PEG20 kDa, a molecule with linear-shaped PEG chain (denoted as ProAgio-PEG), at an introduced
Cys residue (Figure 3.9A). The Cys mutation was introduced at a site that is away from residues
involved in integrin contacts (based on computation modeling). In vitro tests with HUVECs
indicated that the PEGylation did not result in significant decrease in activity (Figure 3.9A). We
tested the effects of PEGylated ProAgio in angiogenesis Matrigel plug assays. Evidently,
ProAgio inhibited angiogenesis in the Matri-gel plug assay. The activity was stronger than that
of Avastin (Figure 3.9B). We further tested the effects of ProAgio in inhibition of tumor growth
in animal models of cancers. We generated xenograft model of PC-3 cells.
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Figure 3.9. PEGylated ProAgio effectively decreases angiogenesis in in vivo matrigel plug assay.
(A) (Left) Model structure of ProAgio. Red color indicates the position of introduced Cys residue for
PEGylation. (Right) Apoptosis of HUVEC cells was measured by cell counting 24 hours after treatment
with buffer, ProAgio, or ProAgio-PEG. Cell apoptosis is presented as % apoptosis by defining the
apoptosis of untreated cells as 0%. (B) Matrix-gel plug assay, 400 l of matrix-gel in mixing with
indicated agents was s.c. implanted on the right flank of Balb/c mice. The matrix-gel GeltrexTM was premixed with other components suggested by vendor before addition of the indicated agents. After two
weeks, pictures of the matrix-gel insertion site were taken. (Left) are representative images of the matrixgel plugs in mix with either ProAgio or buffer saline. (Right), quantitation of angiogenesis in implanted
matrix-gels, the matrix-gels were retrieved from the mice. The hemoglobin contents in the matrix-gel
plagues were analyzed by standard method, and presented as relative hemoglobin content by defining the
hemoglobin levels of buffer gel plague as 100%. ProAgio IP means the ProAgio was administered by i.p.
injection (5 mg/kg one dose every two days) instead of pre-mix with matrigel. Error bars are standard
deviations from measurement of five independent experiments.
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Figure 3.10. ProAgio effectively inhibits tumor growth and disrupts tumor vessels.
(A) Representative phase contrast microscopic images of endothelial tubes of HUVECs under treatment
of indicated agents (5 M). (B), (C), (D), and (E) Growth of xenograft PC-3 tumors under the treatment
of indicated agents was monitored by; (B) and (D) growth curve by measuring tumor volumes every four
days, or (C) and (E) endpoint weights of the harvested tumors. Treatments started 5 days (B)/(C) or 17
days when tumors reached average of 250 mm3 in size (D)/(E) post tumor inoculations. (F)
Representative images of immunofluorescence staining of tissue sections prepared from the harvested
tumors with antibodies against mouse CD31 (Green). The blues are DAPI stains. (G) Quantitative
analyses of vessel lengths, densities, and branch points (manually counting) of the CD31 staining of the
tumor tissue sections. The vessel density and number of branch points are counted in 319.8 X 319.8 m2
view field using image-J. The quantization was average values of randomly selected 3 fields in position
matched 4 sections from each tumor. Error bars in (B), (C), (D), and (E) are standard deviations from
measurements of experimental six mice. In (B), (C), (D), and (E) the data represent the mean ± s.e.m. and
difference were tested by the Student’s t-test; * means p < 0.05, ** means p < 0.01, and *** means p <
0.001. The data are representative of at least three independent biological experiments.

Table 3.2. CD31 Quantification of PC3 xenograft tumors treated with Buffer (PBS), Endostar,
Avastin and ProAgio (n = 6). 5 sections from each tumor was stained and quantified. Quantification
was performed for vessel length, mean vessel density (MVD) and branch points (BP) using ImageJ
software.
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Tumor bearing mice were administered i.p. with various doses of ProAgio-PEG and
PEGylated host protein, and buffer saline for 20 days via one dose every other day. The
treatments started at the fifth day post tumor inoculation. It was clear that ProAgio-PEG
inhibited the tumor growth almost completely at the dose of 10 and 20 mg/kg (two and one
tumors completely disappeared in the 20 and 10 mg/kg dose groups respectively). As controls,
the tumors grew at normal rate in mice treated with buffer and the PEGylated host proteins. The
effects of ProAgio-PEG on tumor growth inhibition showed a clear dose dependency. However,
the dose dependence became less dramatic after 10 mg/kg (Figure 3.10B and 3.10C). ProAgioPEG was also effective when administered at a later time of tumor growth (Figure 3.10D and
3.10E, two tumors shrunk in size). To analyze the effects of the treatment on tumor vessels, we
carried out immunostaining of CD31, an endothelial marker, with the tissue sections prepared
from collected tumors. Immunostaining demonstrated that the blood vessels were dramatically
reduced (Figure 3.10F). Quantitative analyses of the CD31 staining indicated that there were
dramatic reductions in vessel density, branch points, and vessel lengths (Figure 3.10G). To
further assess the effectiveness, we carried out experiments to side-by-side compare the effect of
ProAgio-PEG vs Avastin and ProAgio-PEG vs Endostar using the PC-3 xenografts. ProAgioPEG was significantly more effective in inhibition of tumor growth compared to those of the
Avastin and Endostar treatments (Figure 3.11A, 3.11B, 3.11C and 3.11D). Analyses of tumor
vessels showed that the ProAgio-PEG treatment led to a higher degree of vessel reduction than
those of Avastin and Endostar treatment groups (Table 3.2).
Tumor angiogenesis is affected by the surrounding microenvironment. Thus, we tested
whether the effects of ProAgio-PEG on tumor growth and angiogenesis were also true for an
orthotopic model with immune-compatible mice. We carried out similar treatment experiments
with the orthotopic model of murine breast 4T-1 cells using Balb/c mice. The tumor bearing
mice were treated by the same dose schedule by ProAgio-PEG or buffer as in previous treatment.
The treatment started at 5th day post tumor inoculation. Evidently, there was a large difference in
tumor growth between the ProAgio-PEG treated and buffer treated groups (Figure 3.11E and
3.11F), indicating that ProAgio is highly effective in inhibiting tumor growth with this orthotopic
model.
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Figure 3.11. ProAgio decreases angiogenesis in xenograft and orthotopic tumors.
Growth of xenograft PC-3 tumors (A), (B), (C), and (D) or orthotopic 4T-1 tumors (E) and (F) under the
treatment of indicated agents was monitored by; (A), (C), and (E) growth curve by measuring tumor
volumes every four days, or (B), (D), and (F) endpoint weights of the harvested tumors. Treatments
started 5 days post tumor inoculations. In (F), one tumor completely disappeared in ProAgio treatment
group. The dot line in (E) in the growth curve is due to extra-large size of tumors that led to pretermination of experiment (per IACUC regulation). The pre-terminated tumors were not included in both
growth curve and final tumor weights. Error bars are standard deviations from measurement of six mice.
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3.3.4. ProAgio is not toxic to normal tissue and organs
A specific integrin αVβ3 targeting agent should be less/nontoxic to existing blood vessels
in normal tissue/organs. To assess whether ProAgio disrupted the non-tumor blood vessels, we
prepared tissue sections from liver, lung, heart, spleen, and kidney of the mice that were treated
with different agents. The tissue sections were analyzed by Hematoxylin staining and CD31
immunostaining. Hematoxylin staining revealed that there was no obvious abnormality in tissue
anatomy structure,

and

no

damage

lesion/necrosis

was

observed

(Figure

3.12A).

Immunofluorescence staining using the anti-CD31 antibody suggested that there was no
disruption or reduction of blood vessels in the liver, lung, heart, and kidney upon treatments with
ProAgio-PEG compared to those in the groups that were treated with the PEGylated D1-CD2
and buffer saline (Figure 3.12A). The treatments did not lead to any abnormal weight gain or loss
(Figure 3.12B). To further analyze the toxicity of ProAgio, healthy CD-1 mice were i.v.
administered three doses of 60 mg/kg of ProAgio-PEG in 48 hours and observed for 24 days.
All animals behaved normally. Blood and urine samples were collected. Examination of
plasma AST, ALP, TnT, creatinine, and urine albumin 48 hours after the agent’s administrations
indicated that ProAgio-PEG at the dose did not cause damage to animal’s liver, kidney, and heart
(Figure 3.12C).
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Figure 3.12. ProAgio is non-toxic to normal tissues.
(A) Represent images of Hematoxylin staining (Left) and IF staining using anti- mouse/CD31 antibody
(Right) of tissue sections of kidney and liver collected from the mice that were treated with ProAgio-PEG
20 mg/kg (10 doses for 20 days) or buffer. The images are typical of stains of at least two view fields of
four sections from each organs. (B) Body weights of tumor-bearing mice were measured every four days
during the treatments with ProAgio-PEG 20 mg/kg (10 doses for 20 days) or buffer. (C) Plasma levels of
ALT, ALP, Creatine, and TnT, and urine levels of albumin were measured using corresponding
commercially available kits. Mouse blood and urine samples were collected from CD-1 mice 48 hours
after treatment with three doses of 60 mg/kg ProAgio-PEG or buffer. Error bars in (B) and (C) standard
deviations from measurement of six mice.
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3.4. Discussion
We have successfully developed a protein agent targeting integrin αVβ3 at a novel site by
rational protein design. In vitro and in vivo experiments demonstrate the effectiveness of our
designed protein. The developed agent is not toxic to non-cancerous blood vessels and other
tissue/organs, providing an excellent candidate for future potential clinical development. The A
groove is present in almost all other -integrin. Thus, our approach may be applicable to develop
agents targeting the similar A groove of other integrin pairs.
Due to unique expression patterns and frequent disease association, several pairs of
integrin are promising targets for development of therapeutics for a number of pathological
conditions (Millard, Odde et al. 2011). Most approaches focus on the integrin ligand-binding.
However, significant drawbacks, such as the effect of activation of integrin signaling by ligandbinding, limit the clinical success of the integrin ligand antagonist. Most recently, Van
Agthoven, J. F. and co-workers reported a novel interaction of a variant of physiologic ligand
fibronectin with integrin 3 (Van Agthoven, Xiong et al. 2014). The interaction did not lead to
conformation changes resulting from ligand-binding thus consequentially activation of integrin
outside-in signaling, which provides a novel concept for developing integrin ligand-based
antagonist.

Our approach does not target ligand-binding (Figure 3.13B). In fact, ProAgio

induced HUVEC apoptosis with or without ligand binding, and ProAgio binding did not interfere
with RGD binding (Figure 3.13A and 3.3A), suggesting that the effects of ProAgio are
independent of ligand-binding. Effective induction of cell apoptosis through integrin V3 via a
mechanism different from anoikis is a unique feature of ProAgio.
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Figure 3.13. ProAgio and integrin V3 interaction is independent of RGD binding.
(A) Apoptosis of HUVECs was measured by cell counting 24 hours after treatment with 5 M of
ProAgio. The cells were incubated with 5 M Cilengitide (filled bar) or buffer (open bar) prior to
the ProAgio treatment. Cell apoptosis is presented as % apoptosis by defining the apoptosis of
untreated cells as reference 0%. (B) Docking model of ProAgio (Green) with integrin v3 in the
presence of RGD (Red) using HADDOCK 1.2 program. (C) Levels of v (IB: Integrin V) and
3 (IB: Integrin 3) integrins in COS-7 cells with expression of 3 (COS73) or v3
(COS7V3) were analyzed by immunoblot of cell lysates. Immunoblot of GAPDH
(IB:GAPDH) is a loading control. (D) Cell attachment of COS-7 cells with expression of v3
(COS7V3) or 3 (COS73) to culture plate coated with ProAgio. The cell attachments are
presented as total number of cells attached to the plate per view field (average of three fields). (E)
Apoptosis of COS-7 cells with expression of v3 (COS7V3) or 3 (COS73) treated by 5 M
ProAgio. Cell apoptosis is presented as % apoptosis by defining the apoptosis of untreated cells
as reference 0%. In (A), (D), and (E) the data represent the mean±s.d. and difference were tested
by the Student’s t-test; * means p < 0.05, ** means p < 0.01, and *** means p < 0.001. The data
are representative of five independent biological experiments.

82

This feature may bring a very important advantage in future potential clinical
applications, as ProAgio does not need to compete with strong integrin-ligand interactions, and
does not need to induce anoikis that may not occur in actual situations due to the fact that the
cell-to-ECM adhesions always involve interactions between multiple pairs of integrin and
multiple types of ECM. We believe that our study demonstrated a new concept of developing
therapeutics targeting integrin. The A groove is very close to the RGD binding site in the A
domain. An open question is how the ProAgio-integrin interaction at the groove triggers effects
that are so different from those of RGD-binding. One plausible speculation is that ProAgiobinding to the A groove induces conformation changes that are different from that of RGD
ligand-binding, which consequently trigger different signaling that allows caspase 8 recruiting to
the cytoplasmic domain of 3. Indeed, previous structure study of the integrin-RGD complex
showed that RGD interacts with a site formed by ‘D3-A3’ and ‘D4-A4’ loops of -propeller
domain of V integrin. The Aspartate of RGD interacts with A domain of 3 integrin, where
the carboxylate side chain of the Asp protrudes into a cleft formed by A ‘A’-2’, and ‘C’-3’
loops. These interactions are critical for an inward conformational change of the A domain and
the consequential integrin signaling (Mould, Barton et al. 2003, Arnaout, Mahalingam et al.
2005). However, our modeling, crosslinking, and mutations demonstrate that ProAgio does not
contact these RGD interacting elements. Instead, ProAgio contacts 2 helix, ‘B-C’ loop and ‘23’ loop (Figure 3.3E and 3.13B) which are not involved in RGD-binding. An ultimate answer
to the question may require a comprehensive structural study to understand the differences in
structure/conformation changes upon ProAgio-binding and RGD ligand-binding.
In our modeling, ProAgio only contacts 3. It is intriguing why ProAgio has a specificity
for αVβ3. Careful examination of x-ray crystal structures of αVβ3 and IIb3, the other
authentic  subunit that paired with 3, reveals that the ProAgio binding site, the -groove is
different in both cases (Figure 3.14). The key contact residues K, K, and Q locate in a region of
1 -helix in αVβ3, while the same region forms a loop in IIb3. The relative orientation of 1
and 2 helices are important for the ProAgio binding (from our docking and modeling), while
these two helices are pushed far apart in IIb3 (Figure 3.14). Thus, ProAgio can only bind to
αVβ3 but not IIb3 as shown in our binding and cell attachment studies. Apparently, the fact
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that ProAgio interacts with αVβ3 but not IIb3 provides another support for the ProAgio and
αVβ3 interaction site. Interestingly, COS-7 cells expressing 3 (without V) were able to attach
to ProAgio. ProAgio was also able to less effectively induce apoptosis of the 3 expressing
COS-7 cells (Figure 3.13 C, D, and E). These results provide an additional support for our design
that ProAgio mainly contacts with 3.

Figure 3.14. Figure depicting the folding of integrin β3 with αV and αIIb.
Structure features of the -groove and nearby regions of integrin V3 with/without RGD binding (Left
and middle) and IIb3 (Right). The structures in figures are adopted from the indicated PDB files in
protein structure data bank.
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3.5. Materials and Methods
3.5.1. Reagents, antibodies, cell lines, and protein expression/purifications
Cell lines PC-3, 4T-1, CHO, HEK299, and COS-7 were purchased from ATCC, and
HUVECs were purchased from Invitrogen. The cells were cultured as per vendor’s instructions.
Caspase 8 Inhibitor II, Caspase 9 Inhibitor III, Cilengitide, Integrin pairs, v3, 11, and IIb3,
Rhodamine Phalloidin, BS2G, and glutraldehyde were purchased from EMD Millipore, Billerica,
Roche R&D, Invitrogen, and Sigma Aldrich respectively. Avastin was a prescription drug
purchased from Walgreens. Endostar was purchased from SIMCERE China. PEGylation agent
Maleimide-20K for protein Cys pegylation was purchased from JenKem Technology. Antibodies
against β3-integrin, αV-integrin, αIIb-integrin, FAK (D2R2E), Phospho-FAK (Tyr397),
Caspase-8, Cleaved Caspase-8, Caspase-9, Cleaved Caspase-9, Caspase-3, Cleaved Caspase-3,
Caspase-7, Cleaved Caspase-7, mouse CD31, vinculin, and GAPDH were purchased from
Millipore, Cell Signaling, Danvers, Abcam, and Santa Cruz Biotechnology respectively.
Antibody against ProAgio was raised using recombinant ProAgio expressed/purified from E.
coli. as an antigen. The cDNAs that encode D1-CD2 was adapted from our previous studies
(Yang, Yang et al. 2008). The cDNAs for D1-CD2 and variants were subcloned into bacterial
expression vector pGEX-2T. The recombinant proteins were purified from bacterial lysates by a
two-column procedure established in our laboratories. The cDNAs encode for integrins V,
IIb, and 3 were purchased from Addgene. The cDNAs were subcloned into a mammalian
expression vector pCDNA3.1 for exogenous expression of different integrins in cultured cells.
3.5.2. Computation modeling/docking
Integrin coordinates were taken from the RCSB Protein Data Bank (PDB ID: 1L5G)
(Xiong, Stehle et al. 2002). The domain 1 of cell adhesion protein CD2-CD1 (PDB ID: 1HNF)
(Bodian, Jones et al. 1994) was used as a starting point for docking. The docking was performed
with HADDOCK 1.2, supporting docking to make use of experimental information to drive the
docking while allowing for various degrees of flexibility (Dominguez, Boelens et al. 2003). D1CD2 was first randomly docked into A domain of 3. For comparison, three different variants
were also randomly docked into βA domain of β3. In order to further refine the binding of
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integrin and ProAgio, ProAgio (variant 3) was docked into integrins αVβ3 together with our
crosslinking-drive refinements. The active residues used to define the ambiguous interaction
restraints (AIRs) were those showing the direct crosslinking contacts and solvent-accessible. The
surface accessibility data was calculated with the program NACCESS. Only the residues having
either backbone or side-chain relative solvent accessibility above 40% were retained for the
definition of active and passive residues. The passive residues correspond to the residues that are
surface neighbors of the active residues as identified by visual inspection and that have a high
level of solvent-accessibility (40%). A total of 1000 conformers of the integrin with ProAgio or
CD2-CD1 complex were generated using only the AIRs, vander waals energy, and electrostatic
terms in CNS. The 200 conformers with lowest molecular energies were subsequently subjected
to semi-flexible simulated annealing and refinement with explicit water and only backbone
restraints for residues outside the interface. The solutions were clustered using an arbitrary
RMSD and ranked according to their intermolecular interaction energy (sum of Vander Waals,
Eelec; electrostatic, Evdw and AIRs energy terms, EAIR). The lowest-energy structures of each
cluster were selected for analysis.
3.5.3. ELISA binding
The commercial recombinant integrins α1β1, αvβ3, and IIb3 were immobilized on
ELISA plates. Various concentrations of ProAgio were added into the plates. In some cases, poly
Lysine was co-added into the plates at a final concentration of 3 mM. After incubation and
extensive washing, antibody that recognizes ProAgio was added into the mixture. The plates
were incubated at room temperature for 4 hours. Excessive antibody was removed by washing.
The bound ProAgio was quantified by secondary antibody that recognizes anti-ProAgio
antibody. The binding data were plotted and analyzed via Scatchard analyses to deduce the Kd
and binding stoichiometry.
3.5.4. SPR
The commercial recombinant integrins α1β1, αvβ3, and IIb3 were diluted to a
concentration of 100 µg/ml and immobilized on to the CM5 chip with response units (RU)
around 500. Then PEGylated ProAgio bindings were carried out at various concentrations with
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the running buffer of 1x HBSS 10 mM HEPES, 150 mM NaCl, 5 mM MgCl2, pH 7.4. The flow
rate of 50 µl/min, and the binding time was 12 minutes. Kds were deduced by calculation via
binding curves of various concentrations.
3.5.5. Nude mice xenograft treatments and toxicity
All animal experiments were carried out in accordance with the guidelines of IACUC of
Georgia State University and all the mice were obtained from Harlan. Six-week-old male nude
mice or Balb/c mice were subcutaneously injected with 5 × 106 of PC-3 or 4T-1 cells. Tumor
formation and volumes were assessed every 2 - 4 days. Tumor volumes were measured by two
perpendicular diameters of the tumors with the formula ½ (length) × (width) 2. The tumor bearing
mice were subjected to i.p. injections of appropriate agents as indicated frequencies. The
treatments started five days post tumor inoculations or till tumor reached the average size of 230
mm3. The tumors were collected and weighed at the end of the experiments. Tissue sections were
prepared from harvested tumors or other organs. For toxicity studies, six-week-old healthy male
CD-1 mice were injected i.v. with appropriate agents as indicated frequencies and doses. The
animals were returned to their cages after injection. The behaviors of animals were closely
monitored. Blood samples were collected at appropriate time points. For analyses of urine
albumin, animals were placed in metabolic cages. Urine samples were collected in 24 hours. At
the end of experiments, animals were euthanized. Tissue samples from various organs were
collected for tissue sections. The tissue sections were analyzed by IF or H&E stains using
commercially available antibodies as indicated. Statistical analyses were done in comparison to
the control group with unpaired two-tailed Student’s t test.
3.5.6. Determination of the integrin binding site by chemical crosslinking followed by MS
analyses
Crosslinking by BS2G (Figure 3.4A). Recombinant integrins v3 were mixed with histagged ProAgio in 1:0.8 ratio. After 40 minutes incubation, the crosslinking agents BS2G were
added to the mixture in 40 folds molar excess. After crosslinking reaction for 150 minutes, the
crosslink mixture was denatured and separated by 5% SDS-PAGE. Crosslinking of ProAgio to
the integrins was verified by immunoblot using antibodies against ProAgio and integrins 3
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(Figure 3.4B). The identified crosslinking bands were sliced out and subjected to trypsin
digestion followed by LC-MS analyses. The crosslinked peptides were identified by the
procedure similar to that described by Bing Yang et al. using pLink analyses. The identified
crosslinking peptides were then analyzed by ms/ms to determine the aa sequence of the peptides.
Several crosslinked peaks were identified (Figure 2C and 3.4E, sequence derived from ms/ms is
shown on top). There were many crosslinks between integrins (Figure 2E as examples). The
ProAgio-integrin crosslink was observed in three independent repeating crosslinking
experiments.
3.5.6.1. Crosslinking by glutaraldhyde (Figure 3.4A)
His-ProAgio was mixed with recombinant integrin αVβ3 in 0.7:1 ratio in HEPES buffer.
The freshly prepared glutaraldhyde was added into the mixture in 3 folds of molar excess. After
1 hour incubation on ice, the crosslinking was stopped by adding 1M Tris-HCl pH = 7.4 buffer.
The crosslinking mixture was separated by electrophoresis and Gel-code staining (Figure 3.4C,
right panel). The crosslinking mixture was then denatured by 8 M urea. The crosslinked HisProAgio and the integrins were pulled down by Ni-NTA beads. The precipitations were analyzed
by SDS-PAGE followed by immunoblot using antibody against integrin 3 (Figure 3.4C, left
panel). Clearly, His-ProAgio crosslinked to integrin 3 (Figure 3.4C). After elution from the NiNTA beads, precipitates were dialysed against HEPES buffer pH = 6.9. The recovered ProAgiointegrin crosslinks were digested by trypsin and subsequently analyzed by MALDI-MS. An
identical procedure was performed without addition of crosslinking agent glutaraldehyde and
without Ni-NTA beads pull-down. The resultant mass spectrum with/without addition of
glutaraldehyde and pull-down were closely compared. Several peptide ms peaks were detected in
the glutaraldehyde crosslinked mixture while they were absent in non-crosslinked mixture. An
identical ms peak at 2907.9 Da was detected in three independent repeating crosslink
experiments. This peak was further subjected to MALDI-MS/MS analyses to identify the
crosslinked peptide (Figure 3.3C, sequence derived from ms/ms and manual analysis is shown on
top). All RP-HPLC−MS/MS experiments were performed on a LTQ-Orbitrap Elite mass
spectrometer equipped with EASY-spray source and nano-LC UltiMate 3000 high-performance
liquid chromatography system.
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3.5.7. Endothelial tube formation assays
Endothelial tube formations were carried out with the endothelial tube kit (Invitrogen).
Briefly, HUVECs were seeded in culture plate coated with Geltrex TM. After 30 minutes
incubation, agents, e.g. FBS, proteins, and other agents, were added to the HUVEC’s. The cells
were further cultured for additional 16 hours. The formed endothelial tubes were analyzed under
light microscope and quantified.
3.5.8. Cell attachment assays
The cells were cultured overnight under standard conditions. Next day, different cells
(with appropriate cell numbers) were transferred to a new plate with wells that were coated with
different proteins (indicated in the figures) with fresh medium with addition of appropriate
agents (indicated in the figures). The cells were further cultured for 35 min and washed three
times gently. The attached cells were either directly counted. In all attachment assays, the
attachment is presented as total number of cells attached to the plate per microscopic view field
(calculated from average of three view fields).
3.5.9. Apoptosis assays
For determination of EC50 of ProAgio and the effects of caspase 8/9 inhibitors, HUVECs
were cultured overnight. The cells were shifted to fresh medium next morning. Various
concentrations of ProAgio or D1-CD2, or caspase 8/9 inhibitors with 5 M ProAgio were added
into culture medium. After 10 hours incubation, the apoptosis was determined using an apoptosis
kit. For all other apoptosis measurements, appropriate cells were cultured overnight. The cells
were shifted to fresh medium next morning. Appropriate agents were added into the medium to
appropriate concentrations. After 24 hours incubation, the cell apoptosis was determined by cell
counting using untreated cells as a reference. The cell counting was repeated five times in each
experiment.
3.5.10. Immunofluorescence staining
HUVECs

were

grown

on

glass

coverslips

coated

with

fibronectin

for

immunofluorescence microscopy. After treatment with proteins, cells were fixed with cold (4˚C)
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4% PFA in PBS (UBS) for 15 min and blocked by incubating with 3% BSA/PBS at 37˚C for 1 h.
Vinculin antibody (1:1000 dilution) was incubated with the coverslips for 45 min at 37˚C. The
cells were washed with PBS for 10 min at room temperature before incubating with a 1:500
dilution of Alexa-488 conjugated secondary antibody. The cells were then incubated with
Phalloidin conjugated rhodamine for 30 min at 37˚C. Cells were mounted with Prolong-Gold
antifade reagent that contained DAPI (Invitrogen, Carlsbad). For IF staining of tissue sections,
snap frozen tissue blocks were sliced into 10 µM thick sections using a cryostat. The procedure
similar to that used in immunostaining of fixed cells was used for tissue section IF staining.
3.5.11. Vessel quantitation
Sections from tumors or various organs of mice that were treated by appropriate agents
were stained using an anti-mouse CD31 antibody and a green fluorescence conjugated secondary
antibody. After the highest vessel density within a section was determined under lower objective
lens (5X), an area of 319.8 X 319.8 µM with the highest amount of vessels was scanned under a
20X objective lens and 10X ocular lens. The CD31 immunofluorescence staining was quantified
by manual counting using Imaging-J. Vessel Length, the total number of vessels length within
each image was measured using a Zeiss LSM image browser. Mean Vessel Density (MVD) was
determined using methods described by Weidner and coworkers (Weidner, Carroll et al. 1993).
Briefly, any clear pattern of fluorescent stained or a cluster within the tumor tissue that separated
from connective tissues was counted as one vessel. Microvessels in sclerotic areas or adjacent to
connective tissues were not considered. Branch Points (BP) was determined by manually
counting the number of branch points under the microscopic view. Any junction of two lines of
CD31 stains counts as one branch point. All data were shown in 319.8 X 319.8 µm2 area of view
field and are the average of repeating three view fields per section. Four sections from each
tumor/organ were counted.
3.6. Statistical calculations
Data were statistically analyzed by comparing two appropriate groups. The p values were
calculated using unpaired two-tailed Student t-test. In all figures and tables, NS means p > 0.05
and statistically insignificant, * means p < 0.05, ** means p < 0.01, and *** means p< 0.001.
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4. INDUCTION OF INTEGRIN V3 MEDIATED APOPTOSIS BY A
RATIONALLY DESIGNED PROTEIN IS AN EFFECTIVE TREATMENT FOR
CHRONIC LIVER DISEASES
4.1. Abstract
Chronic liver diseases (CLD) and related complications are caused by inflammatory
responses to insults such as liver toxins or viral infections, which lead to abnormal accumulation
of collagen fibrils, neo-angiogenesis, and sinusoidal remodeling in liver. Activation of Hepatic
Stellate Cells (HSCs) and resistance of these activated HSCs to apoptosis are the main reasons of
collagen accumulation. On the other hand, neo-angiogenesis and sinusoidal remodeling result in
blood flow resistance. In CLD liver, activation of HSCs, sinusoidal remodeling and neoangiogenesis are tightly coupled. Here, we report an effective strategy for CLD treatment by a
mechanism of integrin αVβ3 mediated cell apoptosis using a rationally designed protein,
ProAgio. ProAgio is designed to target integrin αVβ3 at a novel site. Due to high expressions of
αVβ3 in activated HSCs, capillarized LSEC, and endothelial cells of neo-angiogenic vessels,
ProAgio effectively induces apoptosis of these cells. Tests with liver fibrosis mouse model
demonstrate effectiveness of ProAgio in depletion of activated HSCs, capillarized LSEC, and
newly grown vessels in fibrotic liver. Our studies demonstrate a novel and effective approach for
CLD treatment.
4.2. Introduction
Liver fibrosis and subsequent progression to cirrhosis is a classic situation of most
chronic liver diseases (CLD) regardless of the resources of liver injury. Persistent inflammation
due to liver insults lead to constant activation of HSCs and apoptosis resistance of the activated
HSCs (Zhou, Murphy et al. 2004, Kisseleva, Cong et al. 2012, Troeger, Mederacke et al. 2012).
Activation of HSCs accomplishes trans-differentiation of HSCs into myofibroblast phenotype.
Activated HSCs release high amounts of extracellular matrix, mostly collagen, and MMP
inhibitors, which leads to accumulation of collagen in liver. On the other hand, inflammation and
activated HSCs strongly stimulate sinusoidal remodeling and neo-angiogenesis. Angiogenesis
and capillarized liver sinusoid endothelial cells (LSEC) in-turn promote more HSCs activation,
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excessive collagen deposition leads to fibrotic scar that eventually disrupts liver cytoarchitecture,
while sinusoidal remodeling and excessive angiogenesis often leads to dysregulated blood flow
in liver, especially in sinusoidal space. The consequence is liver failure and other related
complications (Iwakiri, Shah et al. 2014, Mehta, Gustot et al. 2014). Several strategies have been
explored for treatment of CLDs, such as suppression of liver inflammation and antiangiogenesis. Although, many of these current strategies can improve liver fibrosis scores, the
improvements are usually unpredictable, slow, and often small. In addition, significant portions
of patients do not response to such treatments (Yang, Kwon et al. 2014). Up-to-date, there is no
effective treatment for portal hypertension. Due to critical function of HSCs in collagen
accumulation in fibrotic liver, it was suggested that it would be beneficial to specifically deplete
activated HSCs as a treatment strategy for CLDs (Kisseleva and Brenner 2011). However,
specifically removal of activated HSCs from fibrotic liver has not yet been achieved. In addition,
activation of HSCs, neo-angiogenesis, and sinusoidal remodeling is tightly coupled in fibrotic
liver. It may be less effective to target a single process. We envision that one agent that
simultaneously depletes activated HSCs, capillarized LSEC, and newly grown blood vessels will
potentially bring very important advantages in treatment of patients with CLDs.
4.3. ProAgio induces cell death in activated HSCs
A growing body of evidence suggests that activation of HSC plays a major role in CLD
development and progression. It is reported that activated HSCs express high levels of integrin
v3. We previously reported design and development of a protein drug candidate, ProAgio, that
targets integrin αVβ3 at a novel site, -groove (a non-ligand binding site at A domain of
integrin 3). ProAgio induces apoptosis of integrin αVβ3 expressing angiogenic endothelial cells
by recruiting/activating caspase 8 to cytoplasmic domain of the targeted integrin. Thus, we
reasoned whether ProAgio would be effective in induction of apoptosis of activated HSCs, which
would potentially be an effective strategy for CLD treatment. We first probed expression of
integrin αVβ3 in activated/inactivated HSCs using human primary HSC. Our experiments
confirmed that activated HSCs indeed expressed high levels of integrin αVβ3 (Figure 4.1A).
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Figure 4.1. ProAgio effectively induces HSC and LX-2 apoptosis.
(A) Immunoblot of quiescent and activated HSC on day 1 and day 7 respectively. GAPDH is the loading
control. (B-C) Apoptosis of (B) HSC at day 1 and day 7 and (C) LX-2 cells that were treated by 5 and
10 μM ProAgio was analyzed by apoptosis kit. Apoptosis was presented as % Apoptosis by defining the
cells that were untreated as 0%. (D) ProAgio increases the recruitment of caspase-8 to integrin β3
cytoplasmic tails. Error bars are standard deviations from measurement of five independent experiments.
***P<0.001 calculated by unpaired two-tailed student t-test.

We then tested whether ProAgio would induce apoptosis of activated HSCs. Freshly
isolated HSC primary cells were cultured on plastic plate for 8 days for activation. ProAgio was
added to the culture plate subsequently. Clearly, massive apoptosis was induced among the
activated HSCs, while no apoptosis was observed with the HSCs without activation (Figure
4.1B). To confirm that the apoptosis induction was due to integrin αVβ3 targeting by ProAgio,
we used an immortalized human HSC line, LX-2 cells. ProAgio induced LX-2 cell apoptosis
(Figure 4.1C). We previously demonstrated that ProAgio induced apoptosis of integrin αVβ3
expressing HUVECs by recruiting caspase 8 to cytoplasmic domain of integrin 3. Thus, we
questioned whether the apoptosis was induced via similar mechanism with LX-2 cells. To this
end, we probed the co-precipitation of caspase 8 with integrin 3 in LX-2 cells upon ProAgio
treatment. Evidently, caspase 8 co-immunoprecipitated with integrin 3. As a control, caspase 8
did not co-immunoprecipitate with 3 without ProAgio treatment (Figure 4.1D). We conclude
that ProAgio specifically induces apoptosis of activated HSCs by recruitment/activation of
caspase 8 to a cytoplasmic domain of integrin 3.
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4.4. ProAgio effectively reduces portal hypertension
One main complication encountered by CLD patients is portal hypertension, a leading
cause of death and liver transplantations, due to excessive deposition of collagen fibrils,
abnormal neo-angiogenesis, and sinusoidal remodeling in fibrotic liver. Excessive angiogenesis
and sinusoidal remodeling also leads to development of intrahepatic shunts, which further
exacerbates portal hypertension. It is well documented that integrin v3 is highly expressed in
angiogenic endothelial cells. Our previous studies have demonstrated that ProAgio effectively
induced apoptosis of angiogenic endothelial cells. The main event of liver sinusoidal remodeling
is capillarization of liver sinusoidal endothelial cells (LSECs). Interestingly, studies in several
laboratories showed that expression of integrin αVβ3 in the capillarized LSEC is upregulated.
Since ProAgio is effective in inducing apoptosis of integrin αVβ3 expressing cells, we reasoned
whether ProAgio would be effective in induction of apoptosis of capillarized LSEC, thus
potentially can act as a treatment for liver portal hypertension. To test the conjecture, we first
examined integrin αVβ3 expressions in capillarized LSEC. Freshly isolated human primary
LSECs were cutured and immunoblot of CD31, a marker of capillarized LSEC, before and after
activation verified capllarization of the primary LSEC upon activation (Figure 4.5C).
Immunoblots of integrin v and 3 in extracts of activated LSEC demonstrated upregulation of
the integrin upon the activation (Figure 4.5A). We therefore questioned whether ProAgio could
induce apoptosis of the capillarized LSECs. Apoptosis analyses demonstrated that incubation of
ProAgio with the activated human primary LSECs led to a strong apoptosis induction, while the
activity of apoptosis induction was (Figure 4.5B).
4.5. ProAgio decreases liver fibrosis in TAA induced fibrosis model
Our previous studies (Turaga, Yin et al. 2016) and the above in vitro tests with cultured
cells suggest that ProAgio can potentially be an effective treatment agent for CLDs by
simultaneously depleting activated HSC, capillarized LSEC, and newly grown blood vessels; one
stone would kill three bad birds.
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Figure 4.2. ProAgio induces HSC apoptosis and decreases collagen deposition in liver fibrosis.
(A) Endpoint weights of the harvested livers of normal, buffer and ProAgio treated mice. (B) Body
weights of buffer and ProAgio treated mice. 10 doses of ProAgio were given after 3 months when livers
became fibrotic. (C) H&E stained livers of buffer and ProAgio treated mice showing dead hepatocytes.
(D) Quantitative analysis of number of apoptotic bodies/field. (E) Size of apoptotic bodies. (F)
Representative images of Picro-Sirius red staining of normal, buffer and ProAgio treated mice. The lower
panel represents a higher magnification of 30X. (G) Quantitative analysis of %collagen area in normal,
buffer and ProAgio treated mice. (H-K) Quantitative analysis of (i) MMP2, (ii) MMP9, (iii) TIMP2 and
(iv) TIMP1 in buffer and ProAgio treated mice. (L) Representative images of αSMA and (M)
Quantitative analysis of SMA in normal, buffer and ProAgio treated mice. Error bars are s.d. from
measurement of five independent experiments. P>0.05, **P<0.005, ***P<0.001 calculated by unpaired
two-tailed Student’s t-test

95

Figure 4.3. (A) Raw images of normal, buffer and ProAgio liver. (B-H) Quantitative analysis of liver
function tests.
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To test whether ProAgio would indeed exert these activities in vivo and be an effective
treatment for CLDs, we used a well-established TAA-alcohol induced liver fibrosis mouse
model. Liver fibrosis was induced in Balb/C mice by administration of TAA and 10% ethanol in
drinking water. At the end of fibrosis/cirrhosis induction, the fibrotic animals were treated with
PEGylated ProAgio and buffer by i.p. injection. The animals were sacrificed at the end of
experiment. Animal body weights, liver weights, and out-surface of livers were closely
examined. Clearly, ProAgio treatment led to increase in mouse body weights and decrease in
liver weights and size compared to those of buffer treated group (Figure 4.2A and 4.2B).
Fibrosis features on the surface of liver of ProAgio treated group were clearly not apparent as
compared to the buffer treated group (Figure 4.3A). Examination of serum markers that typically
reflect liver damages suggest that there were sharp differences between the ProAgio treated
group and the buffer treated group. The levels of these serum markers of ProAgio treated animals
were very close to those of non-fibrotic mice (Figure 4.3B-H), indicating improvement of liver
function by ProAgio treatment. CLD fibrosis progression often leads to apoptosis of hepatocytes
indicated by formation of hepatic apoptosis bodies in fibrotic liver. H&E staining of liver tissue
sections showed that there were substantially less hepatic apoptosis bodies in the livers of
ProAgio treated mice compared to buffer treated mice (Figure 4.2C). The experiments suggest
that ProAgio is effective in fibrosis reversal.
The most apparent feature of CLD progression is accumulation of collagen fibrils in
fibrotic liver. It is well known that activated HSC is not only the major source of collagen
production but also the main player for decreased collagen degradation by altering tissue levels
of metalloproteases (MMPs) and tissue inhibitor of metalloproteinase (TIMPs). We reasoned that
induction of apoptosis of activated HSC would have effects on collagen accumulations and tissue
MMP/TIMP levels/activities in fibrotic liver. Sirius red stain of liver tissue sections
demonstrated lesser and thinner collagen accumulation in the livers of ProAgio treated group,
especially the early cirrhosis feature, dense collagen band networks, disappeared. To test whether
ProAgio treatment would lead to altered MMPs and TIMPs levels/activities in fibrotic liver, we
examined TIMP1, TIMP2, MMP2, and MMP9 levels in the liver extracts by ELISA. TIMP1
levels were substantially reduced in livers of ProAgio treated group, while the levels of MMP2
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and MMP9 did not experience significant changes in both ProAgio and buffer treated groups
(Figure 4.2H-K). Examination of collagenase activity of the liver extracts by Abcam Collagenase
assay kit showed that collagenase activity was 1.5 folds increased in ProAgio treated groups as
compared to the buffer group (Figure 4.4A and 4.4B), which well explained the strong reduction
in collagen contains in livers of ProAgio treated animals.
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Figure 4.4. ProAgio reduces collagen crosslinking in fibrotic liver.
(A) Quantitative analysis of collagenase activity in normal, buffer with TAA-induced fibrosis and ProAgio
treated mice. (B) Representative images of Picro-Sirius Red staining done on liver tissue sections and (C)
the quantitative analysis from normal, buffer with TAA-induced fibrosis and ProAgio treated mice. The
upper panel represents the polarized contrast and the lower panel represents bright field. (D)
Representative images of Lysyl oxidase and (E) the quantitative analysis of LOX expression in liver tissue
sections from normal, buffer with TAA-induced fibrosis and ProAgio treated mice.
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Extensive collagen crosslinking is a hallmark of liver fibrosis progression to cirrhosis.
Analyses of crosslinks of collagens from the sirius red stains of tissue sections revealed that
ProAgio treatment led to substantially less collagen crosslinks compared to buffer treated group
(Figure 4.4B and 4.4C). It is intriguing that ProAgio treatment reduced collagen crosslinks.
During liver fibrosis progression, lysyl oxidase (LOX) upregulation is the key player that is
responsible for collagen crosslinking. We analyzed the levels of lysyl oxidase in the liver tissue
extracts by immunoblot. ProAgio treatment led to a reduced level of LOX (Figure 4.4D and
4.4E). Co-immunostaining of LOX and -SMA showed that, in the liver of buffer treated
animals, most LOX co-stains with -SMA inside cells, while there were high levels of
extracellular LOX. In liver of ProAgio treated animals, there were only residual co-stains of both
LOX and -SMA inside cells, and there were dramatically reduced extracellular LOX stain.
These results suggest that activated HSC are the major source of LOX during liver fibrosis
progression, and removal of activated HSC by ProAgio would reduce both LOX and -SMA
positive cells, consequently reducing collagen crosslinking.
ProAgio exhibits anti-angiogenic activity in tumors (Turaga, Yin et al. 2016). We
speculate that ProAgio may also exert its anti-angiogenic effects on neo-angiogenesis in CLD
liver. Histological analyses were carried out with the collected liver tissue sections using
antibody against CD31, an endothelial marker and expressed in capillarized LSECs. Apparently,
the TAA-alcohol fibrosis induction led to an increase in CD31 staining, while the well-formed
large vessels were not affected. ProAgio treatment reversed the blood vessel abnormality in
fibrotic liver (Figure 4.5D). The sections were also co-stained with anti-CD31 antibody,
treatment with ProAgio dramatically reduced CD31 stain (Figure 4.6). The results suggest that
ProAgio treatment reduced neo-angiogenesis in the fibrotic liver. CLD progression to liver
fibrosis and cirrhosis almost always lead to sinusoidal remodeling characterized by
capillarization of LSEC in fibrotic liver. Since ProAgio induced capillarized LSEC apoptosis, we
reasoned that ProAgio treatment might have novel effects on sinusoidal remodeling. We
analyzed sections prepared from fibrotic, non-fibrotic and ProAgio treated livers by
Electromicroscopy (EM) imaging. EM analyses revealed that percent of porosity areas on
sinusoids in TAA-alcohol induced fibrotic liver decreased, a typical characteristic of loss of liver
sinusoidal fenestrations or sinusoidal remodeling. ProAgio treatment led to the recovery of
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percent of porosity on sinusoids almost to the level of non-fibrotic liver (Figure 4.5D-F). Our
analyses suggest that ProAgio is involved in both anti-angiogenesis and anti-sinusoidal
remodeling.
Accumulation of collagen fibrils, neo-angiogenesis, and sinusoidal remodeling resulted
from CLD progression cause intra-hepatic vascular resistance in fibrotic liver. If ProAgio
dissolves collagen, depletes angiogenic vessels and capillarized LSEC, we would expect that
ProAgio treatment should effectively reduce the blood flow resistance. Thus, we measured blood
flow in-and-out of liver by doppler ultrasound imaging (Figure 4.5H). The TAA + alcohol
fibrosis induction resulted in reduction of blood flow into liver, while ProAgio treatment
recovered the liver blood flow almost to the level of non-fibrotic liver. One consequence of such
blood flow resistance is hypoxia (Figure 4.7). If ProAgio treatment led to relieve of blood flow
resistance, it would be expected that ProAgio treatment would reduce hypoxia condition in
fibrotic liver. We carried out immunoblot analyses of Hif-1 with the liver extracts. Evidently,
fibrosis induction resulted in increased Hif-1 levels in liver extracts, while ProAgio treatment
led to Hif-1 reduction to a level similar to that of non-fibrotic liver (Figure 4.7). To further
prove that ProAgio treatment reduced the hypoxia condition of fibrotic liver, we performed IHC
staining of tissue sections using Hif1α, a hypoxia marker.
Animal model studies demonstrate that ProAgio treatment reduced collagen contents,
neo-angiogenesis, and increased liver sinusoidal fenestrations in fibrotic liver, which is
consistent with our in vitro tests that ProAgio induced apoptosis of activated HSC and
capillarized LSEC.
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Figure 4.5. ProAgio reduces sinusoidal remodeling effectively.
(A) Levels of V (IB: Integrin V), 3 (IB: Integrin 3), PECAM-1 (IB: PECAM-1) and Caspase-8 (IB:
Caspase-8) in LSEC were analyzed by immunoblot of cell lysates. Immunoblot of GAPDH (IB: GAPDH)
is a loading control. (B) Quantitative analysis of LSEC viability at passage 2 and 9 upon ProAgio
treatment at 5 and 10 M. Cell viability is presented as % viability by defining the viability of untreated
cells as 100%. (C) Representative images of LSEC. The upper panel represents LSEC from liver tissue
sections in bright field and the lower panel represents SEM images of LSEC depicting fenestrae from
normal, buffer and ProAgio treated mice. (D, E, F, I) Quantitative analysis of: (D) LSEC, (E) Number of
fenestrae/field, (F) Fenestrae diameter, (I) Space of Disse in normal, buffer and ProAgio treated mice. (G)
Blood flow velocity in hepatic portal vein, and (H) Representative images of Space of Disse. Error bars in
B, C, E, F and I are s.d. from measurement of five independent experiments. *P>0.05, **P<0.005,
***P<0.001 calculated by unpaired two-tailed Student’s t-test.
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4.6. ProAgio is non-toxic to liver
Does ProAgio treatment induce apoptosis of other liver cell types, especially hepatocyte
cells, differentiated LSEC, and kupffer cells? Evidently, ProAgio treatment did not lead to
apoptosis of hepatocytes, differentiated sinusoidal endothelial cells, and kupffer cells (Figure
4.8A and 4.8B). Immunoblotting of integrin v3 with cultured primary hepatocyte cells and
inactivated sinusoidal endothelial cells indicated that the cells did not express high levels of the
integrin (Figure 4.8C). ProAgio therefore did not induce apoptosis of these two cell types. In
fact, ProAgio treatment of healthy mice without fibrosis induction did not lead to any apparent
alteration in sinusoids and hepatocytes, suggesting that ProAgio did not target normal
hepatocytes and sinusoids. Interestingly, immunoblotting of integrin v3 with cultured activated
primary kupffer cells indicated that the cells expressed high levels of the integrin. However,
ProAgio did not induce apoptosis of kupffer cells (Figure 4.8B). The experiment indicates that
ProAgio treatment specifically induces apoptosis of angiogenic endothelial cells and activated
HSC. The fact that ProAgio did not induce apoptosis of kupffer cells further supports that
apoptosis induction by ProAgio is indeed mediated by recruiting/activating caspase 8 at
cytoplasmic domain of integrin 3.

Figure 4.6. CD31 expression of liver tissue.
Representative images of CD31 and its quantitative analysis in normal, buffer and ProAgio treated mice.
***P<0.001 calculated by unpaired two-tailed Student’s t-test.
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Figure 4.7. Hif1α expression of liver tissue.
Representative images of Hif1α and its quantitative analysis in normal, buffer and ProAgio treated mice.
***P<0.001 calculated by unpaired two-tailed Student’s t-test.

Figure 4.8. ProAgio does not induce cell death in hepatocytes and kupffer cells.
(A) Quantitative analysis of viable hepatocytes/field when treated with ProAgio at 5 and 10 M concentration.
(B) Quantitative analysis of viable kupffer cells/field when treated with ProAgio at 5 and 10 M
concentration. (C) Levels of v (IB: 3 integrin), 3 (IB: 3 integrin), albumin and caspase 8 were analyzed in
HUVEC and hepatocyte cell lysates. GAPDH (IB: GAPDH) is a loading control. NS, non-significant.

104

Persistent activation of HSCs is the major cause of liver fibrosis and subsequent
progression to cirrhosis. It has long been a goal to directly induce HSC apoptosis or reverse the
HSC activation as an anti-fibrotic strategy. Efforts were made to develop effective inhibitors that
would inhibit effects of particular growth factors and cytokines, such as PDGF and TGF-.
Using different toxins, e.g. Gliotoxin, HSC apoptosis induction were also explored. However,
up-to-date, specifically inducing apoptosis of activated HSC has not been achieved. Expression
of integrin v3 is elevated upon HSC activation. Although, the functional significance of upregulation of this integrin in HSC activation is not understood, it is quickly realized that this
integrin may be a target of activated HSC due to unique expression pattern. Inhibition of integrin
v3 using the integrin ligand mimic, cilengitide was tested. Interestingly, cilengitide exhibited
effects in inhibiting proliferation of activated HSC in vitro. However, experiments with animal
models of liver fibrosis indicated that cilengitide treatment actually exacerbated the disease.

Figure 4.9. Cartoon depicting ProAgio acting on HSC, LSEC in pathological fibrosis.
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Clearly, cilengitide did not induce apoptosis of activated HSC in the fibrotic liver.
Integrin αVβ3 is also highly expressed on angiogenic endothelial cells, which leads to active
angiogenesis. ProAgio induces cell apoptosis via cell surface integrin αVβ3. This unique
mechanism of drug action allows ProAgio to be an agent of both anti-fibrosis and antiangiogenesis in fibrotic liver. Dual action of ProAgio in fibrotic liver certainly brings a very
important advantage of breaking down the vicious cycle of angiogenesis-fibrogenesis in liver
fibrosis progression (Figure 4.9).
4.7. Materials and methods
4.7.1. Cell culture
LX-2 (Human Hepatic Stellate Cell Line (EMD Millipore, SCC064)), Hepatic stellate
cells, hepatic sinusoidal endothelial cells were maintained as per the vendor. LX-2 cells were
maintained in DMEM containing 4.5 g/L D-glucose, L-glutamine (ThermoFisher #11965) and
supplemented

with

10%

FBS

(ThermoFisher)

and

Penicillin/Streptomycin

(ThermoFisher #15140-163). All cell lines were maintained at 37°C and 5% CO2.
4.7.2. Kupffer cells
Kupffer thawing/plating medium was used, which comprised of Advanced DMEM
supplemented with FBS and a cocktail solution of fetal bovine serum (FBS), penicillinstreptomycin, human recombinant insulin, GlutaMAX™-I supplement, and HEPES. 500 mL of
Kupffer thawing/plating medium was prepared by asceptically mixing the following
components: Advanced DMEM, FBS Thawing/Plating Cocktail-A (Cat. no. CM3000). Kupffer
Maintenance Medium was also prepared, which comprised of Advanced DMEM supplemented
with FBS and a cocktail solution of penicillin-streptomycin, ITS+ (insulin, transferrin, selenium
complex, BSA, and linoleic acid), GlutaMAX™-I supplement, and HEPES. Kupfer cells were
activated by adding lipopolysaccharide (LPS, 1 µg/mL) to the culture medium for 2-24 hours
(depending on experimental design) prior to experiment in either Kupffer cell monoculture or coculture to mimic liver inflammation. LPS activation changes were noticed fairly quickly, and
morphological changes in the cells were observed in less than 2 hours. After 1-4 hours, cells
started out darker and more elongated (human), and then became spindle-like with longer, thin
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cytoplasmic projections and appeared dendritic-like. Cells exhibited high level of motility by
migrating around the plate. After 4-8 hours, cells returned to a rounder morphology. Eventually
after 8-12 hours, cells were observed as flat and their cytoplasm enlarged, thereby creating large
round cells with many vacuoles inside (macrophage-like). Cells exhibited lower motility.
4.7.3. Immunoblotting
The cells were washed twice with PBS and the pellets were re-suspended in RPMI lysis
buffer in presence of protease inhibitor cocktail V (EMD Millipore) for 60 min rotation in a cold
box. They were then centrifuged at 10,000g for 10 min, the supernatant was further dissolved in
Laemmli buffer and heated at 95°C for 5 min. Equal amounts of cellular proteins were separated
on 10% SDS-polyacrylamide gel electrophoresis and electrotransfered to nitrocellulose
membranes. The membranes were blocked with 5% bovine serum albumin, and the presence of
indicated protein on the blots was detected with speciﬁc antibody and developed on X-ray film
using chemiluminescent substrate. The antibodies and their dilutions used were as follows:
integrin αV, integrin β3, GAPDH, PECAM-1. Integrin β3 siRNA (h) (SCBT, Cat No. sc-29375),
Lipofectamine® RNAiMAX Transfection Reagent (Thermo Scientific, Cat No. 13778030) was
used for transfection. Apoptosis was determined by Alexa Fluor® 488 annexin V/Dead Cell
Apoptosis Kit with Alexa® Fluor 488 annexin V and PI for Flow Cytometry (Thermo Scientific,
Catalog no. V13241).
4.7.4. Immunostaining of tissue sections
Liver histology was carried out at Georgia State University. At least 6 representative
formalin-ﬁxed livers from each treatment group were embedded in a wax block and paraffin
embedded livers were cut into 5 mm sections and mounted onto a microscope slide to be
processed for H&E, Sirius Red, and IHC (immunohistochemistry). H&E, Sirius Red imaging
was performed on Nanozoomer 2.0 HT (Hamamatsu) whole slide scanner to generate high
resolution digital images of the whole liver sections at 40X in a bright field mode, and the
images were exported as tiff files, analyzed through aerio software. IHC images were captured in
Axiocam using ZEN software at 10X magnification and were exported in tiff format for further
quantification and analysis. Quantification was done by FIJI image J software. IHC was done
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using antibodies against β3-integrin (Millipore, Cat No. AB2984), αV-integrin (CST, Cat No.
4711), Hif1α, Lysyl oxidase, αVβ3 integrin (LM609), Citrate buffer, Protein UV block (Thermo
Scientific, Cat No. TA-060-PBQ), antibody diluent (Thermo Scientific, Cat No. TA-125-ADQ),
MACH 2 Rabbit AP polymer (Biocare, Cat No. RALP525 G, H, L) and MACH 2 Mouse HRPPolymer (Biocare, Cat No. MHRP520 G, H, L, MM), DAB Chromogen (Biocare, Cat No.
BDB2004 H, L, MM), hematoxylin.
4.7.5. Enzyme-linked immunosorbent assay
Concentrations of the MMP2, MMP9, TIMP-1, TIMP-2 in the cell lysates were detected
using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers’
instructions (R&D systems, Catalog Nos. MMP200, DMP900, DTM100, DTM200).
4.7.6. Collagenase assay
Colorimetric Collagenase Activity Assay Kit (Abcam, ab196999) was used to determine
collagenase activity in liver tissue lysates, and assay was performed as per the protocol
mentioned by the vendor with 1mg of protein in the tissue lysate.
4.7.7. Statistical calculations
Data were statistically analyzed by comparing two appropriate groups. The p values were
calculated using unpaired two-tailed Student t-test. In all figures and tables, NS means p > 0.05
and statistically insignificant, * means p < 0.05, ** means p < 0.01, and *** means p < 0.001.
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5. TARGETING INTEGRIN V3 FOR OCULAR ANGIOGENESIS
5.1. Introduction
The leading cause of irreversible blindness results from complications associated with
retinal neovascularization, commonly seen in patients with ischemic ocular diseases such as wet
AMD (age related macular degeneration), diabetic retinopathy, retinal vein occlusion, and
retinopathy of prematurity. This phenomenon is commonly seen due to increased proliferation of
retinal endothelial cells due to secreted mitogen, VEGF. Angiogenesis in eye is also associated
with ocular melanoma, which constitutes a small portion of entire cancer population, but has a
high mortality rate and very low 5-year survival rate among the patients. The primary cause for
vision loss in proliferative retinal diseases is the increased vascular permeability leading to
retinal edema, vascular fragility resulting in hemorrhage, or fibrovascular proliferation with
tractional and rhegmatogenous retinal detachment. Just like any angiogenesis associated disease,
pro- and antiangiogenic factors regulate the balance of “angiogenic switch” and this imbalance
towards pro angiogenic factors leads to the pathogenesis of the above ocular diseases. During the
progression of ocular diseases, neovascularization is known to occur at a relatively late stage,
making it an attractive and promising target for therapeutic intervention. Dr. Judah Folkman's
group identified VEGF as the angiogenesis regulator and suggested that the anti angiogenic
approach should be similar to that of cancer, and targeting this growth factor can effectively
prevent blindness. Thus, VEGF appears to be important for development of ischemia-induced
retinal angiogenesis. Since VEGF levels increase in these disorders, it appears that VEGF could
be one of the direct causative factors for clinically observed neovascularization in certain
ischemic retinal diseases. The finding that 50% of retinal neovascularization was not inhibited by
anti-VEGF treatment could imply that other angiogenic substances account for the remaining
stimulatory activity. Our results demonstrate that soluble ProAgio binding to integrin αVβ3
reduced laser induced retinal neovascularization in vivo without discernible short-term retinal
toxicity. Thus αVβ3 appears to be important for developmental of retinal angiogenesis. The
major hindrance for protein-based drugs is immune reactivity and even lucentis is not an
exception. During the lucentis® treatment, there is an increased rate of systemic
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immunoreactivity at the end of 2 years, which was not observed in 1 year treatment, however,
further examination revealed no effect on efficacy or safety.

Figure 5.1. Integrin αVβ3 is upregulated in retinal angiogenesis.
Co-immunostaining of integrin αV with CD31 and integrin β3 with CD31 in normal group and patients with
wet AMD. Wet AMD tissue samples exhibited strong positivity for integrin V and integrin β3 with CD31.
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5.2. ProAgio decreases retinal angiogenesis.
To assess in vivo response, animals with corneal damage received intravitreal injections
of ProAgio. Wet AMD was induced in mice using LASER, and the mice were treated with single
dose of buffer and ProAgio. Control treatments had no effect. Retinal neovascularization was
quantitated using fluroscein angiogram (Figure 2), and retinal neovascularization in the eye
injected with ProAgio was reduced by 100% and completely, compared to the control treated
eye. Histological analyses showed no retinal toxicity when observed by light microscopy (Figure
3).

Figure 5.2. ProAgio decreases retinal angiogenesis.
(A) Fluorescein angiogram showing areas of choroidal neovascularization (hyperfluorescent areas) diffused,
(B) Quantification of area of CNV in buffer and ProAgio treated groups
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These data demonstrate integrin αVβ3 significant role in retinal angiogenesis and the
potential of integrin αVβ3 inhibition as a specific therapy for diseases associated with ocular
neovascularization. The findings in the current study suggest that inhibition of integrin αVβ3 can
be used to prevent intraocular neovascularization without the retinal destruction.

Figure 5.3. Representative H&E stained cross-sections of subretinal choroidal neovascularization
lesions.
Membranes extended into the subretinal space between the retinal pigment epithelium (RPE) monolayer
and the photoreceptor outer segments of the neurosensory retina. Focal damage of Bruch’s membrane and
choriocapillaris is present in all lesions in buffer treatment, but completely restored to normalcy after 14
days of single ProAgio treatment.

5.3. Discussion
Lucentis® or Avastin® which target circulating VEGF are now being used for the
treatment of wet AMD, proliferative diabetic retinopathy and other diseases involving retinal
neovascularization (Jardeleza and Miller, 2009). Therapeutic targeting of integrin Vβ3 is not
only a viable option but also a better solution in part, since integrin inhibitors can inhibit
angiogenesis induced by not only VEGF, but also other growth factors including FGF-2
(Somanath et al., 2009a). In this study, we demonstrated a novel therapeutic protein, ProAgio, to
prevent ocular neovascularization in a mouse model. ProAgio binds to integrin αVβ3 at βA
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domain and induces cell death by recruiting caspase 8 to the cytoplasmic tail of 3 integrin. Our
results are in accordance with tumor studies. Taken together, our data suggests that ProAgio can
effectively induce cell death in retinal endothelial cells and prevent neo-vascularization. The use
of integrin targeting molecules is a very promising alternative to current approved clinical
treatment as they are mainly focused on VEGF dependent angiogenesis only. ProAgio can inhibit
both VEGF and FGF induced neovascularization. The use of VEGF is ineffective in nearly 50%
of diabetic retinopathy cases as they are not dependent on VEGF. The present approach of
targeting integrin αVβ3 and inducing cell death is a more promising approach as agents targeting
VEGF cannot induce cell death but can only inhibit later events during the tube formation. In
case of tumor angiogenesis, integrin αVβ3 inhibitors have shown to inhibit the pro-angiogenic
actions of VEGF and FGF-2 (Mousa et al., 2008) and platelet-derived growth factor (PDGF) in
both in vitro and in vivo studies. This anti-angiogenic effect of ProAgio on multiple proangiogenic molecules further increases its attractiveness as a therapeutic agent. In conclusion,
ProAgio therapy can offer much more clinical benefits as compared to ranibizumab or avastin,
with respect to visual acuity as ProAgio can directly induce cell death in activated endothelial
cells. As the treatment up to 60 mg/kg had no adverse events, it is considered to be safe and a
better approach in targeting neovascularization disorders.
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6. CONCLUSIONS AND DISCUSSION
6.1. ProAgio – engineered protein with a novel mechanism and enhanced pharmacological
features
Protein engineering has been a major focus of current clinical and biomedical research,
which involves discovery and optimization of protein structures. It provides new functions to
known proteins by structurally engineering them. There have been many successes in this area
such as TSP peptides, anginex, cilengitide, and many are still under development, such as
ProCA. This study presents a highly selective and potent inhibitor for angiogenesis. A
thoroughly characterized anti-angiogenic protein, ProAgio has been developed for the first time.
6.1.1. ProAgio binds to integrin αVβ3 and induces apoptosis
It is well known that cell death can be induced externally by targeting death ligand
(FADD [Fas associated death domain]). Along with FADD, it has been demonstrated by several
different groups that cell death can be induced with β integrins (β3 and/or β1), known as integrinmediated death. Designed ProAgio induces apoptosis preferably in endothelial cells through
IMD. As discovered earlier by some groups, apoptosis induced by IMD can be rescued by
inhibiting caspase-8 and not by caspase-9, which is the initiator caspase for extrinsic and
intrinsic apoptotic pathways, respectively. It is noteworthy from our experiments that ProAgio
induces apoptosis in COS7 cell lines, but the effect is less compared to the endothelial cells. This
mode of action of ProAgio mimics the natural way of endothelial cell death where β3 and/or β1
integrin cannot find the appropriate extracellular matrix ligand, forcing the integrin to recruit
caspase 8 in order to initiate extrinsic apoptotic pathway. Targeting pathological angiogenesis
through IMD can be most effective as this event mostly happens during tissue remodeling, which
is mostly associated during the primary growth or wound repair. Several groups earlier showed
that caspase-8 can directly or indirectly interact with β3 or β1 integrin. Upon treatment with
ProAgio, a change in confirmation of integrin resulting in dissociation of FAK and empty
integrin cytoplasmic tails was observed. It is known that integrin αVβ3 is present in clusters on
the cell membrane. Caspase-8 may not be activated upon recruitment to β3 and β1 integrin but it
gets recruited to the cytoplasmic tails of β3 integrin in clusters, which may cause activation due
to its proximity. Upon treatment with ProAgio, integrin is forced to change its confirmation to
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unliganded integrin and once FAK is dissociated from the cytoplasmic tails of integrin, the
cytoskeletal architecture gets disturbed as the integrin is no more tethered to the actin stress
fibers, which eventually triggers intrinsic apoptotic pathway.
6.1.2. ProAgio has enhanced pharmacological properties
Over the last few decades, hundreds of endogenous proteins or peptides have been found
to inhibit angiogenesis. All these proteins or peptides showed phenomenal effects in lab but none
of them made their way to the clinic due to several reasons such as solubility and bioavailability.
Even though recombinant endostatin cleared maximum hurdles in order to enter the clinic, but it
eventually failed in 3 independent phase III trials performed in the United States and hence
couldn’t enter clinic. However, experimental evidences suggest that ProAgio can make a
difference which other anti-angiogenic proteins or peptides could not, as no side-effects were
observed even at much higher doses than IC50. The potential reasons for ProAgio not entering the
clinic would be (i) Uptake by non-targeting tissues which express high levels of αVβ3 integrin
(ii) Degradation of ProAgio in plasma (iii) Half-life of small proteins is very less. ProAgio is
pegylated and hence its half-life is increased by four fold without change in the therapeutic
efficacy. However, ProAgio is very specific for αVβ3 integrin and it can have other applications
in addition to the therapeutic aspect. ProAgio can be used as a targeting molecule as well;
ProAgio when conjugated with anti-cancer drugs can decrease their presence in non-targeting
tissues. Since ProAgio is highly specific for receptors expressed in tumor proximity, it can be
used for liposomal mediated drug delivery where drug is loaded onto nano particles in order to
increase their efficacies.
6.1.3. ProAgio has fewer side effects
Since αVβ3 is not expressed in any organ other than pathological tissues, it is expected
to not accumulate in any other tissues other than the pathological site such as tumor site,
metastatic site or uncontrolled wound healing site leading to fibrosis or angiogenesis and related
diseases. ProAgio is expected to have decreased or no therapeutic immunogenicity as it was
engineered from one of the endogenous human proteins, CD2-D1. In addition, it just has about 9
% variation in its peptide sequence. A 30 KDa PEGylation on M26C further reduced the
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immunogenicity, as pegylation is known to reduce antigen presentation and therefore immune
response.
6.1.4. Why ProAgio can be a better anti-angiogenic agent?
After Judah Folkman initially proposed the regulation of angiogenesis as a new line of
therapeutics for cancer treatment, anti-angiogenic drugs were developed, which targeted growth
factors. These drugs, such as monoclonal antibody or a small molecule kinase inhibitor,
eliminated growth factors from circulation by inhibiting growth factor receptor. The other line of
therapeutics such as antagonists for the adhesion receptors, targeting angiogenesis were also
developed, as adhesion is the most important feature of endothelial cells. Integrins, the
predominant adhesion receptors and certain domains of ECM subsequently tried to enter clinics.
Despite integrin being targeted by both specific monoclonal antibodies and fragments of ECM,
αV integrin knockout mice have raised several interesting questions. Reynolds et al., in their
research article showed that mice lacking αV integrin have enhanced pathological angiogenesis,
questioning the necessity of αV integrin in physiological angiogenesis and revisiting therapeutics
targeting αV paired integrin. The results of knockout and integrin targeting studies were
completely contradicting, but a concept put forward by Dwayne G. Stupack et al., showing that
unliganded integrin αVβ3 can actually induce apoptosis in endothelial cells, linked these two
contradicting theories. In one of the studies, they showed that αVβ3 and α5β1 integrins recruited
caspase-8 in 3D collagen matrix, known as integrin mediated death (IMD). Till date, many
therapeutics targeting integrin were mainly focused on RGD binding site of the integrin.
Therapeutics targeting RGD binding site induced apoptosis in endothelial cells by anoikis, which
is a programmed cell death induced only in anchorage-dependent cells when they are detached
from the surrounding extracellular matrix (ECM). In the IMD theory put forward by David
Cheresh et al., αVβ3 is seen as a feedback mechanism for the growth of vasculature, where
integrin can support the growth and facilitate apoptosis through IMD. An interesting observation
by Heil et al. was that activated endothelial cells express high levels of αVβ3 compared to the
endothelial cells surrounded by smooth muscle cells, even though it has not been demonstrated
in theory that genetic elimination of the αVβ3 favors reduced pro-apoptotic stimuli and increases
endothelial cell survival.
116

Since the recent advancement of molecular therapeutics, which are more specific targets
for angiogenesis, there is a lot of room for improvement in the field of angiogenesis.
Bevacizumab was approved in 2004 by FDA; since then anti-angiogenic therapy has been
noticed as a new line of treatment in cancer therapy. Upon initial success of bevacizumab,
several other anti-angiogenics have been approved, such as Aflibercept, Sorafenib & Sunitinib,
small molecule tyrosine kinase inhibitors targeting VEGF and its receptors. Even though initial
studies were very promising, there has been no significant improvement in life of cancer patients.
ProAgio has several advantages compared to conventional or existing therapies in the following
ways. Firstly, ProAgio directly induces apoptosis of endothelial cells and inhibits angiogenesis as
compared to targeting VEGF, as growth factor targeting can be redundant. Upon inhibiting
VEGF/VEGFR, it has been observed that tumors become resistant by expressing redundant
growth factors such as FGF, PDGF, or PIGF. Targeting multiple growth factors such as
panitumumab (anti-EGF) along with bevacizumab (anti-VEGF) simultaneously proved to be
toxic. Secondly, ProAgio could be a better therapeutic compared to drugs targeting growth
factors, as ProAgio was effective in in vitro experiments, irrespective of the growth factors or the
surrounding environmental conditions. It induced apoptosis at a concentration of 5

M on every

matrix like fibronectin, collagen & laminin, whereas a slightly higher concentration was
necessary to induce apoptosis in case of vitronectin due to its survival benefits. Thirdly, side
effects of current growth factor targeting therapeutics have shown many side effects such as
portal hypertension as these growth factors such as VEGF, EGF etc. have normal physiological
functions.
6.1.5. ProAgio induces cell death in endothelial cells
In Chapter 1 and 3, ProAgio was evaluated for its effects on endothelial cells using
different in vitro bio-assays and in vivo PC3 xenograft and 4T1 orthotopic mouse model. Our
designed protein agent, ProAgio, is a potential candidate for inhibiting tumor angiogenesis.
Endothelial cells form the inner layer of blood vessels, and EC proliferation and migration are
required prior to the vessel formation. In order to test the efficacy of pro and anti-angiogenics,
various assays have been characterized such as MTT, Annexin V/PI, ATP aassay [3H] thymidine,
and BrdU that measure proliferation/viability rates of cultured ECs. Apoptotic assays and/or cell
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viability assays were performed in order to measure the in vitro efficacy and it was observed that
ProAgio at a cellular level induces apoptosis in ECs. Several different ECs from various tissue
origins tend to behave differently as these cells cannot be immortalized. Primary cultured cells
were used in the experiments, which are commercially available now (Jackson and Nguyen
1997, Staton, Reed et al. 2009) and among all the cell types, HUVECs are widely used ECs in in
vitro angiogenesis bio-assays (Bouis, Hospers et al. 2001, Staton, Reed et al. 2009).
Commercially available primary HUVECs were purchased and maintained in our laboratory. As
HUVECs are primary cells, they tend to lose all the characteristic angiogenic features and
become senescent when cultured for long in culture medium, therefore, HUVECs within 5-10
passages were employed. As shown in Figure 2.1, ProAgio clearly induces apoptosis in
HUVECs (~ 70% reduction at concentration of 5 µM compared to cells treated with buffer
controls). The IC50 value mostly assessed is about 3.5 µM, although it generally varies from
batch to batch based on purification. The anti-angiogenic efficacy was compared with clinically
approved Avastin®, Endostar® and Cilengitide®. Avastin did not have any impact on the
endothelial cells, whereas Cilengitide had anoikis effect at a very high concentration of 50 µM
but had little or no effect at 5 µM concentration whereas endostar had a significant effect on
endothelial cells at IC50 of about 4 µM, similar to that of ProAgio (Presta, Chen et al. 1997).
6.1.6. ProAgio inhibits angiogenesis in in vivo xenograft tumors
Tumors beyond size of 3-4 mm depend on angiogenesis for their growth (Folkman 1971,
Gimbrone, Leapman et al. 1972, Knighton, Ausprunk et al. 1977). Xenograft tumors are one of
the widely used models to mimic tumor growth in animals. Nude mice were employed for this
study as they lack immune system and hence tumors from other species can be injected in them
for study (Weidner, Carroll et al. 1993, Brawer, Deering et al. 1994, Ravindranath, Wion et al.
2001). Xenograft tumor growth has several advantages compared to other angiogenesis models
such as chick embryonic assay, Zebrafish angiogenesis assay or matrigel plug assay. First, it is
easy to monitor the study, as the tumors are grown subcutaneously. Second, tumor angiogenesis
can be easily studied as they can be surgically removed and histology studies can be performed.
Third, PK/PD studies can be performed and it involves a less expensive laboratory study. PC3
xenograft nude mice model was employed to test the efficacy of ProAgio. In the preliminary
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studies, ProAgio has demonstrated efficacy in stopping tumor growth as compared to buffer
treated group. ProAgio significantly inhibited tumor progression compared to the control as
shown in Figure 3.1. A detailed study of ProAgio was examined further in a dose dependent
manner. Since all the existing angiogenesis based therapeutics were targeting VEGF/VEGFR, it
was very important to compare the ProAgio efficacy with VEGF/VEGFR targeting drugs. In
order to test the aforementioned, we used Avastin (Bevacizumab) as a control since it is FDA
approved protein drug for treatment of solid tumors. Avastin not only differs from ProAgio in
targeting growth factor but also in PK/PD values. Avastin, a monoclonal antibody, has a half-life
of about 23 days, therefore Avastin was administered twice weekly, whereas ProAgio was
administered daily throughout the experiment. Platelet endothelial cell adhesion molecule-1
(PECAM-1), known as CD-31, present in intracellular junctions of endothelial cells, is a specific
marker for EC’s, and quantification of CD-31 is proportional to the EC growth. CD-31
immunofluorescence staining was performed in tumor cryosections, and detailed vessel length,
vascular density and branch points were analyzed using unpaired t-test. ProAgio-PEG
significantly reduced the mean vascular density and decreased branch points to a great extent.
Decrease in branch points strongly opposes the angiogenesis as it is a primary event in the
growth of tumor vasculature. The anti-angiogenic effects and staining patterns of Avastin and
ProAgio were analyzed for the anti-angiogenic efficacy, and end point tumor analysis showed
that both ProAgio-PEG and avastin treatments significantly reduced tumor masses (P < 0.01),
however the buffer and control protein (CD2D1-PEG, 20 mg/kg/day) showed no effect on the
tumor growth. A 20 day ProAgio-PEG (20 mg/kg/day) treatment resulted in 68% reduction in
tumor mass, compared to that of Avastin® which is 59%. As mentioned in chapter 3, the endpoint tumor mass showed 65% reduction when treated with 10 mg/kg of ProAgio. Based on the
end point data, it can be clearly interpreted that 10 mg/kg ProAgio-PEG achieved the same level
of anti-tumor effect as Avastin 20 mg/kg; however, this comparison is not direct and can be
attributed to differences in circulating half-lives, dosage in terms of molarity and distinct antiangiogenic mechanisms, one targeting growth factor VEGF and the other targeting integrin
αVβ3. Histological analysis of CD31 has been a common tool for identification of vasculatures
in different human and mouse tissues. Cluster of differentiation 31 (CD31), also known as
platelet endothelial cell adhesion molecule-1 (PECAM-1) is one of the receptors expressed on
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endothelial cell surface in newly growing endothelial cells. To determine the anti-angiogenic
efficacy of ProAgio, xenograft tumor tissues dissected from various treatment groups were IFstained with CD31 and data is listed in Figure 3.10G. Three common measurements, which
include mean vessel length, mean vascular density (MVD), and mean branch points were
performed and statistically analyzed using unpaired student’s t tests (n = 6, two-tailed). ProAgio
(5 mg/kg/day) reduced angiogenesis by 65% in vessel length and about 83% in branch points in
PC3 xenografts, when compared to buffer control. The detailed MVD calculation is mentioned in
Table 3.2. ProAgio-PEG at 5 and 10 mg/kg/day resulted in 36% and 46% reductions in MVD.
Major impact of ProAgio was seen when ProAgio-PEG treated xenograft groups at a dose of 2.5,
5 and 10 mg/kg/day exhibited inhibition of new vascular branches, and reduction in branch
points/field at 30%, 72%, and 80%, respectively. Avastin efficacy was similar to that of 10
mg/kg ProAgio treatment in terms of tumor size and angiogenic features: 58% (mean vessel
length), 46% (mean vessel density) and 73% (mean branch points) compared to 10 mg/kg
ProAgio at 67%, 46%, and 81% reduction in angiogenic features. ProAgio-PEG (20 mg/kg/day)
resulted in a better reduction of tumor, mean vessel length (80%), MDV (65%), and branch
points were almost completely eliminated (95%).
In summary, ProAgio-PEG from 2.5 to 20 mg/kg/day showed dose-dependent anti-tumor
and anti-angiogenic effects in vivo, a daily treatment of 5 mg/kg significantly inhibited tumor
growth and angiogenesis in PC3 tumor xenografts. Based on several studies, 10 mg/kg treatment
was considered as an ideal dose for tumor studies in xenograft and orthotopic mice models.
Angiogenesis was inhibited at same levels for treatments with 10 mg/kg/day of ProAgio-PEG
and avastin 20 mg/kg/twice weekly consequently inhibiting tumor growth. The better therapeutic
efficacy may be due to the mechanism of action and therapeutic design. Avastin is a large
monoclonal antibody specifically eliminating circulating VEGF whereas ProAgio targets integrin
αVβ3, which is an adhesion receptor. ProAgio is 1/5th of the molecular weight of Avastin® and
therefore exhibits enhanced delivery to the tumor site. The other key reason for failure of Avastin
is that there are other growth factors in the tumor microenvironment such as FGF, PDGF and
EGF, which promote angiogenesis and at 20 mg/kg/day, ProAgio completely reduces tumor
angiogenesis and therefore shows higher efficacy.
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6.2. Fibrosis conclusion
In case of cirrhosis, the density of HSCs as well as their spread across the sinusoidal
lumens is increased, which leads to increased susceptibility of contractile features of activated
HSCs eventually leading to high resistance. The mechanism of assembly of this contractile
machinery along the sinusoidal lumen is not yet well understood, but it is quite likely that the
migration of HSCs plays a prominent role in this condition. This vessel constriction due to HSCs
further assists the process of sinusoidal remodeling. It is well known that TGF-β is mainly
responsible for collagen deposition during chronic liver diseases, but HSC motility is also
dependent on PDGF signaling; indeed this phenomenon has been observed in case of vascular
remodeling in lung. TGF-β and PDGF pathways were seen to converge at c-abl kinase, which
suggests that imatinib can be used to restrict the vascular remodeling changes. Along with HSCs,
the sinusoidal lumen structural changes in sinusoids are often seen in late stage cirrhosis where
LSEC lose their sinusoids. ProAgio has demonstrated specific binding to integrin αVβ3 and
induced apoptosis of HSCs and LSECs. LSECs during normal liver physiological function do not
express integrin αVβ3, however, during sinusoidal remodeling, LSECs start proliferating and
eventually they loose fenestrae or it is believed that fenestrae do not form as the cell undergoes
rapid proliferation. ProAgio can induce cell death in proliferating LSEC via integrin αVβ3.
HSCs, endothelial cells and sinusoidal endothelial cells are affected and play a major role
in chronic liver diseases. HSCs upon activation acquire myofibroblast like features and play a
prominent role in collagen secretion, collagen crosslinking and contraction of vessels upon
binding to endothelial cells. Sinusoidal endothelial cells are present in liver to allow smooth flow
of blood. LSECs have fenestrae, which allow the flow of fluids through them to the hepatocytes
for the normal function of the liver. Upon activation, these LSECs proliferate and loose fenestrae
obstructing the blood flow, which consequently generates massive back resistance of blood flow
leading to portal hypertension. HSCs, ECs and LSECs, all the three cell types are responsible for
pathological progression of liver disease. All these three cell types upon activation have different
gene expressions but all of them have one common expression of integrin αVβ3 and all these cell
types are susceptible for integrin-mediated death. In TAA-induced liver fibrosis, ProAgio
showed a remarkable recovery of the mouse liver. ProAgio induced cell death in activated HSCs
but not normal quiescent HSCs. LX-2, a cell line established from the activation of quiescent
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stellate cells, which mimics activated HSCs exhibited apoptosis upon ProAgio treatment.
ProAgio also induced cell death in activated LSEC, but not quiescent LSEC. Other cell types
such as kupffer cells and hepatocytes have also been tested and ProAgio is ineffective in their
apoptosis induction.
In TAA-induced liver fibrosis model, TAA was injected along with 10% ethanol in
drinking water to mice for 12 to 15 weeks and body weight was monitored along the course of
fibrosis induction. Fibrosis induction lead to the reduced body weight of mice and thereafter they
were grouped randomly in buffer and ProAgio treated groups. Buffer group received PBS while
the ProAgio treated group received ProAgio in PBS. 10 doses of ProAgio were given and the
mice were sacrificed for histological analysis. ProAgio treated mice showed several contrasting
features over mice receiving PBS only. ProAgio treated mice showed better body weight
recovery, the weight of the livers was less as compared to the fibrotic livers and the liver
function tests such as cholesterol, protein levels were close to normal. But the AST, ALT and
ALP levels were still high as compared to the control group, which could be attributed to
apoptosis in 3 different cell types.
In summary, several groups believe that integrins are one of the key participants in
TGFβ mediated fibrosis as TGF gets activated directly or indirectly or through integrins, which
in turn affects the downstream signaling of TGFβ. Thus targeting integrin αVβ3 is a more
promising anti-fibrotic therapy than targeting TGFβ. The role of ILK in TGFβ-induced liver
fibrosis and kidney fibrosis has been well established but it is yet to be elucidated whether ILK
function is αVβ3 dependent or not. Targeting βA domain of αVβ3 integrin can induce apoptosis
in myofibroblasts/activated HSCs in the liver. Integrin mediated death is extremely specific for
myofibroblasts involved in ECM secretions. This therapeutic approach prevents liver fabric from
being damaged or destroyed, as stellate cells constitute nearly 10% of the liver. Targeting TGFβ
can be more toxic to liver as it helps in maintaining liver physiology. This is the first time
regeneration of liver from fibrosis has been reported. However, it would be quite interesting to
study if cirrhosed liver could be recovered or not during late stage fibrosis. Also, it is speculated
that ProAgio treatment can stop from further pathological progression and halt the extent of liver
damage. Collagen accumulation can normally be reversed, but in case of cirrhosis, the collagen
fibers are intertwined, thus making it inaccessible for MMPs to degrade.
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The advantages of ProAgio in CLDs are multifold. ProAgio addresses the following
pathological consequences in CLD- 1) ProAgio induces cell death in activated HSCs which are
the major source for collagen secretion, 2) ProAgio specifically induces cell death in activated
LSECs, reducing sinusoidal remodeling, 3) ProAgio induces apoptosis in activated endothelial
cells and mitigate angiogenesis, 4) In addition, ProAgio does not induce cell death in αVβ3
expressing immune cells, which can clear excess collagen. In summary, regulating all three
fibroblasts, endothelial cells and sinusoidal endothelial cells will aid the smooth flow of blood
and fluids across the sinusoids. The normalized smooth flow of fluids across the liver will
decrease portal hypertension, which is a leading cause of death in chronic liver diseases.
6.3. Why integrin αVβ3?
αVβ3 integrin is upregulated in angiogenic blood vessels, activated myofibroblasts and a
wide range of diseases. Several groups have independently demonstrated that αVβ3 provides a
feedback mechanism from environment to the cell, acting as a biomechanical sensor. This
sensing results in death of certain cell types including endothelial cells when engaged
inappropriately to extracellular matrix (ECM). This feedback mechanism facilitates vessel
pruning and morphogenesis and eliminates the unwanted vessels or prevents formation of new
vessels at unwanted sites. This could be the most likely explanation believed by many groups in
order to explain the apparent paradox information obtained from genetically manipulated mice of
integrin αVβ3. Genetic elimination of a pro-apoptotic stimulus such as αVβ3 would thus be
predicted to increase endothelial-cell survival in vivo, contributing to increased blood-vessel
density. This may be particularly evident under pathological conditions when blood vessels are
undergoing active and continuous remodeling. Tumstatin, a collagen IV fragment, antagonizes
integrin αVβ3, and inhibits angiogenesis by inducing endothelial cell apoptosis, has no effect
on β3-deficient endothelial cells. However, despite the conundrum in understanding the integrin
αVβ3, it is still believed to be a promising target.
6.4. Integrin αVβ3 direct access to the apoptotic machinery
Integrin αVβ3 can sense survival signals for endothelial cells. During this event of
development, endothelial cells initiate apoptosis on losing attachment or contact with the
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Figure 6.1. Schematic representation of integrin targeting drugs inducing cell death through different
mechanisms.

surrounding environment. A cell can receive conflicting signals from integrin αVβ3 i.e. they can
either attenuate or promote growth and in that way, they differ from death receptor.
Integrin αVβ3 can promote growth immediately when they find ligand and in a similar
fashion, they can induce death in the absence of ligand. Integrin cannot trigger apoptosis in many
cancer cell lines as they have many survival pathways, whereas they can induce apoptosis
through integrin-mediated death in ECs, HSCs and LSECs. The idea of targeting integrin αVβ3
has been attractive since they can have direct access to cell survival and cell apoptotic
machinery. VEGF targeting drugs that regulate endothelial cell growth indirectly can be
redundant, eventually leading to drug resistance, however, integrin targeting drugs can be
promising as they simultaneously inhibit growth and induce cell death.
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Targeting αVβ3 and α5β1 integrin differ from conventional death receptor targeting as
TNF and CD95L have several severe side effects. First, death receptors (DR4 & DR5) are
expressed on a wide variety of tissues especially in liver along with tumors; therefore targeting
DR will have toxic effects. αVβ3 and α5β1 are highly specific in activated endothelial cells, so
targeting these integrins would be specific for sprouting angiogenesis. Second, integrin αVβ3 do
not induce cell death in epithelial cells, but only in cells of endothelial origin. Third, DcR1 &
DcR2 are decoy receptors, which can decrease the efficacy of therapeutic DRs, which is not the
case with integrin αVβ3. Fourth, due to great diversity in integrins, targeting them would be
highly specific with minimal side effects. This mechanism of integrin αVβ3 inducing cell death
is yet to be completely elucidated, as there may be accessory molecules involved in the
regulation of this interaction. The most inquisitive aspect of this mechanism is, even though there
are 24 different pairs of integrins, not all integrins are proapototic and not all cells are susceptible
to cell death induced by integrin αVβ3. Further investigations have to be performed to identify
the factors governing this cascade.
6.5. Conclusions and Future directions
A growing body of preclinical and clinical evidence indicates that integrin αVβ3 is a
promising target for anti-angiogenic therapy. Several integrin αVβ3-targeted therapeutic
approaches such as the direct signaling inhibition using antibodies, peptides, peptidomimetics,
and other antagonists, as well as indirect tumor-targeted drug delivery systems have been
summarized. Since integrin αVβ3 is not the only molecule involved in tumor angiogenesis, the
combined inhibition of integrin αVβ3 with other angiogenic molecules such as VEGF, FGF,
EGF, and other integrins is expected to generate significantly greater anti-angiogenic and antitumor benefits over monospecific αVβ3 antagonists. Additionally, the inhibition of integrin
αVβ3 combined with other therapeutic modalities, such as chemotherapy and radiotherapy,
should be much more effective than using integrin αVβ3 alone. Importantly, this study provides
an example of proof-of-concept targeting a single agent to target tumor microenvironment by
harnessing both anti-angiogenic and anti-fibrotic activity. The developed agent, ProAgio, is not
toxic to established vasculature, inactive fibroblasts, inactive HSCs, resting pancreatic stellate
cells and fenestrated sinusoidal endothelial cells. But all the above-mentioned cell types once
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activated promote the pathological progression of fibrosis and related diseases, cancer being the
common one. ProAgio is a potential candidate for clinical applications in various diseases as
demonstrated by various in vitro and in vivo experiments. However, the specific synergistic
interactions among different modalities should be investigated and clearly understood for the
personalized treatment.

Targeting the microenvironment in Hepatocellular carcinoma - Tumor microenvironment
has a crucial role in HCC development and progression. Modulating the dynamic crosstalk
between stroma and hepatocytes as a treatment for HCC holds a very strong rationale, especially
in HCC prevention. Liver fibrosis reversal using antifibrotic therapies has been shown in patients
with chronic liver diseases. Also, targeting of various immune cells and specific molecules that
are present in the pro-tumorigenic microenvironment in the liver is also feasible. Despite these
options, enhanced understanding of the relative contribution of different molecules and cells
contributing to HCC pathogenesis, and interpretation of the hierarchy of pathological
mechanisms occurring in liver, are essential for planning preventive therapies or therapeutics.
This will require an improved comprehension of the various complex interactions that occur in
chronically inflamed human livers, along with careful testing of their functional significance in
animal models that could translate to different etiologies of hepatic inflammation (metabolic,
viral etc.) in humans. The ideal preventive treatment in HCC should change a pro-tumorigenic
microenvironment into an anti-tumorigenic one. It has been clearly demonstrated that hepatic
fibrosis and cirrhosis play a pivotal role in causing HCC. Several mechanisms through which
activated hepatic stellate cells lead to HCC progression include increased tissue stiffness,
angiogenesis, and secretion of cytokines, pro-tumorigenic extracellular matrix components and
immunosuppression. However, these mechanisms and their contribution in HCC in concert to
humans remains to be elucidated. In summary, chronic liver inflammation generates a protumorigenic microenvironment, infiltrated by stellate cells, immune cells, together producing a
pathological milieu, which is comprised of multiple extracellular matrix proteins, collagens,
cytokines and growth factors that can form a pro-tumorigenic stroma. Hence, targeting the
microenvironment could be a promising therapeutic approach.
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Targeting the microenvironment in Pancreatic ductal adenocarcinoma – Pancreatic cancers
have an abundant and dense collagenous stroma, also known as desmoplasia, that results in
hypoxia in cancer cells. This stroma is composed of extracellular matrix proteins such as
collagens, laminin and fibronectin as well as non-collagenous proteins such as glycoproteins,
glycosaminoglycans and proteoglycans. The factors in the stroma that probably mediate the
interaction of cancer cells with the ECM include growth factors, periostin, osteopontin and serine
protein acidic and rich in cysteine. Similar to HCC, pancreatic cancer stellate cells (PSCs) form
the pathological microenvironment in pancreatic cancer. PSCs produce collagenous matrix, aid
in infiltration of immune cells, endothelial cells and neuronal cells. However, the co-relation
between extent of stromal expansion and the clinical outcome is debatable. The association
between the numbers of activated pancreatic stellate cells and poor clinical outcome was
reported in several studies individually, pancreatic cancer patients showed that in early-stage
(T1–T2) pancreatic tumors, moderate or strong α-sma expression was related with poorer clinical
outcomes than tumors with low levels of α-sma expression, as evaluated by overall and
progression-free survival.
The interaction between cancer cells and stromal stellate cells has been demonstrated by
both in vitro and in vivo studies. Stellate cells can inhibit apoptosis of cancer cells, increase their
survival, and aid cancer stem cell niche formation that possibly has a role in recurrence of the
disease and chemo-resistance. In addition, PSCs can metastasize from the primary tumor to
distant sites, where they might facilitate the seeding and progression of metastatic cancer cells. It
is important clinically because factors that ward off immune system such programmed cell death
protein ligand 1 (PD-L1), expressed on cancer cells form the basis of novel immunotherapeutic
strategy that is currently under investigation in pancreatic cancer.
Targeting the microenvironment in lung metastasis – Lung metastasis is the most commonly
observed metastatic site for various cancers including breast liver, pancreas and prostate.
Homing of circulating cancer cells is enhanced in lung due to the microenvironment which has a
rich supply of nutrients due to dispersed capillaries, high oxygen and moreover the fibroblasts in
lung which secrete collagen and form a premetastatic niche which aid to colonize the circulating
tumor cells. We believe that this activation of lung tissue provides an ideal niche for colonizing
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the metastatic cells. It is not yet clear whether cancer cells go to the metastatic site and activate
or they activate and colonize. This study will establish the story of breast cancer metastasizing to
lungs with and with our pre-activation. This pre-metastatic niche mainly comprises of ECM and
fibroblasts. In orthotopic breast cancer 4T1 metastatic breast cancer model we studied we have
observed remarkable decrease in lung metastasis which we mainly attribute to the decreased
activated lung fibroblasts. It has always been challenging to regulate the tumor growth. Starting
with a chemotherapy specifically killing cancer cells, then with additional anti angiogenic
therapy and still the cancer progression has lot more factors than anticipated. To our recent
understanding of tumor microenvironment, it came to light that not only cancer cells and
endothelial cells but also fibroblasts, pericytes and stem cells also known to play a prominent
role in cancer progression. It has always been challenging to target resident fibroblasts or
fibroblasts formed from other sources such as pericytes, stem cells or epithelial cell derived.
TGF-β and TGF-βR even though are responsible for its major function couldn't become
optimistic targets. We believe that integrin v3 which is also highly expressed in these cells
could be most viable option as v3 is expressed on endothelial cells, fibroblasts and pericytes.
Making a potential drug that can effectively target this receptor can effectively have a great
impact on tumor microenvironment enhancing both chemotherapy and immunotherapy.

To summarize, a novel anti-angiogenic and anti-fibrotic agent has been successfully
developed by rational protein design. Cancer therapeutics are moving away from cytotoxic to
specifically targeted molecules having minimum side effects and ProAgio will serve as a perfect
therapeutic agent as it will address angiogenesis and its related diseases such as age related
macular degeneration, cirrhosis and fibrosis (liver and pancreatic fibrosis). It will also be
effective in various cancers where angiogenesis and fibrosis are either a cause or a consequence,
especially in life threatening cancers such as pancreatic cancer, HCC, lung cancer and various
other organ related cancers. In the aforementioned cases, tumor microenvironment plays a
prominent role in tumor growth and cancer progression and there is no cure available yet.
ProAgio has also exhibited significant therapeutic efficacy in regulating metastatic progression
in various models discussed in this thesis.
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ProAgio has a wide range of applications in pathological conditions beyond any known
therapeutic agent. Therefore, a careful and thorough analysis has to be performed before putting
it into the clinic. Historically, not all animal models faithfully translate to the human state,
(exemplified by the disparate results of TNFα inhibition in rodents as compared to human
alcoholic liver disease, thalidomide for morning sickness, endostatin and cilengitide for tumor
xenografts). Clearly, human investigations with all proper safety measures need to be pursued.

“With great power comes great responsibility”
François-Jean Baudouin May 8, 1793.

Thank you
Ravi Chakra Turaga
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